0001628280-22-012634.txt : 20220506 0001628280-22-012634.hdr.sgml : 20220506 20220505160812 ACCESSION NUMBER: 0001628280-22-012634 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 71 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220505 DATE AS OF CHANGE: 20220505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CareTrust REIT, Inc. CENTRAL INDEX KEY: 0001590717 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 463999490 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36181 FILM NUMBER: 22896255 BUSINESS ADDRESS: STREET 1: 905 CALLE AMANECER, SUITE 300 CITY: SAN CLEMENTE STATE: CA ZIP: 92673 BUSINESS PHONE: (949) 542-3140 MAIL ADDRESS: STREET 1: 905 CALLE AMANECER, SUITE 300 CITY: SAN CLEMENTE STATE: CA ZIP: 92673 10-Q 1 ctre-20220331.htm 10-Q ctre-20220331
0001590717--12-312022Q1falseP3Y00015907172022-01-012022-03-3100015907172022-05-04xbrli:shares00015907172022-03-31iso4217:USD00015907172021-12-31iso4217:USDxbrli:shares00015907172021-01-012021-03-310001590717us-gaap:CommonStockMember2021-12-310001590717us-gaap:AdditionalPaidInCapitalMember2021-12-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2021-12-310001590717us-gaap:CommonStockMember2022-01-012022-03-310001590717us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2022-01-012022-03-310001590717us-gaap:CommonStockMember2022-03-310001590717us-gaap:AdditionalPaidInCapitalMember2022-03-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2022-03-310001590717us-gaap:CommonStockMember2020-12-310001590717us-gaap:AdditionalPaidInCapitalMember2020-12-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2020-12-3100015907172020-12-310001590717us-gaap:CommonStockMember2021-01-012021-03-310001590717us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2021-01-012021-03-310001590717us-gaap:CommonStockMember2021-03-310001590717us-gaap:AdditionalPaidInCapitalMember2021-03-310001590717us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2021-03-3100015907172021-03-310001590717ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember2022-03-31ctre:facility0001590717ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember2022-01-012022-03-31ctre:bedctre:state0001590717ctre:VariousOtherOperatorsMemberctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMemberctre:TripleNetLeasesMember2022-03-310001590717ctre:ShortTermLeaseTermUnderOneYearMember2022-03-310001590717us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2022-03-310001590717ctre:AssistedLivingFacilityMemberctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2034NextOption2022Member2022-03-31ctre:property0001590717ctre:SkilledNursingFacilityMemberctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2030NextOption2022Member2022-03-310001590717ctre:SkilledNursingFacilityMemberctre:PropertiesWithPurchaseOptionLeaseExpirationMarch2029NextOption2022Member2022-03-310001590717ctre:SkilledNursingAndCampusFacilitiesMemberctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2032NextOption2023Member2022-03-310001590717ctre:SkilledNursingFacilityMemberctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2034NextOption2024Member2022-03-310001590717ctre:AssistedLivingFacilityMemberctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2034NextOption2026Member2022-03-310001590717ctre:LeaseIncomeOperatingExpenseReimbursementsMember2022-01-012022-03-310001590717ctre:LeaseIncomeContractualRentMember2022-01-012022-03-310001590717ctre:LeaseIncomeStraightLineRentMember2022-01-012022-03-310001590717ctre:MetronMember2021-01-012021-03-310001590717ctre:SkilledNursingPropertiesMember2022-01-012022-03-31ctre:unit0001590717ctre:MultiServiceCampusPropertiesMember2022-01-012022-03-310001590717ctre:EnsignMemberctre:AssistedLivingFacilityMember2022-03-010001590717ctre:EnsignAmendedTripleNetMasterLeaseMember2022-03-01ctre:extension_option0001590717ctre:SkilledNursingFacilityMember2022-02-012022-02-010001590717ctre:EduroAmendedTripleNetMasterLeaseMember2022-02-010001590717ctre:MultiServiceCampusPropertiesMember2022-03-012022-03-010001590717ctre:WLCManagementFirmAmendedTripleNetMasterLeaseMember2022-03-01xbrli:pure0001590717us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2022-01-012022-03-310001590717us-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MinimumMember2022-03-310001590717us-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMembersrt:MaximumMember2022-03-310001590717us-gaap:FairValueInputsLevel3Membersrt:WeightedAverageMemberus-gaap:MarketApproachValuationTechniqueMember2022-03-310001590717us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberctre:AssistedLivingFacilityMember2021-12-310001590717ctre:SkilledNursingFacilityMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2022-02-220001590717ctre:SkilledNursingFacilityMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2022-02-222022-02-220001590717ctre:MezzanineLoanReceivableMember2022-03-310001590717ctre:MezzanineLoanReceivableMember2021-12-310001590717us-gaap:LoansReceivableMember2022-03-310001590717us-gaap:LoansReceivableMember2021-12-310001590717us-gaap:LoansReceivableMember2022-01-012022-03-31ctre:loan0001590717ctre:MezzanineLoanReceivableMember2022-01-012022-03-310001590717ctre:MezzanineLoanReceivableMember2021-01-012021-03-310001590717us-gaap:LoansReceivableMember2021-01-012021-03-310001590717us-gaap:FairValueMeasurementsRecurringMemberctre:MezzanineLoanMemberus-gaap:FairValueInputsLevel1Member2022-03-310001590717us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberctre:MezzanineLoanMember2022-03-310001590717us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberctre:MezzanineLoanMember2022-03-310001590717us-gaap:FairValueMeasurementsRecurringMemberctre:MezzanineLoanMember2022-03-310001590717us-gaap:FairValueMeasurementsRecurringMemberctre:MezzanineLoanMemberus-gaap:FairValueInputsLevel1Member2021-12-310001590717us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberctre:MezzanineLoanMember2021-12-310001590717us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberctre:MezzanineLoanMember2021-12-310001590717us-gaap:FairValueMeasurementsRecurringMemberctre:MezzanineLoanMember2021-12-310001590717us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember2022-03-310001590717us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember2021-12-310001590717us-gaap:SeniorNotesMemberctre:ThreePointEightSevenFiveSeniorNotesDue2028Member2022-03-310001590717us-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMemberctre:ThreePointEightSevenFiveSeniorNotesDue2028Member2022-03-310001590717us-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMemberctre:ThreePointEightSevenFiveSeniorNotesDue2028Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-03-310001590717us-gaap:SeniorNotesMemberctre:ThreePointEightSevenFiveSeniorNotesDue2028Member2021-12-310001590717us-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SeniorNotesMemberctre:ThreePointEightSevenFiveSeniorNotesDue2028Member2021-12-310001590717us-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMemberctre:ThreePointEightSevenFiveSeniorNotesDue2028Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310001590717us-gaap:LoansPayableMemberctre:SeniorUnsecuredTermLoanMember2022-03-310001590717us-gaap:LoansPayableMemberctre:SeniorUnsecuredTermLoanMember2021-12-310001590717us-gaap:RevolvingCreditFacilityMember2022-03-310001590717us-gaap:RevolvingCreditFacilityMember2021-12-310001590717us-gaap:SeniorNotesMemberctre:ThreePointEightSevenFiveSeniorNotesDue2028Member2021-06-170001590717us-gaap:SeniorNotesMemberctre:ThreePointEightSevenFiveSeniorNotesDue2028Member2021-06-172021-06-170001590717us-gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:SeniorNotesMemberctre:ThreePointEightSevenFiveSeniorNotesDue2028Member2021-06-172021-06-170001590717us-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMemberctre:ThreePointEightSevenFiveSeniorNotesDue2028Member2021-06-172021-06-170001590717us-gaap:SeniorNotesMemberctre:ThreePointEightSevenFiveSeniorNotesDue2028Memberus-gaap:DebtInstrumentRedemptionPeriodOneMember2021-06-172021-06-170001590717us-gaap:RevolvingCreditFacilityMember2019-02-080001590717us-gaap:LetterOfCreditMember2019-02-080001590717ctre:SwinglineLoanMember2019-02-080001590717us-gaap:LoansPayableMemberctre:SeniorUnsecuredTermLoanMember2019-02-080001590717us-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2019-02-082019-02-080001590717us-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2019-02-082019-02-080001590717us-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMembersrt:MinimumMember2019-02-082019-02-080001590717us-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberus-gaap:LondonInterbankOfferedRateLIBORMember2019-02-082019-02-080001590717us-gaap:LoansPayableMemberus-gaap:BaseRateMembersrt:MinimumMemberctre:SeniorUnsecuredTermLoanMember2019-02-082019-02-080001590717us-gaap:LoansPayableMemberus-gaap:BaseRateMembersrt:MaximumMemberctre:SeniorUnsecuredTermLoanMember2019-02-082019-02-080001590717us-gaap:LoansPayableMemberus-gaap:LondonInterbankOfferedRateLIBORMembersrt:MinimumMemberctre:SeniorUnsecuredTermLoanMember2019-02-082019-02-080001590717us-gaap:LoansPayableMembersrt:MaximumMemberus-gaap:LondonInterbankOfferedRateLIBORMemberctre:SeniorUnsecuredTermLoanMember2019-02-082019-02-080001590717us-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2019-02-082019-02-080001590717us-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2019-02-082019-02-080001590717us-gaap:RevolvingCreditFacilityMember2019-02-082019-02-080001590717srt:MaximumMemberctre:AtTheMarketOfferingProgramMember2020-03-100001590717ctre:AtTheMarketOfferingProgramMember2022-01-012022-03-310001590717ctre:AtTheMarketOfferingProgramMember2021-01-012021-03-310001590717ctre:AtTheMarketOfferingProgramMember2022-03-3100015907172020-03-2000015907172020-03-202022-03-310001590717us-gaap:RestrictedStockMember2022-01-012022-03-310001590717ctre:RestrictedStockAndPerformanceSharesMember2021-12-310001590717ctre:RestrictedStockAndPerformanceSharesMember2022-01-012022-03-310001590717ctre:RestrictedStockAndPerformanceSharesMember2022-03-310001590717ctre:EnsignAndPennantMember2022-03-310001590717ctre:CapitalImprovementsAtTripleNetLeasedFacilitiesMember2022-03-310001590717ctre:SkilledNursingFacilityMemberctre:EnsignMember2022-03-310001590717ctre:MultiServiceCampusPropertiesMemberctre:EnsignMember2022-03-310001590717ctre:EnsignMemberctre:AssistedAndIndependentLivingPropertiesMember2022-03-31ctre:beds0001590717us-gaap:CustomerConcentrationRiskMemberctre:EnsignMemberus-gaap:SalesRevenueNetMember2022-01-012022-03-310001590717ctre:SkilledNursingFacilityMemberctre:PriorityManagementGroupLLCMember2022-03-310001590717ctre:MultiServiceCampusPropertiesMemberctre:PriorityManagementGroupLLCMember2022-03-310001590717ctre:PriorityManagementGroupLLCMemberctre:AssistedAndIndependentLivingPropertiesMember2022-03-310001590717us-gaap:CustomerConcentrationRiskMemberctre:PriorityManagementGroupLLCMemberus-gaap:SalesRevenueNetMember2022-01-012022-03-310001590717ctre:SkilledNursingFacilityMemberctre:EnsignMember2021-03-310001590717ctre:MultiServiceCampusPropertiesMemberctre:EnsignMember2021-03-310001590717ctre:EnsignMemberctre:AssistedAndIndependentLivingPropertiesMember2021-03-310001590717us-gaap:CustomerConcentrationRiskMemberctre:EnsignMemberus-gaap:SalesRevenueNetMember2021-01-012021-03-310001590717ctre:SkilledNursingFacilityMemberctre:PriorityManagementGroupLLCMember2021-03-310001590717ctre:MultiServiceCampusPropertiesMemberctre:PriorityManagementGroupLLCMember2021-03-310001590717ctre:PriorityManagementGroupLLCMemberctre:AssistedAndIndependentLivingPropertiesMember2021-03-310001590717us-gaap:CustomerConcentrationRiskMemberctre:PriorityManagementGroupLLCMemberus-gaap:SalesRevenueNetMember2021-01-012021-03-310001590717ctre:SkilledNursingFacilityMemberstpr:CA2022-03-310001590717ctre:MultiServiceCampusPropertiesMemberstpr:CA2022-03-310001590717stpr:CActre:AssistedAndIndependentLivingPropertiesMember2022-03-310001590717stpr:CAus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-03-310001590717stpr:TXctre:SkilledNursingFacilityMember2022-03-310001590717stpr:TXctre:MultiServiceCampusPropertiesMember2022-03-310001590717stpr:TXctre:AssistedAndIndependentLivingPropertiesMember2022-03-310001590717stpr:TXus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2022
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     

Commission File Number: 001-36181
CareTrust REIT, Inc.
(Exact name of registrant as specified in its charter)
Maryland46-3999490
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
905 Calle Amanecer, Suite 300, San Clemente, CA
92673
(Address of principal executive offices)(Zip Code)
(949) 542-3130
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareCTREThe Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.      Yes      No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).      Yes      No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).      Yes      No
As of May 4, 2022, there were 97,028,742 shares of common stock outstanding.





INDEX






PART I—FINANCIAL INFORMATION
Item 1. Financial Statements.

CARETRUST REIT, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
(Unaudited)
 
March 31, 2022December 31, 2021
Assets:
Real estate investments, net$1,402,889 $1,589,971 
Other real estate investments15,155 15,155 
Assets held for sale, net141,716 4,835 
Cash and cash equivalents26,586 19,895 
Accounts and other receivables1,110 2,418 
Prepaid expenses and other assets, net5,668 7,512 
Deferred financing costs, net817 1,062 
Total assets$1,593,941 $1,640,848 
Liabilities and Equity:
Senior unsecured notes payable, net$394,484 $394,262 
Senior unsecured term loan, net199,189 199,136 
Unsecured revolving credit facility105,000 80,000 
Accounts payable, accrued liabilities and deferred rent liabilities23,785 25,408 
Dividends payable26,900 26,285 
Total liabilities749,358 725,091 
Commitments and contingencies (Note 11)
Equity:
Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued and outstanding as of March 31, 2022 and December 31, 2021
  
Common stock, $0.01 par value; 500,000,000 shares authorized, 96,487,066 and 96,296,673 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively
965 963 
Additional paid-in capital1,195,586 1,196,839 
Cumulative distributions in excess of earnings(351,968)(282,045)
Total equity844,583 915,757 
Total liabilities and equity$1,593,941 $1,640,848 










See accompanying notes to condensed consolidated financial statements.

1

CARETRUST REIT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(Unaudited)
 
 For the Three Months Ended March 31,
 20222021
Revenues:
Rental income$46,007 $45,246 
Interest and other income469 505 
Total revenues46,476 45,751 
Expenses:
Depreciation and amortization13,575 13,473 
Interest expense5,742 5,762 
Property taxes1,420 696 
Impairment of real estate investments59,683  
Provision for loan losses, net3,844  
Property operating expenses447  
General and administrative5,215 5,142 
Total expenses89,926 25,073 
Other income (loss):
Gain (loss) on sale of real estate186 (192)
Net (loss) income$(43,264)$20,486 
(Loss) earnings per common share:
Basic$(0.45)$0.21 
Diluted$(0.45)$0.21 
Weighted-average number of common shares:
Basic96,410 95,378 
Diluted96,410 95,385 












See accompanying notes to condensed consolidated financial statements.
2

CARETRUST REIT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(in thousands, except share and per share amounts)
(Unaudited)


Common StockAdditional
Paid-in
Capital
Cumulative
Distributions in Excess of Earnings
Total
Equity
SharesAmount
Balance at January 1, 202296,296,673 $963 $1,196,839 $(282,045)$915,757 
Vesting of restricted common stock, net of shares withheld for employee taxes190,393 2 (2,774)— (2,772)
Amortization of stock-based compensation— — 1,521 — 1,521 
Common dividends ($0.275 per share)
— — — (26,659)(26,659)
Net loss— — — (43,264)(43,264)
Balance at March 31, 202296,487,066 $965 $1,195,586 $(351,968)$844,583 











































See accompanying notes to condensed consolidated financial statements.

3

CARETRUST REIT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(in thousands, except share and per share amounts)
(Unaudited)
 Common StockAdditional
Paid-in
Capital
Cumulative
Distributions in Excess of Earnings
Total
Equity
SharesAmount
Balance at January 1, 202195,215,797 $952 $1,164,402 $(251,212)$914,142 
Issuance of common stock, net702,000 7 16,184 — 16,191 
Vesting of restricted common stock, net of shares withheld for employee taxes63,265 1 (1,331)— (1,330)
Amortization of stock-based compensation— — 1,585 — 1,585 
Common dividends ($0.265 per share)
— — — (25,633)(25,633)
Net income— — — 20,486 20,486 
Balance at March 31, 202195,981,062 $960 $1,180,840 $(256,359)$925,441 





















See accompanying notes to condensed consolidated financial statements.
4

CARETRUST REIT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(Unaudited)
 For the Three Months Ended March 31,
 20222021
Cash flows from operating activities:
Net (loss) income$(43,264)$20,486 
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization (including below-market ground leases)13,594 13,486 
Amortization of deferred financing costs520 487 
Amortization of stock-based compensation1,521 1,585 
Straight-line rental income(6)(12)
Adjustment for collectibility of rental income977  
(Gain) loss on sale of real estate(186)192 
Impairment of real estate investments59,683  
Provision for loan losses, net3,844  
Change in operating assets and liabilities:
Accounts and other receivables337 (100)
Prepaid expenses and other assets, net(404)278 
Accounts payable, accrued liabilities and deferred rent liabilities(2,037)(2,453)
Net cash provided by operating activities34,579 33,949 
Cash flows from investing activities:
Acquisitions of real estate, net of deposits applied(21,915)(138,151)
Purchases of equipment, furniture and fixtures and improvements to real estate(1,918)(1,319)
Investment in other loans receivable(2,086)(700)
Principal payments received on real estate mortgage and other loans receivable 888 56 
Net proceeds from sales of real estate959 6,814 
Net cash used in investing activities(24,072)(133,300)
Cash flows from financing activities:
Proceeds from the issuance of common stock, net 16,191 
Borrowings under unsecured revolving credit facility25,000 120,000 
Net-settle adjustment on restricted stock(2,772)(1,330)
Dividends paid on common stock(26,044)(23,960)
Net cash (used in) provided by financing activities(3,816)110,901 
Net increase in cash and cash equivalents6,691 11,550 
Cash and cash equivalents as of the beginning of period19,895 18,919 
Cash and cash equivalents as of the end of period$26,586 $30,469 
Supplemental disclosures of cash flow information:
Interest paid$1,355 $1,325 
Supplemental schedule of noncash investing and financing activities:
Increase in dividends payable$615 $1,673 
Transfer of pre-acquisition costs to acquired assets$7 $358 







See accompanying notes to condensed consolidated financial statements.
5

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)



1. ORGANIZATION
Description of Business—CareTrust REIT, Inc.’s (“CareTrust REIT” or the “Company”) primary business consists of acquiring, financing, developing and owning real property to be leased to third-party tenants in the healthcare sector. As of March 31, 2022, the Company owned and leased to independent operators, 228 skilled nursing facilities (“SNFs”), multi-service campuses, assisted living facilities (“ALFs”) and independent living facilities (“ILFs”) consisting of 23,834 operational beds and units located in 29 states with the highest concentration of properties by rental income located in California, Texas, Louisiana, Idaho and Arizona. As of March 31, 2022, the Company also had other real estate investments consisting of one mezzanine loan receivable with a carrying value of $15.2 million.
COVID-19—The COVID-19 pandemic has had and may continue to have an adverse impact on the economy generally and the Company’s business, results of operations and financial condition. The duration and extent of the COVID-19 pandemic’s effect on the Company’s operational and financial performance, and the operational and financial performance of the Company’s tenants, will depend on future developments, which are highly uncertain and cannot be predicted at this time, including the rate of public acceptance and usage of vaccines and the effectiveness of vaccines in limiting the spread of COVID-19 and its variants, resurgences of COVID-19 and, in particular, new and more contagious and/or vaccine resistant variants, actions taken to contain the spread of COVID-19 and how quickly and to what extent normal economic and operating conditions can resume. The adverse impact of the COVID-19 pandemic on the Company’s business, results of operations and financial condition could be material.
 
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation—The accompanying condensed consolidated financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, the condensed consolidated financial statements do not include all of the disclosures required by GAAP for a complete set of annual audited financial statements. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. In the opinion of management, all adjustments which are of a normal and recurring nature and considered necessary for a fair presentation of the results of the interim periods presented have been included. The results of operations for the interim periods are not necessarily indicative of results for the full year. All intercompany transactions and account balances within the Company have been eliminated.
 Recent Accounting Pronouncements—In March 2020, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), that provides optional relief to applying reference rate reform to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”). For U.S. Dollar LIBOR, the overnight, one-month, three-month, six-month and one-year LIBOR rates will be discontinued in June 2023, while other U.S. Dollar LIBOR rates were discontinued at the end of 2021. The amendments in this update are effective immediately and may be applied through December 31, 2022. Adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.

6

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


3. REAL ESTATE INVESTMENTS, NET
The following table summarizes the Company’s real estate properties held for investment at March 31, 2022 and December 31, 2021 (dollars in thousands):
March 31, 2022December 31, 2021
Land$236,986 $251,787 
Buildings and improvements1,431,631 1,622,019 
Integral equipment, furniture and fixtures95,997 104,722 
Identified intangible assets2,658 1,257 
Real estate investments1,767,272 1,979,785 
Accumulated depreciation and amortization(364,383)(389,814)
Real estate investments, net$1,402,889 $1,589,971 
As of March 31, 2022, 226 of the Company’s 228 facilities were leased to various operators under triple-net leases. All of these leases contain annual escalators based on the percentage change in the Consumer Price Index (“CPI”) (but not less than zero), some of which are subject to a cap, or fixed rent escalators. Two of the Company’s 228 facilities are non-operational and are leased under a short term lease with an expected term of less than one year as of March 31, 2022. As of March 31, 2022, 27 facilities were held for sale.
As of March 31, 2022, the Company’s total future contractual minimum rental income for all of its tenants, excluding operating expense reimbursements, was (dollars in thousands):
YearAmount
2022 (nine months)$146,848 
2023195,547 
2024194,202 
2025194,173 
2026194,278 
2027191,589 
Thereafter998,873 
Total$2,115,510 
Tenant Purchase Options
Certain of the Company’s operators hold purchase options allowing them to acquire properties they currently lease from the Company. A summary of these purchase options is presented below (dollars in thousands):
Asset TypePropertiesLease ExpirationNext Option Open Date
Option Type(1)
Current Cash Rent(2)
ALF7October 20341/1/2022
(3)
A$3,383 
SNF11November 20301/1/2022
(3)
C4,944 
SNF1March 20294/1/2022
(4)
B / C(5)
779 
SNF / Campus2October 20321/1/2023
(3)
B1,065 
SNF4November 203412/1/2024
(4)
B3,796 
ALF2October 20341/1/2026
(3)
A1,598 
(1) Option type includes:
A - Fixed base price plus a specified share on any appreciation.
B - Fixed base price.
C - Fixed capitalization rate on lease revenue.
(2) Based on annualized cash revenue for contracts in place as of March 31, 2022.
(3) Option window is open for six months.
(4) Option window is open until the expiration of the lease term.
(5) Purchase option reflects two option types.
7

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


Rental Income
The following table summarizes components of the Company’s rental income (dollars in thousands):
For the Three Months Ended March 31,
Rental Income20222021
Contractual rent due(1)
$46,978 $45,171 
Straight-line rent6 12 
Adjustment for collectibility(2)
(977) 
Lease termination revenue(3)
 63 
Total$46,007 $45,246 
(1) Includes initial cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received.
(2)    During the three months ended March 31, 2022, and in accordance with Accounting Standards Codification 842, the Company evaluated the collectibility of lease payments through maturity and determined that it was not probable that the Company would collect substantially all of the contractual obligations from four existing and former operators. As such, the Company reversed $0.7 million of operating expense reimbursements, $0.2 million of contractual rent and $0.1 million of straight-line rent during the three months ended March 31, 2022. If lease payments are subsequently deemed probable of collection, the Company will increase rental income for such recoveries.
(3) During the three months ended March 31, 2021, in connection with the agreement to terminate its lease agreements with Metron Integrated Health Systems (“Metron”) and to sell the facilities to a third party, the Company received approximately $0.1 million in lease termination revenue from Metron affiliates.
Recent Real Estate Acquisitions
The following table summarizes the Company’s acquisitions for the three months ended March 31, 2022 (dollars in thousands):
Type of Property
Purchase Price(1)
Initial Annual Cash RentNumber of Properties
Number of Beds/Units(2)
Skilled nursing$8,918 $815 1 135 
Multi-service campuses13,003 1,235 1 130 
Total$21,921 $2,050 2 265 
(1) Purchase price includes capitalized acquisition costs.
(2) The number of beds/units includes operating beds at the acquisition date.
Lease Amendments
Pennant Partial Lease Termination and Amended Ensign Master Lease. On March 1, 2022, operations at one ALF in Arizona operated by affiliates of The Pennant Group, Inc. (“Pennant”) were transferred to affiliates of The Ensign Group, Inc. (“Ensign”). In connection with the transfer, the Company amended the Pennant master lease to reflect the removal of the ALF and amended an existing triple-net master lease with Ensign to include the one ALF. The applicable Ensign master lease has a remaining term of approximately 11 years, with two five-year renewal options and CPI-based rent escalators. Annual cash rent under the applicable Ensign master lease, as amended, increased by approximately $0.3 million and annual cash rent under the Pennant master lease, as amended, decreased by the same amount.
Amended Eduro Master Lease. On February 1, 2022, the Company acquired one SNF. In conjunction with the acquisition, the Company amended its existing triple-net master lease with affiliates of Eduro Healthcare, LLC (“Eduro”) to include the one SNF and extended the initial lease term. The Eduro master lease, as amended, has a remaining term of approximately 12 years, with two five-year renewal options and CPI-based rent escalators. Annual cash rent under the Eduro master lease, as amended, increased by approximately $0.8 million.
Amended WLC Master Lease. On March 1, 2022, the Company acquired one multi-service campus. In conjunction with the acquisition, the Company amended its existing triple-net master lease with affiliates of WLC Management Firm, LLC (“WLC”) to include the one multi-service campus. The WLC master lease, as amended, has a remaining term of approximately 12 years, with two five-year renewal options and CPI-based rent escalators. Annual cash rent under the WLC master lease, as amended, increased by approximately $1.2 million.
8

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


4. IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE, NET AND ASSET SALES
In connection with the Company’s ongoing review and monitoring of its investment portfolio and the performance of its tenants, the Company determined to pursue the sale of 27 properties and repurposing three properties representing an aggregate of approximately 10% of contractual cash rent as of March 31, 2022. As of March 31, 2022, the Company determined that these 27 properties met the criteria to be classified as assets held for sale and, in connection with this determination, the Company recognized an aggregate impairment charge of $59.7 million related to 20 of the 27 held for sale properties, which is reported in impairment of real estate investments in the condensed consolidated statements of operations for the three months ended March 31, 2022. The impairment charge was recognized to write down the properties’ aggregate carrying value to their aggregate fair value, less estimated costs to sell. As of March 31, 2022, the net book value of these 27 properties was $141.7 million, which is comprised of the real estate assets.
The fair value of the assets held for sale was based on estimated sales prices, which are considered to be Level 3 measurements within the fair value hierarchy. Estimated sales prices were determined using a market approach (comparable sales model), which relies on certain assumptions by management, including: (i) comparable market transactions, (ii) estimated prices per unit, and (iii) negotiations with prospective buyers. There are inherent uncertainties in making these assumptions. For the Company’s impairment calculations, the Company’s fair value estimates primarily relied on a market approach and utilized prices per unit ranging from $40,000 to $175,000, with a weighted average price per unit of $91,000.
During the first quarter of 2022, the Company determined that one ALF that was classified as held for sale at December 31, 2021 no longer met the held for sale criteria. The Company reclassified this ALF’s carrying value of $4.8 million out of assets held for sale and recorded catch-up depreciation of approximately $0.1 million during the three months ended March 31, 2022.
On February 22, 2022, the Company closed on the sale of one SNF, operated by affiliates of Cascadia Healthcare, LLC (“Cascadia”), consisting of 83 beds located in Washington with a carrying value of $0.8 million, for net sales proceeds of $1.0 million. During the three months ended March 31, 2022, the Company recorded a gain of $0.2 million in connection with the sale. There was no rent reduction under the Cascadia master lease in connection with the sale.

9

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


5. OTHER REAL ESTATE INVESTMENTS
As of March 31, 2022 and December 31, 2021, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):
As of March 31, 2022
InvestmentFinancial Statement Line Item
Principal Balance as of March 31, 2022
Book Value as of March 31, 2022
Book Value as of December 31, 2021
Weighted Average Contractual Interest RateMaturity Date
Mezzanine loan receivableOther real estate investments$15,000 $15,155 $15,155 12.0 %11/30/2025
Other loans receivablePrepaid expenses and other assets, net5,516 5,523 3,161 8.0 %9/1/2023 - 12/31/2023
Expected credit lossPrepaid expenses and other assets, net(4,594)(4,594) 
Total$15,922 $16,084 $18,316 
Expected credit losses and recoveries are recorded in provision for loan losses, net in the condensed consolidated statements of operations. During the three months ended March 31, 2022, the Company recorded a $4.6 million expected credit loss related to two other loans receivable that were placed on non-accrual status, including an unfunded loan commitment of $0.4 million, net of a loan loss recovery of $0.8 million related to a loan previously written-off. As of December 31, 2021, the Company had no expected credit loss and did not consider any loan receivable investments to be impaired.
The following table summarizes the interest and other income recognized from the Company’s loans receivable and other investments during the quarter ended March 31, 2022 and 2021 (dollars in thousands):
For the Three Months Ended March 31,
Investment20222021
Mezzanine loan receivable$450 $450 
Other19 55 
Total$469 $505 
6. FAIR VALUE MEASUREMENTS
The Company determines fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment. GAAP guidance defines three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.

Level 3 – Unobservable inputs reflect the entity’s own assumptions about the assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.

The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and, depending on various factors, it is possible that an asset or
10

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


liability may be classified differently from quarter to quarter. Changes in the type of inputs may result in a reclassification for certain assets. The Company does not expect that changes in classifications between levels will be frequent.
Items Measured at Fair Value on a Recurring Basis
The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021, aggregated by the level in the fair value hierarchy within which those instruments fall (dollars in thousands):
Level 1Level 2Level 3
Balance as of March 31, 2022
Assets:
Mezzanine loan receivable$ $ $15,155 $15,155 
Level 1Level 2Level 3
Balance as of December 31, 2021
Assets:
Mezzanine loan receivable$ $ $15,155 $15,155 

Mezzanine loan receivable: The fair value of the mezzanine loan receivable was estimated using an internal valuation model that considered the expected future cash flows of the investment, the underlying collateral value, market interest rates and other credit enhancements. As such, the Company classifies the instrument as Level 3 due to the significant unobservable inputs used in determining market interest rates for investments with similar terms. Future changes in market interest rates could materially impact the estimated discounted cash flows. As of March 31, 2022 and December 31, 2021, the Company did not have any loans measured at fair value that were 90 days or more past due.
For the three months ended March 31, 2022, there were no classification changes in assets and liabilities with Level 3 inputs in the fair value hierarchy.

Items Disclosed at Fair Value

Considerable judgment is necessary to estimate the fair value disclosure of financial instruments. The estimates of fair value presented herein are not necessarily indicative of the amounts that could be realized upon disposition of the financial instruments. A summary of the face value, carrying amount and fair value of the Notes (as defined in Note 7, Debt, below) as of March 31, 2022 and December 31, 2021 using Level 2 inputs is as follows (dollars in thousands):  
 March 31, 2022December 31, 2021
 LevelFace
Value
Carrying
Amount
Fair
Value
Face
Value
Carrying
Amount
Fair
Value
Financial liabilities:
Senior unsecured notes payable2$400,000 $394,484 $377,000 $400,000 $394,262 $410,500 

Cash and cash equivalents, accounts and other receivables, accounts payable, and accrued liabilities: The carrying value for these instruments approximate their fair values due to the short-term nature of these instruments.

Senior unsecured notes payable: The fair value of the Notes was determined using third-party quotes derived from orderly trades.

Unsecured revolving credit facility and senior unsecured term loan: The fair values approximate their carrying values as the interest rates are variable and approximate prevailing market interest rates for similar debt arrangements.

11

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


7. DEBT
The following table summarizes the balance of the Company’s indebtedness as of March 31, 2022 and December 31, 2021 (dollars in thousands):
March 31, 2022December 31, 2021
Principal AmountDeferred Loan FeesCarrying ValuePrincipal AmountDeferred Loan FeesCarrying Value
Senior unsecured notes payable$400,000 $(5,516)$394,484 $400,000 $(5,738)$394,262 
Senior unsecured term loan200,000 (811)199,189 200,000 (864)199,136 
Unsecured revolving credit facility105,000  105,000 80,000  80,000 
$705,000 $(6,327)$698,673 $680,000 $(6,602)$673,398 

Senior Unsecured Notes Payable
2028 Senior Notes. On June 17, 2021, the Company’s wholly owned subsidiary, CTR Partnership, L.P. (the “Operating Partnership”), and its wholly owned subsidiary, CareTrust Capital Corp. (together with the Operating Partnership, the “Issuers”) completed a private offering of $400.0 million aggregate principal amount of 3.875% Senior Notes due 2028 (the “Notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended. The Notes were issued at par, resulting in gross proceeds of $400.0 million and net proceeds of approximately $393.8 million after deducting underwriting fees and other offering expenses. The Notes mature on June 30, 2028. The Notes accrue interest at a rate of 3.875% per annum payable semiannually in arrears on June 30 and December 30 of each year, commencing on December 30, 2021.
The Issuers may redeem some or all of the Notes at any time prior to March 30, 2028 at a price equal to 100% of the principal amount of the Notes redeemed plus accrued and unpaid interest on the Notes, if any, to, but not including, the redemption date, plus a “make-whole” premium. At any time on or after March 30, 2028, the Issuers may redeem some or all of the Notes at a redemption price equal to 100% of the principal amount of the Notes redeemed plus accrued interest on the Notes, if any, to, but not including, the redemption date. In addition, at any time on or prior to June 30, 2024, up to 40% of the aggregate principal amount of the Notes may be redeemed with the net proceeds of certain equity offerings at a redemption price of 103.875% of the aggregate principal amount of Notes to be redeemed plus accrued and unpaid interest on the Notes, if any, to, but not including, the redemption date. If certain changes of control of the Company occur, the Issuers will be required to make an offer to holders of the Notes to repurchase their Notes at a price of 101% of their principal amount plus accrued and unpaid interest, if any, to, but not including, the repurchase date.
The obligations under the Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by the Company and all of CareTrust’s existing and future subsidiaries (other than the Issuers) that guarantee obligations under the Amended Credit Facility (as defined below); provided, however, that such guarantees are subject to automatic release under certain customary circumstances.
The indenture governing the Notes contains customary covenants such as limiting the ability of the Company and its restricted subsidiaries to: incur or guarantee additional indebtedness; incur or guarantee secured indebtedness; pay dividends or distributions on, or redeem or repurchase, capital stock; make certain investments or other restricted payments; sell assets; enter into transactions with affiliates; merge or consolidate or sell all or substantially all of their assets; and create restrictions on the ability of the Issuers and their restricted subsidiaries to pay dividends or other amounts to the Issuers. The indenture governing the Notes also requires the Company and its restricted subsidiaries to maintain a specified ratio of unencumbered assets to unsecured indebtedness. These covenants are subject to a number of important and significant limitations, qualifications and exceptions. The indenture governing the Notes also contains customary events of default.
As of March 31, 2022, the Company was in compliance with all applicable financial covenants under the indenture governing the Notes.

Unsecured Revolving Credit Facility and Term Loan
On February 8, 2019, the Operating Partnership, as the borrower, the Company, as guarantor, CareTrust GP, LLC, and certain of the Operating Partnership’s wholly owned subsidiaries entered into an amended and restated credit and guaranty
12

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


agreement with KeyBank National Association, as administrative agent, an issuing bank and swingline lender, and the lenders party thereto (the “Amended Credit Agreement”). The Amended Credit Agreement, which amended and restated the Company’s prior credit agreement, provides for: (i) an unsecured revolving credit facility (the “Revolving Facility”) with revolving commitments in an aggregate principal amount of $600.0 million, including a letter of credit subfacility for 10% of the then available revolving commitments and a swingline loan subfacility for 10% of the then available revolving commitments and (ii) an unsecured term loan credit facility (the “Term Loan” and, together with the Revolving Facility, the “Amended Credit Facility”) in an aggregate principal amount of $200.0 million. Borrowing availability under the Revolving Facility is subject to no default or event of default under the Amended Credit Agreement having occurred at the time of borrowing. Future borrowings under the Amended Credit Facility will be used for working capital purposes, for capital expenditures, to fund acquisitions and for general corporate purposes.
The interest rates applicable to loans under the Revolving Facility are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.10% to 0.55% per annum or LIBOR plus a margin ranging from 1.10% to 1.55% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). The interest rates applicable to loans under the Term Loan are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.50% to 1.20% per annum or LIBOR plus a margin ranging from 1.50% to 2.20% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). In addition, the Operating Partnership will pay a facility fee on the revolving commitments under the Revolving Facility ranging from 0.15% to 0.35% per annum, based on the debt to asset value ratio of the Company and its consolidated subsidiaries (unless the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt and the Operating Partnership elects to decrease the applicable margin as described above, in which case the Operating Partnership will pay a facility fee on the revolving commitments ranging from 0.125% to 0.30% per annum based on the credit ratings of the Company’s senior long-term unsecured debt). As of March 31, 2022, the Operating Partnership had $200.0 million of borrowings outstanding under the Term Loan and $105.0 million outstanding under the Revolving Facility.
The Revolving Facility has a maturity date of February 8, 2023, and includes, at the sole discretion of the Operating Partnership, two, six-month extension options. The Term Loan has a maturity date of February 8, 2026.
The Amended Credit Facility is guaranteed, jointly and severally, by the Company and its wholly owned subsidiaries that are party to the Amended Credit Agreement (other than the Operating Partnership). The Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend organizational documents and pay certain dividends and other restricted payments. The Amended Credit Agreement requires the Company to comply with financial maintenance covenants to be tested quarterly, consisting of a maximum debt to asset value ratio, a minimum fixed charge coverage ratio, a minimum tangible net worth, a maximum cash distributions to operating income ratio, a maximum secured debt to asset value ratio, a maximum secured recourse debt to asset value ratio, a maximum unsecured debt to unencumbered properties asset value ratio, a minimum unsecured interest coverage ratio and a minimum rent coverage ratio. The Amended Credit Agreement also contains certain customary events of default, including the failure to make timely payments under the Amended Credit Facility or other material indebtedness, the failure to satisfy certain covenants (including the financial maintenance covenants), the occurrence of change of control and specified events of bankruptcy and insolvency.
As of March 31, 2022, the Company was in compliance with all applicable financial covenants under the Amended Credit Agreement.

8. EQUITY
Common Stock
At-The-Market Offering—On March 10, 2020, the Company entered into a new equity distribution agreement to issue and sell, from time to time, up to $500.0 million in aggregate offering price of its common stock through an “at-the-market” equity offering program (the “ATM Program”).
13

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


There was no ATM Program activity for the three months ended March 31, 2022. The following table summarizes the ATM Program activity for the three months ended March 31, 2021 (in thousands, except per share amounts).
For the Three Months Ended
March 31, 2021
Number of shares702 
Average sales price per share$23.62 
Gross proceeds(1)
$16,579 
(1) Total gross proceeds is before $0.2 million of commissions paid to the sales agents during the three months ended March 31, 2021 under the ATM Program.
As of March 31, 2022, the Company had $476.5 million available for future issuances under the ATM Program.
Share Repurchase Program—On March 20, 2020, the Company’s Board of Directors authorized a share repurchase program for up to $150.0 million of outstanding shares of the Company’s common stock (the “Repurchase Program”). Repurchases under the Repurchase Program, which expires on March 31, 2023, may be made through open market purchases, privately negotiated transactions, structured or derivative transactions, including accelerated share repurchase transactions, or other methods of acquiring shares, in each case subject to market conditions and at such times as shall be permitted by applicable securities laws and determined by management. Repurchases under the Repurchase Program may also be made pursuant to a plan adopted under Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. The Company expects to finance any share repurchases under the Repurchase Program using available cash and may also use short-term borrowings under the Revolving Facility. Through March 31, 2022, the Company has not repurchased any shares of common stock under the Repurchase Program. As of March 31, 2022, $150.0 million remained available under the Repurchase Program. The Repurchase Program may be modified, discontinued or suspended at any time.
Dividends on Common StockThe following table summarizes the cash dividends per share of common stock declared by the Company’s Board of Directors for the first quarter of 2022 (dollars in thousands, except per share amounts):
For the Three Months Ended
March 31, 2022
Dividends declared per share$0.275 
Dividends payment dateApril 15, 2022
Dividends payable as of record date$26,691 
Dividends record dateMarch 31, 2022

9. STOCK-BASED COMPENSATION
All stock-based awards are subject to the terms of the CareTrust REIT, Inc. and CTR Partnership, L.P. Incentive Award Plan (the “Plan”). The Plan provides for the granting of stock-based compensation, including stock options, restricted stock, performance awards, restricted stock units, relative total stockholder return based stock awards (“TSR Awards”) and other incentive awards to officers, employees and directors in connection with their employment with or services provided to the Company. Under the Plan, 5,000,000 shares have been authorized for awards.
Under the Plan, restricted stock awards (“RSAs”) granted in fiscal 2022 vest in equal annual installments beginning on the first anniversary of the grant date over a three year period.
The following table summarizes the RSAs and performance award activity for the three months ended March 31, 2022:
SharesWeighted Average Share Price
Unvested balance at December 31, 2021891,333 $20.91 
Granted:
RSAs9,684 17.56 
Vested(329,080)20.10 
Forfeited(1,900)21.50 
Unvested balance at March 31, 2022570,037 $21.32 
14

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


As of March 31, 2022, the weighted-average remaining vesting period of such awards was 1.6 years.
The following table summarizes the stock-based compensation expense recognized (dollars in thousands):
 For the Three Months Ended March 31,
 20222021
Stock-based compensation expense$1,521 $1,585 
As of March 31, 2022, there was $10.0 million of unamortized stock-based compensation expense related to the unvested RSAs, performance stock awards and TSR Awards.
10. (LOSS) EARNINGS PER COMMON SHARE
The following table presents the calculation of basic and diluted (loss) earnings per common share (“EPS”) for the Company’s common stock for the three months ended March 31, 2022 and 2021, and reconciles the weighted-average common shares outstanding used in the calculation of basic EPS to the weighted-average common shares outstanding used in the calculation of diluted EPS (amounts in thousands, except per share amounts):
 
 For the Three Months Ended March 31,
 20222021
Numerator:
Net (loss) income$(43,264)$20,486 
Less: Net income allocated to participating securities(117)(119)
Numerator for basic and diluted earnings available to common stockholders$(43,381)$20,367 
Denominator:
Weighted-average basic common shares outstanding96,410 95,378 
Dilutive performance stock awards 7 
Weighted-average diluted common shares outstanding96,410 95,385 
(Loss) earnings per common share, basic$(0.45)$0.21 
(Loss) earnings per common share, diluted$(0.45)$0.21 
Antidilutive unvested RSAs, performance awards and TSR Awards excluded from the computation534 446 
11. COMMITMENTS AND CONTINGENCIES
The Company and its subsidiaries are and may become from time to time a party to various claims and lawsuits arising in the ordinary course of business, which are not individually or in the aggregate anticipated to have a material adverse effect on the Company’s results of operations, financial condition or cash flows. Claims and lawsuits may include matters involving general or professional liability asserted against the Company’s tenants, which are the responsibility of the Company’s tenants and for which the Company is entitled to be indemnified by its tenants under the insurance and indemnification provisions in the applicable leases.
Capital expenditures for each property leased under the Company’s triple-net leases are generally the responsibility of the tenant, except that, for the facilities leased to subsidiaries of Ensign and Pennant, the tenant will have an option to require the Company to finance certain capital expenditures up to an aggregate of 20% of the Company’s initial investment in such property, subject to a corresponding rent increase at the time of funding. For the Company’s other triple-net master leases, the tenants also have the option to request capital expenditure funding that would generally be subject to a corresponding rent increase at the time of funding, which are subject to tenant compliance with the conditions to the Company’s approval and funding of their requests. As of March 31, 2022, the Company had committed to fund expansions, construction and capital improvements at certain triple-net leased facilities totaling $5.5 million, of which $4.4 million is subject to rent increase at the time of funding.

15

CARETRUST REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS —
(Unaudited)


12. CONCENTRATION OF RISK
Concentrations of credit risk arise when one or more tenants, operators, or obligors related to the Company’s investments are engaged in similar business activities or activities in the same geographic region, or have similar economic features that would cause their ability to meet contractual obligations, including those to the Company, to be similarly affected by changes in economic conditions.
Major operator concentration - The Company has operators from which it derived 10% or more of its rental revenue for the three months ended March 31, 2022 and 2021. The following table sets forth information regarding the Company’s major operators as of March 31, 2022 and 2021:
 Number of FacilitiesNumber of Beds/Units
Percentage of Total Revenue(1)
Operator(2)
SNFCampusALF/ILFSNFCampusALF/ILF
March 31, 2022
Ensign83 85 8,756 997495 34 %
Priority Management Group13 2 1,742 402 16 %
March 31, 2021
Ensign77 84 8,129 1,027 395 32 %
Priority Management Group13 2 1,742 402  16 %
(1)    The Company’s rental income, exclusive of operating expense reimbursements.
(2)    Ensign is subject to the registration and reporting requirements of the SEC and is required to file with the SEC annual reports containing audited financial information and quarterly reports containing unaudited financial information. Ensign’s financial statements, as filed with the SEC, can be found at http://www.sec.gov. The Company has not verified this information through an independent investigation or otherwise.
Major geographic concentration – The following table provides information regarding the Company’s concentrations with respect to certain states, from which the Company derived 10% or more of its rental revenue for the three months ended March 31, 2022:
 Number of FacilitiesNumber of Beds/Units
Percentage of Total Revenue(1)
StateSNFCampusALF/ILFSNFCampusALF/ILF
CA27 85 3,048 1,359 449 26 %
TX38 33 4,829 536242 22 %
(1)    The Company’s rental income, exclusive of operating expense reimbursements.
16

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Forward-Looking Statements
Certain statements in this report may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Those forward-looking statements include all statements that are not historical statements of fact and those regarding our intent, belief or expectations, including, but not limited to, statements regarding: future financing plans, business strategies, growth prospects and operating and financial performance; expectations regarding the making of distributions and the payment of dividends; and compliance with and changes in governmental regulations.

Words such as “anticipate(s),” “expect(s),” “intend(s),” “plan(s),” “believe(s),” “may,” “will,” “would,” “could,” “should,” “seek(s)” and similar expressions, or the negative of these terms, are intended to identify such forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks and uncertainties that could lead to actual results differing materially from those projected, forecasted or expected. Although we believe that the assumptions underlying the forward-looking statements are reasonable, we can give no assurance that our expectations will be attained. Factors which could have a material adverse effect on our operations and future prospects or which could cause actual results to differ materially from our expectations include, but are not limited to: (i) the COVID-19 pandemic, including the risk of additional surges of COVID-19 infections due to the rate of public acceptance and efficacy of COVID-19 vaccines or to new and more contagious and/or vaccine resistant variants, and the measures taken to prevent the spread of COVID-19 and the related impact on our business or the businesses of our tenants; (ii) the ability and willingness of our tenants to meet and/or perform their obligations under the triple-net leases we have entered into with them, including, without limitation, their respective obligations to indemnify, defend and hold us harmless from and against various claims, litigation and liabilities; (iii) the risk that we may have to incur additional impairment charges related to our assets held for sale if we are unable to sell such assets at the prices we expect; (iv) the ability of our tenants to comply with applicable laws, rules and regulations in the operation of the properties we lease to them; (v) the ability and willingness of our tenants to renew their leases with us upon their expiration, and the ability to reposition our properties on the same or better terms in the event of nonrenewal or in the event we replace an existing tenant, as well as any obligations, including indemnification obligations, we may incur in connection with the replacement of an existing tenant; (vi) the availability of and the ability to identify (a) tenants who meet our credit and operating standards, and (b) suitable acquisition opportunities, and the ability to acquire and lease the respective properties to such tenants on favorable terms; (vii) the ability to generate sufficient cash flows to service our outstanding indebtedness; (viii) access to debt and equity capital markets; (ix) fluctuating interest rates; (x) the ability to retain our key management personnel; (xi) the ability to maintain our status as a real estate investment trust (“REIT”); (xii) changes in the U.S. tax law and other state, federal or local laws, whether or not specific to REITs; (xiii) other risks inherent in the real estate business, including potential liability relating to environmental matters and illiquidity of real estate investments; and (xiv) any additional factors included under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021, including in the section entitled “Risk Factors” in Item 1A of Part I of such report, as such risk factors may be amended, supplemented or superseded from time to time by other reports we file with the Securities and Exchange Commission (the “SEC”).
Forward-looking statements speak only as of the date of this report. Except in the normal course of our public disclosure obligations, we expressly disclaim any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any statement is based.
Overview
CareTrust REIT is a self-administered, publicly-traded REIT engaged in the ownership, acquisition, financing, development and leasing of skilled nursing, seniors housing and other healthcare-related properties. As of March 31, 2022, we owned and leased to independent operators, 228 skilled nursing facilities (“SNFs”), multi-service campuses, assisted living facilities (“ALFs”) and independent living facilities (“ILFs”) consisting of 23,834 operational beds and units located in 29 states with the highest concentration of properties by rental revenues located in California, Texas, Louisiana, Idaho and Arizona. As of March 31, 2022, we also had other real estate investments consisting of one mezzanine loan receivable with a carrying value of $15.2 million.
We generate revenues primarily by leasing healthcare-related properties to healthcare operators in triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property (including property taxes, insurance, maintenance and repair costs and capital expenditures, subject to certain exceptions in the case of properties leased to Ensign and Pennant). From time to time, we also extend secured mortgage loans to healthcare operators, secured by healthcare-related properties, and secured mezzanine loans to healthcare operators, secured by membership interests in healthcare-related properties. We conduct and manage our business as one operating segment for internal reporting and internal decision-making
17

purposes. We expect to grow our portfolio by pursuing opportunities to acquire additional properties that will be leased to a diverse group of local, regional and national healthcare providers, which may include new or existing skilled nursing operators, as well as seniors housing operators, behavioral health facilities and related businesses. We also anticipate diversifying our portfolio over time, including by acquiring properties in different geographic markets, and in different asset classes. In addition, we actively monitor the clinical, regulatory and financial operating results of our tenants, and work to identify opportunities within their operations and markets that could improve their operating results at our facilities. We communicate such observations to our tenants; however, we have no contractual obligation to do so. Moreover, our tenants have sole discretion with respect to the day-to-day operation of the facilities they lease from us, and how and whether to implement any observation we may share with them. We also actively monitor the overall occupancy, skilled mix, and other operating metrics of our tenants on at least a monthly basis including, beginning in the quarter ended June 30, 2020, any stimulus funds received by each tenant. We have replaced tenants in the past, and may elect to replace tenants in the future, if they fail to meet the terms and conditions of their leases with us. The replacement tenants may include tenants with whom we have had no prior landlord-tenant relationship as well as current tenants with whom we are comfortable expanding our relationships. We have also provided select tenants with strategic capital for facility upkeep and modernization, as well as short-term working capital loans when they are awaiting licensure and certification or conducting turnaround work in one or more of our properties, and we may continue to do so in the future. In addition, we periodically reassess the investments we have made and the tenant relationships we have entered into, and have selectively disposed of facilities or investments, or terminated such relationships, and we expect to continue making such reassessments and, where appropriate, taking such actions.

Recent Developments

COVID-19 and Market Conditions Update
Tenants of our properties operating pursuant to triple-net master leases have been adversely impacted, and we expect that they will continue to be adversely impacted, by the COVID-19 pandemic. Our tenants are experiencing increased operating costs as a result of actions they are taking to prevent or mitigate the outbreak or spread of COVID-19 at their facilities, including in connection with their implementation of safety protocols and procedures and other regulatory requirements. Our tenants are also experiencing labor shortages resulting in limited admissions, reduced occupancy and higher agency expense.

At a portfolio wide level, occupancy levels at our seniors housing facilities remained relatively stable from the onset of the COVID-19 pandemic until the beginning of the fourth quarter of 2020, at which time we began to see a decline. This decline in occupancy continued through the first quarter of 2021 then remained flat through the fourth quarter of 2021. Seniors housing occupancy modestly increased during the first quarter of 2022 compared to the fourth quarter of 2021. Occupancy levels at our SNFs, which declined at the onset of the COVID-19 pandemic and continued to decline through January 2021, had been on a slow incline from February through December 2021. SNF occupancy held stable during the first quarter of 2022 compared to the fourth quarter of 2021. Beginning in early 2020, the federal government temporarily suspended the three-day hospital stay requirement for a patient’s Medicare benefits to refresh. Providers can now “skill in place,” eliminating the risk of transferring the patient to the hospital. Because of the temporary waiver of the three-day hospital stay requirement, overall skilled mix remained slightly elevated in the three months ended March 31, 2022 compared to the pre-pandemic skilled mix during the three months ended March 31, 2020. An increase in skilled mix can, but may not necessarily, offset some or all of the adverse financial impact to the operator of the SNF from a decline in occupancy. However, the skilled mix in our SNFs during the three months ended March 31, 2022 was lower than the peak level seen in December 2020, and we anticipate that the skilled mix in our SNFs will continue to decline as cases of COVID-19 decline or if the suspension of the three-day hospital stay requirement is lifted.
The U.S. Department of Health and Human Services (“HHS”) recently renewed the COVID-19 Public Health Emergency, which is currently set to be in force through July 2022, and that allows HHS to continue providing temporary regulatory waivers, including the waiver of the three-day hospital stay requirement for a patient’s Medicare benefits to refresh. The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) included a temporary suspension of a 2% Medicare sequestration cut through the end of March 2022. Beginning April 1, 2022, a 1% sequestration cut went into effect through June 30, 2022 with the full 2% cut resuming thereafter. A temporary increase in Federal Medical Assistance Percentages, which was approved retroactive to January 1, 2020, is effective through June 30, 2022.
The current limited availability or unavailability of grants and other funds being made available to our seniors housing facilities for healthcare related expenses or lost revenues attributable to COVID-19, as well as the tapering of grants and other funds for our SNFs, has also impacted some of our tenants’ ability to continue to meet some of their financial obligations, as they continue to experience lower occupancy levels and higher operating costs.
18

As a result of the foregoing impacts of the COVID-19 pandemic, our tenants’ ability to continue to meet some of their financial obligations to us has been negatively impacted. See “Impairment of Real Estate Assets, Assets Held for Sale and Asset Sales” below. During the three months ended March 31, 2022, we collected 94.9% of contractual rents due from our operators including cash deposits used to offset rent shortfalls, and 91.8% excluding cash deposits. During the three months ended March 31, 2022, we determined that it was not probable that we would collect substantially all of the contractual obligations from four existing and former operators and, accordingly, we reversed $0.7 million of operating expense reimbursements, $0.2 million of contractual rent and $0.1 million of straight-line rent. In addition, we determined that the collectibility of contractual rents from two operators is not reasonably assured and we moved these two operators to a cash basis method of accounting during the three months ended March 31, 2022. Approximately 93.2% of our contractual rent obligations due for April 2022 have been collected and no cash deposits on hand were applied.
For more information regarding the potential impact of COVID-19 on our business, see “Risk Factors” in Item 1A of Part I of our Annual Report on Form 10-K for the year ended December 31, 2021.
On April 11, 2022, the Centers for Medicare and Medicaid Services (“CMS”) issued a proposed rule that would decrease the aggregate net payment by 0.7% for fiscal year 2023. CMS estimates that the aggregate impact of the payment policies in the proposed rule would result in a decrease of approximately $320 million in Medicare Part A payments to SNFs in fiscal year 2023 compared to fiscal year 2022.

Impairment of Real Estate Assets, Assets Held for Sale and Asset Sales
In connection with our ongoing review and monitoring of our investment portfolio and the performance of our tenants, we determined to pursue the sale of 27 properties and repurposing three properties, representing an aggregate of approximately 10% of contractual cash rent as of March 31, 2022. As of March 31, 2022, we determined that these 27 properties met the criteria to be classified as assets held for sale and, in connection with this determination, we recognized an aggregate impairment charge of $59.7 million related to 20 of the 27 held for sale properties, which is reported in impairment of real estate investments in the condensed consolidated statements of operations for the three months ended March 31, 2022. The impairment charge was recognized to write down the properties’ aggregate carrying value to their aggregate fair value, less estimated costs to sell. As of March 31, 2022, the net book value of these 27 properties was $141.7 million.
During the first quarter of 2022, we determined that one ALF that was classified as held for sale at December 31, 2021 no longer met the held for sale criteria. We reclassified this ALF’s carrying value of $4.8 million out of assets held for sale and recorded catch-up depreciation of approximately $0.1 million during the three months ended March 31, 2022.

During the first quarter of 2022, we closed on the sale of one SNF consisting of 83 beds located in Washington with a carrying value of $0.8 million, for net sales proceeds of $1.0 million. During the three months ended March 31, 2022, we recorded a gain of $0.2 million in connection with the sale.

Recent Investments
From January 1, 2022 through May 5, 2022, we acquired 1 SNF and 1 multi-service campus for approximately $21.9 million, which includes capitalized acquisition costs. These acquisitions are expected to generate initial annual cash revenues of approximately $2.1 million and an initial blended yield of approximately 9.4%. See Note 3, Real Estate Investments, Net in the Notes to condensed consolidated financial statements for additional information.

19

At-The-Market Offering of Common Stock
On March 10, 2020, we entered into a new equity distribution agreement to issue and sell, from time to time, up to $500.0 million in aggregate offering price of our common stock through an “at-the-market” equity offering program (the “ATM Program”).
There was no ATM Program activity for the three months ended March 31, 2022. The following table summarizes the ATM Program activity for the three months ended March 31, 2021 (in thousands, except per share amounts).
For the Three Months Ended
March 31, 2021
Number of shares702 
Average sales price per share$23.62 
Gross proceeds(1)
$16,579 
(1) Total gross proceeds is before $0.2 million of commissions paid to the sales agents during the three months ended March 31, 2021 under the ATM Program.
As of March 31, 2022, we had $476.5 million available for future issuances under the ATM Program.

Results of Operations
In the first quarter of 2022, we elected to discuss any material changes in our results of operations by comparing our most recently completed quarter to the immediately preceding sequential quarter, as permitted under the recently amended Item 303 of Regulation S-K. Because our business is not seasonal, we believe this comparison provides a more relevant and informative representation of the changes to our results of operations over time. For purposes of this Quarterly Report on Form 10-Q, we also continue to discuss any material changes in our results of operations for the most recently completed quarter compared to the corresponding prior year period pursuant to Item 303 of Regulation S-K.
Operating Results
Three Months Ended March 31, 2022 Compared to Three Months Ended December 31, 2021:
 Three Months EndedIncrease
(Decrease)
Percentage
Difference
 March 31, 2022December 31, 2021
 (dollars in thousands)
Revenues:
Rental income$46,007 $49,118 $(3,111)(6)%
Interest and other income469 619 (150)(24)%
Expenses:
Depreciation and amortization13,575 14,056 (481)(3)%
Interest expense5,742 5,689 53 %
Property taxes1,420 1,108 312 28 %
Impairment of real estate investments59,683 — 59,683 *
Provision for loan losses, net3,844 — 3,844 *
Property operating expenses447 — 447 *
General and administrative5,215 10,738 (5,523)(51)%
Other income:
Gain on sale of real estate186 115 71 62 %
Not meaningful     
Rental income. The $3.1 million, or 6%, decrease in rental income is primarily due to a $2.6 million decrease in rental income and tenant reimbursements related to moving certain tenants to a cash basis method of accounting, a $1.0 million write-off of uncollectible rent, and a $0.1 million decrease in tenant reimbursements, partially offset by an increase of $0.3 million due to contractual increases in rental rates for our existing tenants and $0.2 million from real estate investments made after October 1, 2021.
Interest and other income. The $0.2 million, or 24%, decrease in interest and other income was primarily due to a decrease of $0.1 million related to a forfeited sales deposit recognized in the three months ended December 31, 2021 and a
20

decrease of $0.1 million due to placing one other loan receivable on non-accrual status during the three months ended March 31, 2022.
Depreciation and amortization. The $0.5 million, or 3%, decrease in depreciation and amortization was primarily due to a decrease of $0.5 million due to assets reclassified as held for sale and a decrease of $0.2 million due to assets becoming fully depreciated after October 1, 2021, partially offset by an increase of $0.2 million related to new real estate investments and capital improvements made after October 1, 2021.
Interest expense. The $0.1 million, or 1%, increase in interest expense was primarily due to a higher weighted average debt balance and a higher interest rate under the Revolving Facility during the three months ended March 31, 2022.
Property taxes. The $0.3 million, or 28%, increase in property taxes was primarily due to changes in estimates of property taxes expected to be paid directly by us as a result of certain assets being designated as held for sale during the three months ended March 31, 2022.
Impairment of real estate investments. During the three months ended March 31, 2022, we recognized an aggregate impairment charge of $59.7 million related to 20 properties that all met the held for sale criteria during the quarter. See above under “Recent Developments” for additional information. No impairment charges were recognized during the three months ended December 31, 2021.
Provision for loan losses, net. During the three months ended March 31, 2022, we recorded a $4.6 million expected credit loss related to two other loans receivable that were placed on a non-accrual status, partially offset by a $0.8 million recovery related to one other loan receivable that was previously written off.
Property operating expenses. During the three months ended March 31, 2022, we recognized $0.5 million of property operating expenses related to assets we plan to sell or repurpose. No similar expenses were incurred during the three months ended December 31, 2021.
General and administrative expense. The $5.5 million, or 51%, decrease in general and administrative expense was primarily related to a decrease in stock compensation expense of $4.1 million and a decrease in non-routine transaction costs of $1.4 million during the three months ended March 31, 2022 compared to the three months ended December 31, 2021.
Gain on sale of real estate. During the three months ended March 31, 2022, we recorded a $0.2 million gain on sale of real estate related to the sale of one SNF. During the three months ended December 31, 2021, we recorded a $0.1 million gain on sale of real estate related to the sale of one land parcel.
21


Three Months Ended March 31, 2022 Compared to Three Months Ended March 31, 2021:
 Three Months Ended March 31,Increase
(Decrease)
Percentage
Difference
 20222021
 (dollars in thousands)
Revenues:
Rental income$46,007 $45,246 $761 %
Interest and other income469 505 (36)(7)%
Expenses:
Depreciation and amortization13,575 13,473 102 %
Interest expense5,742 5,762 (20)— %
Property taxes1,420 696 724 104 %
Impairment of real estate investments59,683 — 59,683 *
Provision for loan losses, net3,844 — 3,844 *
Property operating expenses447 — 447 *
General and administrative5,215 5,142 73 %
Other income (loss):
Gain (loss) on sale of real estate186 (192)378 (197)%
Not meaningful     
Rental income. The $0.8 million, or 2%, increase in rental income is primarily due to a $2.9 million increase in rental income from real estate investments made after January 1, 2021, $0.8 million due to contractual increases in rental rates for our existing tenants and a $0.3 million increase in tenant reimbursements, partially offset by a $2.2 million decrease in rental income and tenant reimbursements related to moving certain tenants to a cash basis method of accounting and a $1.0 million write-off of uncollectible rent.
Interest and other income. The $36,000, or 7%, decrease in interest and other income is primarily due to placing one other loan receivable on non-accrual status during the three months ended March 31, 2022.
Depreciation and amortization. The $0.1 million, or 1%, increase in depreciation and amortization was primarily due to an increase in depreciation and amortization of $1.2 million related to new real estate investments and capital improvements made after January 1, 2021, partially offset by a decrease in depreciation of $0.6 million due to assets becoming fully depreciated after January 1, 2021 and a $0.5 million decrease from assets reclassified as held for sale
Interest expense. Interest expense decreased by $20,000 during the three months ended March 31, 2022 compared to the three months ended March 31, 2021 due to the redemption in full of our 5.25% Senior Notes due 2025 in July 2021, offset by the issuance in June 2021 of our Notes at a lower interest rate.
Property taxes. The $0.7 million, or 104%, increase in property taxes was primarily due to a $0.3 million increase due to changes in estimates of property taxes expected to be paid directly by us as a result of certain assets being designated as held for sale during the three months ended March 31, 2022, a $0.3 million increase due to new real estate investments made after January 1, 2021 and a $0.1 million increase related to the transfer of certain properties to new operators that do not make direct tax payments.
Impairment of real estate investments. During the three months ended March 31, 2022, we recognized an aggregate impairment charge of $59.7 million related to 20 properties that all met the held for sale criteria during the quarter. See above under “Recent Developments” for additional information. No impairment charges were recognized during the three months ended March 31, 2021.
Provision for loan losses, net. During the three months ended March 31, 2022, we recorded a $4.6 million expected credit loss related to two other loans receivable that were placed on non-accrual status, partially offset by a $0.8 million recovery related to one other loan receivable that was previously written off.
22

Property operating expenses. During the three months ended March 31, 2022, we recognized $0.5 million of property operating expenses related to assets we plan to sell or repurpose. No similar expenses were incurred during the three months ended March 31, 2021.
General and administrative expense. The $0.1 million, or 1%, increase in general and administrative expense was primarily related to higher cash wages of $0.3 million, partially offset by lower professional services expense of $0.1 million and lower stock compensation expense of $0.1 million during the three months ended March 31, 2022 compared to the three months ended March 31, 2021.
Gain (loss) on sale of real estate. During the three months ended March 31, 2022, we recorded a $0.2 million gain on sale of real estate related to the sale of one SNF. During the three months ended March 31, 2021, we recorded a $0.2 million loss on sale of real estate related to the sale of one SNF.
Liquidity and Capital Resources
To qualify as a REIT for federal income tax purposes, we are required to distribute at least 90% of our REIT taxable income, determined without regard to the dividends paid deduction and excluding any net capital gains, to our stockholders on an annual basis. Accordingly, we intend to make, but are not contractually bound to make, regular quarterly dividends to common stockholders from cash flow from operating activities. All such dividends are at the discretion of our board of directors.
Our short-term liquidity requirements consist primarily of operating and interest expenses directly associated with our properties, including:
interest expense and scheduled debt maturities on outstanding indebtedness;
general and administrative expenses;
dividend plans;
operating lease obligations; and
capital expenditures for improvements to our properties.
Our long-term liquidity needs consist primarily of funds necessary to pay for acquisitions, capital expenditures, and scheduled debt maturities. We intend to invest in and/or develop additional healthcare and seniors housing properties as suitable opportunities arise and so long as adequate sources of financing are available. We expect that future investments in and/or development of properties, including any improvements or renovations of current or newly-acquired properties, will depend on and will be financed by, in whole or in part, our existing cash, borrowings available to us under the Amended Credit Facility (as defined below), future borrowings or the proceeds from sales of shares of our common stock pursuant to our ATM Program or additional issuances of common stock or other securities. In addition, we may seek financing from U.S. government agencies, including through Fannie Mae and the U.S. Department of Housing and Urban Development, in appropriate circumstances in connection with acquisitions and refinancing of existing mortgage loans.
We believe that our expected operating cash flow from rent collections, interest payments on our other real estate investments, and borrowings under our Amended Credit Facility, together with our cash balance of $26.6 million, available borrowing capacity of $495.0 million under the Revolving Facility (as defined below) and availability under the ATM Program of $476.5 million, each at March 31, 2022, will be sufficient to meet ongoing debt service requirements, dividend plans, operating lease obligations, capital expenditures, working capital requirements and other needs for at least the next 12 months. We expect to meet our long-term liquidity needs with cash flows from operations and financing arrangements. While we are currently pursuing the sale, re-tenanting or repurposing of certain of our assets in connection with our ongoing review and monitoring of our investment portfolio as described under “Recent Developments” above, we currently do not expect to sell any of our properties to meet liquidity needs, although we may do so in the future. Our quarterly cash dividend, any share repurchases under our Repurchase Program (as defined below) and any failure of our operators to pay rent may impact our available capital resources.
On March 20, 2020, our board of directors authorized a share repurchase program to repurchase up to $150.0 million of outstanding shares of our common stock (the “Repurchase Program”). Repurchases under the Repurchase Program, which expires on March 31, 2023, may be made through open market purchases, privately negotiated transactions, structured or derivative transactions, including accelerated share repurchase transactions, or other methods of acquiring shares, in each case subject to market conditions and at such times as shall be permitted by applicable securities laws and determined by management. Repurchases under the Repurchase Program may also be made pursuant to a plan adopted under Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We expect to finance any share repurchases under the Repurchase Program using available cash and may also use short-term borrowings under the Revolving Facility. Through March 31, 2022, we have not repurchased any shares of common stock under the Repurchase Program and, as
23

of March 31, 2022, we had $150.0 million of remaining authorization under the Repurchase Program. The Repurchase Program may be modified, discontinued or suspended at any time.
We have filed an automatic shelf registration statement with the U.S. Securities and Exchange Commission that expires in March 2023, which will allow us or certain of our subsidiaries, as applicable, to offer and sell shares of common stock, preferred stock, warrants, rights, units and debt securities through underwriters, dealers or agents or directly to purchasers, in one or more offerings on a continuous or delayed basis, in amounts, at prices and on terms we determine at the time of the offering.
Although we are subject to restrictions on our ability to incur indebtedness, we expect that we will be able to refinance existing indebtedness or incur additional indebtedness for acquisitions or other purposes, if needed. However, there can be no assurance that we will be able to refinance our indebtedness, incur additional indebtedness or access additional sources of capital, such as by issuing common stock or other debt or equity securities, on terms that are acceptable to us or at all.
We currently are in compliance with all debt covenants on our outstanding indebtedness.
Cash Flows
The following table presents selected data from our condensed consolidated statements of cash flows for the periods presented (dollars in thousands):
 For the Three Months Ended March 31,
 20222021
 
Net cash provided by operating activities$34,579 $33,949 
Net cash used in investing activities(24,072)(133,300)
Net cash (used in) provided by financing activities(3,816)110,901 
Net increase in cash and cash equivalents6,691 11,550 
Cash and cash equivalents as of the beginning of period19,895 18,919 
Cash and cash equivalents as of the end of period$26,586 $30,469 
Net cash provided by operating activities increased $0.6 million for the three months ended March 31, 2022 compared to the three months ended March 31, 2021. Operating cash inflows are derived primarily from the rental payments received under our lease agreements, including as a result of new investments, and interest payments on our other real estate investments. Operating cash outflows consist primarily of interest expense on our borrowings and general and administrative expenses. The net increase of $0.6 million in cash provided by operating activities for the three months ended March 31, 2022 is primarily due to increased rental payments as a result of new investments, partially offset by moving certain tenants to a cash basis method of accounting and an increase in cash paid for general and administrative expenses.
Cash used in investing activities for the three months ended March 31, 2022 was primarily comprised of $24.0 million in acquisitions of real estate and investments in other loans and $1.9 million of purchases of equipment, furniture and fixtures and improvements to real estate, partially offset by $1.0 million in net proceeds from real estate sales and $0.9 million of payments received from other loans receivable. Cash used in investing activities for the three months ended March 31, 2021 was primarily comprised of $138.9 million in acquisitions of real estate and investments in other loans and $1.3 million of purchases of equipment, furniture and fixtures and improvements to real estate, partially offset by $6.8 million in net proceeds from real estate sales and $0.1 million of payments received from other loans receivable.
Our cash flows used in financing activities for the three months ended March 31, 2022 were primarily comprised of $26.0 million in dividends paid and a $2.8 million net settlement adjustment on restricted stock, partially offset by $25.0 million in borrowings under our Amended Credit Facility (as defined below). Our cash flows provided by financing activities for the three months ended March 31, 2021 were primarily comprised of $120.0 million in borrowings under our Amended Credit Facility and $16.2 million of net proceeds from the issuance of common stock under our ATM Program, partially offset by $24.0 million in dividends paid and a $1.3 million net settlement adjustment on restricted stock.
24

Material Cash Requirements
Our material cash requirements from known contractual and other obligations, including commitments for capital expenditures, include:
3.875% Senior Unsecured Notes due 2028
On June 17, 2021, the Issuers completed a private offering of $400.0 million aggregate principal amount of 3.875% Senior Notes due 2028. The Notes accrue interest at a rate of 3.875% per annum payable semiannually in arrears on June 30 and December 30 of each year, commencing on December 30, 2021. As of March 31, 2022, we were in compliance with all applicable financial covenants under the indenture governing the Notes. See Note 7, Debt, to our condensed consolidated financial statements included in this report for further information about the Notes.
Unsecured Revolving Credit Facility and Term Loan
Our amended and restated credit and guaranty agreement with KeyBank National Association, as administrative agent, an issuing bank and swingline lender, and the lenders party thereto (the “Amended Credit Agreement”) provides for: (i) an unsecured revolving credit facility (the “Revolving Facility”) with revolving commitments in an aggregate principal amount of $600.0 million, including a letter of credit subfacility for 10% of the then available revolving commitments and a swingline loan subfacility for 10% of the then available revolving commitments and (ii) an unsecured term loan credit facility (the “Term Loan” and, together with the Revolving Facility, the “Amended Credit Facility”) in an aggregate principal amount of $200.0 million. Future borrowings under the Amended Credit Facility will be used for working capital purposes, for capital expenditures, to fund acquisitions and for general corporate purposes.
As of March 31, 2022, we had $200.0 million outstanding under the Term Loan and $105.0 million outstanding under the Revolving Facility. The Revolving Facility has a maturity date of February 8, 2023, and includes, at our sole discretion, two, six-month extension options. The Term Loan has a maturity date of February 8, 2026.
The interest rates applicable to loans under the Revolving Facility are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.10% to 0.55% per annum or LIBOR plus a margin ranging from 1.10% to 1.55% per annum based on the debt to asset value ratio of our consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if we obtain certain specified investment grade ratings on our senior long-term unsecured debt). The interest rates applicable to loans under the Term Loan are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.50% to 1.20% per annum or LIBOR plus a margin ranging from 1.50% to 2.20% per annum based on the debt to asset value ratio of our consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if we obtain certain specified investment grade ratings on our senior long-term unsecured debt). In addition, the Operating Partnership will pay a facility fee on the revolving commitments under the Revolving Facility ranging from 0.15% to 0.35% per annum, based on the debt to asset value ratio of our consolidated subsidiaries (unless we obtain certain specified investment grade ratings on our senior long-term unsecured debt and the Operating Partnership elects to decrease the applicable margin as described above, in which case the Operating Partnership will pay a facility fee on the revolving commitments ranging from 0.125% to 0.30% per annum based off the credit ratings of our senior long-term unsecured debt). Interest payments on the Term Loan and Revolving Facility are due monthly and facility fee payments are due quarterly.
As of March 31, 2022, we were in compliance with all applicable financial covenants under the Amended Credit Agreement. See Note 7, Debt, to our condensed consolidated financial statements included in this report for further information about the Amended Credit Agreement.
Capital Expenditures
As of March 31, 2022, we had committed to fund expansions, construction and capital improvements at certain triple-net leased facilities totaling $5.5 million, of which $4.4 million is subject to rent increase at the time of funding. We expect to fund the capital expenditures in the next one to two years. See Note 11, Commitments and Contingencies, to our condensed consolidated financial statements included in this report for further information regarding our obligation to finance certain capital expenditures under our triple-net leases.
Dividend Plans
We are required to pay dividends in order to maintain our REIT status and we expect to make quarterly dividend payments in cash with the annual dividend amount no less than 90% of our annual REIT taxable income, determined without regard to the dividends paid deduction and excluding any net capital gains. See Note 8, Equity, to our condensed consolidated
25

financial statements included in this report for a summary of the cash dividends per share of our common stock declared by our Board of Directors for the three months ended March 31, 2022.
Critical Accounting Policies and Estimates
Our condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information set forth in the Accounting Standards Codification, as published by the Financial Accounting Standards Board. GAAP requires us to make estimates and assumptions regarding future events that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. We base these estimates on our experience and assumptions we believe to be reasonable under the circumstances. However, if our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, we may have applied a different accounting treatment, resulting in a different presentation of our financial statements. We periodically reevaluate our estimates and assumptions, and in the event they prove to be different from actual results, we make adjustments in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Please refer to “Critical Accounting Policies and Estimates” in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 16, 2022, for further information regarding the critical accounting policies that affect our more significant estimates and judgments used in the preparation of our condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. There have been no material changes in such critical accounting policies during the three months ended March 31, 2022.
 
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Our primary market risk exposure is interest rate risk with respect to our variable rate indebtedness.
Our Amended Credit Agreement provides for revolving commitments in an aggregate principal amount of $600.0 million and an unsecured term loan facility in an aggregate principal amount of $200.0 million from a syndicate of banks and other financial institutions.
The interest rates applicable to loans under the Revolving Facility are, at the Company’s option, equal to either a base rate plus a margin ranging from 0.10% to 0.55% per annum or LIBOR plus a margin ranging from 1.10% to 1.55% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). The interest rates applicable to loans under the Term Loan are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.50% to 1.20% per annum or LIBOR plus a margin ranging from 1.50% to 2.20% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). As of March 31, 2022, we had a $200.0 million Term Loan outstanding and had $105.0 million outstanding under the Revolving Facility.
An increase in interest rates could make the financing of any acquisition by us more costly as well as increase the costs of our variable rate debt obligations. Rising interest rates could also limit our ability to refinance our debt when it matures or cause us to pay higher interest rates upon refinancing and increase interest expense on refinanced indebtedness. Increased inflation may also have a pronounced negative impact on the interest expense we pay in connection with our outstanding indebtedness, as these costs could increase at a rate higher than our rents.
In addition, the Chief Executive of the U.K. Financial Conduct Authority (the “FCA”), which regulates LIBOR, has announced that the FCA will no longer persuade or compel banks to submit rates for the calculation of LIBOR after 2021. However, for U.S. dollar LIBOR, the relevant date was deferred to June 30, 2023 for certain tenors (including overnight and one, three, six and 12 months), at which time the LIBOR administrator will cease publication of U.S. dollar LIBOR. Despite this deferral, the LIBOR administrator has advised that no new contracts using U.S. dollar LIBOR should be entered into after December 31, 2021. These actions indicate that the continuation of U.S. LIBOR on the current basis cannot and will not be guaranteed after June 30, 2023. Moreover, it is possible that U.S. LIBOR will be discontinued or modified prior to June 30, 2023. When LIBOR ceases to exist, we will need to enter into an amendment to the Amended Credit Agreement and we cannot predict what alternative index would be negotiated with our lenders. If our lenders have increased costs due to changes in LIBOR, we may experience potential increases in interest rates on our variable rate debt, which could adversely impact our
26

interest expense, results of operations and cash flows. Based on our outstanding debt balance as of March 31, 2022 described above and the interest rates applicable to our outstanding debt at March 31, 2022, assuming a 100 basis point increase in the interest rates related to our variable rate debt, interest expense would have increased approximately $0.8 million for the three months ended March 31, 2022.
We may, in the future, manage, or hedge, interest rate risks related to our borrowings by means of interest rate swap agreements. However, the REIT provisions of the Internal Revenue Code of 1986, as amended, substantially limit our ability to hedge our assets and liabilities. See “Risk Factors — Risks Related to Our Status as a REIT — Complying with REIT requirements may limit our ability to hedge effectively and may cause us to incur tax liabilities,” which is included in our Annual Report on Form 10-K for the year ended December 31, 2021. As of March 31, 2022, we had no swap agreements to hedge our interest rate risks. We also expect to manage our exposure to interest rate risk by maintaining a mix of fixed and variable rates for our indebtedness.

Item 4. Controls and Procedures.
Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is processed, recorded, summarized and reported within the time periods specified in the SEC’s rules and regulations and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
As of March 31, 2022, we carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, regarding the effectiveness of our disclosure controls and procedures. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, as of March 31, 2022.
Changes in Internal Control over Financial Reporting
There has been no change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended March 31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
27

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.
The Company and its subsidiaries are and may become from time to time a party to various claims and lawsuits arising in the ordinary course of business, but none of the Company or any of its subsidiaries is, and none of their respective properties are, the subject of any material legal proceedings. Claims and lawsuits may include matters involving general or professional liability asserted against its tenants, which are the responsibility of its tenants and for which the Company is entitled to be indemnified by its tenants under the insurance and indemnification provisions in the applicable leases.

Item 1A. Risk Factors.
We have disclosed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 risk factors which materially affect our business, financial condition, or results of operations. There have been no material changes from the risk factors previously disclosed.

28


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
During the three months ended March 31, 2022, we acquired shares of our common stock held by employees who tendered shares to satisfy tax withholding obligations upon the vesting of previously issued restricted stock awards. Specifically, the number of shares of common stock acquired from employees and the average prices paid per share for each month in the first quarter ended March 31, 2022 are shown in the table below.
PeriodTotal Number of Shares PurchasedAverage Price Paid per Share
January 1 - January 31, 202230,556 $20.84 
February 1 - February 28, 2022108,131 19.75 
March 1 - March 31, 2022— — 
Total138,687 $19.99 
On March 20, 2020, our Board of Directors authorized us to repurchase up to $150.0 million of outstanding shares of our common stock. Repurchases under the Repurchase Program, which expires on March 31, 2023, may be made through open market purchases, privately negotiated transactions, structured or derivative transactions, including accelerated share repurchase transactions, or other methods of acquiring shares, in each case subject to market conditions and at such times as shall be permitted by applicable securities laws and determined by management. Repurchases under the Repurchase Program may also be made pursuant to a plan adopted under Rule 10b5-1 promulgated under the Exchange Act. Through March 31, 2022, we have not repurchased any shares of our common stock under the Repurchase Program and $150.0 million remains available for the repurchase of shares of our common stock under the Repurchase Program as of March 31, 2022. The Repurchase Program may be modified, discontinued or suspended at any time.
29


Item 6. Exhibits.
Exhibit
Number
 Description of the Document
 
 
 
 
 
*101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
*101.SCH Inline XBRL Taxonomy Extension Schema Document
*101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
*101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
*101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
*101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
*104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
* Filed herewith
** Furnished herewith

30

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
CareTrust REIT, Inc.
May 5, 2022By:/s/ David M. Sedgwick
David M. Sedgwick
President and Chief Executive Officer
(duly authorized officer)
May 5, 2022By:/s/ William M. Wagner
William M. Wagner
Chief Financial Officer and Treasurer
(principal financial officer and
principal accounting officer)

31
EX-31.1 2 ctre20220331q1ex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION
I, David M. Sedgwick, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of CareTrust REIT, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
By:/s/ David M. Sedgwick
David M. Sedgwick
President and Chief Executive Officer
Date: May 5, 2022

EX-31.2 3 ctre20220331q1ex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION
I, William M. Wagner, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of CareTrust REIT, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
By:/s/ William M. Wagner
William M. Wagner
Chief Financial Officer and Treasurer
Date: May 5, 2022

EX-32.1 4 ctre20220331q1ex321.htm EX-32.1 Document

Exhibit 32.1
Certification of Chief Executive Officer and
Chief Financial Officer Pursuant to
18 U.S.C. Section 1350, As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report on Form 10-Q of CareTrust REIT, Inc. (the “Company”) for the quarterly period ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), David M. Sedgwick, as President and Chief Executive Officer of the Company, and William M. Wagner, as Chief Financial Officer and Treasurer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
/s/ David M. Sedgwick
Name:
David M. Sedgwick
Title:President and Chief Executive Officer
Date:May 5, 2022
/s/ William M. Wagner
Name:William M. Wagner
Title:Chief Financial Officer and Treasurer
Date:May 5, 2022


EX-101.SCH 5 ctre-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Equity link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Organization (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2105103 - Disclosure - Real Estate Investments, Net link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Real Estate Investments, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Real Estate Investments, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Real Estate Investments, Net - Real Estate Properties Held for Investment (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Real Estate Investments, Net - Future Contractual Minimum Rental Income (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Real Estate Investments, Net - Tenant Purchase Options (Details) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - Real Estate Investments, Net - Rental Income (Details) link:presentationLink link:calculationLink link:definitionLink 2412407 - Disclosure - Real Estate Investments, Net - Recent Real Estate Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2413408 - Disclosure - Real Estate Investments, Net - Lease Amendments Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2114104 - Disclosure - Impairment of Real Estate Investments, Assets Held for Sale, Net and Asset Sales link:presentationLink link:calculationLink link:definitionLink 2415409 - Disclosure - Impairment of Real Estate Investments, Assets Held for Sale, Net and Asset Sales (Details) link:presentationLink link:calculationLink link:definitionLink 2116105 - Disclosure - Other Real Estate Investments, Net link:presentationLink link:calculationLink link:definitionLink 2317302 - Disclosure - Other Real Estate Investments, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2418410 - Disclosure - Other Real Estate Investments, Net - Loans Receivable and Other Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2419411 - Disclosure - Other Real Estate Investments, Net - Interest and Other Income (Details) link:presentationLink link:calculationLink link:definitionLink 2420412 - Disclosure - Other Real Estate Investments, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2121106 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2322303 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2423413 - Disclosure - Fair Value Measurements - Items Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2424414 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2425415 - Disclosure - Fair Value Measurements - Face Value, Carrying Amount and Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2126107 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2327304 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2428416 - Disclosure - Debt - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2429417 - Disclosure - Debt - Senior Unsecured Notes Payable Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2430418 - Disclosure - Debt - Unsecured Revolving Credit Facility and Term Loan Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2131108 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2332305 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2433419 - Disclosure - Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2434420 - Disclosure - Equity - At-The-Market Offering (Details) link:presentationLink link:calculationLink link:definitionLink 2435421 - Disclosure - Equity - Dividends on Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2136109 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2337306 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2438422 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2439423 - Disclosure - Stock-Based Compensation - Restricted Stock and Performance Awards Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2440424 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2141110 - Disclosure - (Loss) Earnings Per Common Share link:presentationLink link:calculationLink link:definitionLink 2342307 - Disclosure - (Loss) Earnings Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2443425 - Disclosure - (Loss) Earnings Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2144111 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2445426 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2146112 - Disclosure - Concentration of Risk link:presentationLink link:calculationLink link:definitionLink 2347308 - Disclosure - Concentration of Risk (Tables) link:presentationLink link:calculationLink link:definitionLink 2448427 - Disclosure - Concentration of Risk (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 ctre-20220331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 ctre-20220331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 ctre-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Share repurchase program authorization Stock Repurchase Program, Authorized Amount Integral equipment, furniture and fixtures Fixtures and Equipment, Gross Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Customer [Domain] Customer [Domain] Letter of credit Letter of Credit [Member] Vested (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Skilled nursing, multi-service campuses, assisted living and independent living facilities Skilled Nursing, Multi Service Campuses, Assisted Living, and Independent Living Facilities [Member] Skilled Nursing, Multi Service Campuses, Assisted Living, and Independent Living Facilities Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net (loss) income Net (loss) income Net income (loss) Net Income (Loss) Attributable to Parent Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Preferred stock, outstanding (shares) Preferred Stock, Shares Outstanding Receivable Type [Axis] Receivable Type [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Number of loans receivable with provision Financing Receivable, Allowance For Credit Losses, Number Of Loans Financing Receivable, Allowance For Credit Losses, Number Of Loans Schedule of Real Estate Acquisitions Schedule Of Assets Acquisitions [Table Text Block] Schedule Of Assets Acquisitions [Table Text Block] Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Forfeited (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Additional paid-in capital Additional Paid in Capital, Common Stock Real Estate Properties [Line Items] Real Estate Properties [Line Items] Number of Facilities Number of Facilities Number of Facilities Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Lease Arrangements [Domain] Lease Arrangements [Domain] Lease Arrangements Entity File Number Entity File Number Redemption price of notes (percent) Debt Instrument, Redemption Price, Percentage Rental income Total Operating Lease, Lease Income Schedule of Rental Income Operating Lease, Lease Income [Table Text Block] Amortization of stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Class of Financing Receivable [Axis] Class of Financing Receivable [Axis] Impairment of Real Estate Investments, Assets Held for Sale, Net and Asset Sales Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Impairment expense to reduce carrying value to fair value less costs to sell Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down Dividends on common stock Dividends, Common Stock [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Remaining available authorization Stock Repurchase Program, Remaining Authorized Repurchase Amount Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Antidilutive unvested RSAs, performance awards and TSR Awards excluded from the computation Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Triple-net leases Triple-Net Leases [Member] Triple-Net Leases Sale of Stock [Axis] Sale of Stock [Axis] Dividends payable as of record date Dividends Payable, Current Authorized aggregate offering price of common stock Securities Offering, Authorized Amount Securities Offering, Authorized Amount Provision for loan losses, net Financing Receivable, Credit Loss, Expense (Reversal) Number of states with properties Number of States in which Entity Operates Granted (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Facility fee on revolving commitment fees (percent) Line of Credit Facility, Commitment Fee Percentage Lessor, Lease, Description [Table] Lessor, Lease, Description [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Award Type [Domain] Award Type [Domain] Greater than 90 days past due Financial Asset, Equal to or Greater than 90 Days Past Due [Member] Local Phone Number Local Phone Number Average sales price per share (usd per share) Shares Issued During Period, Average Price Per Share Shares Issued During Period, Average Price Per Share Credit Facility [Domain] Credit Facility [Domain] Assets: Assets [Abstract] Initial Annual Cash Rent Operating Leases, Anticipated Initial Annual Lease Revenues Operating Leases, Anticipated Initial Annual Lease Revenues Acquisitions of real estate, net of deposits applied Payments to Acquire Commercial Real Estate Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Concentration risk (percent) Concentration Risk, Percentage Class of Financing Receivable [Domain] Class of Financing Receivable [Domain] Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued and outstanding as of March 31, 2022 and December 31, 2021 Preferred Stock, Value, Issued Adjustment for collectibility of rental income Sales-type Lease, Net Investment in Lease, Credit Loss Expense (Reversal) Principal Amount Financing Receivable, Principal Amount Financing Receivable, Principal Amount Debt Instrument [Axis] Debt Instrument [Axis] Prepaid expenses and other assets, net Increase (Decrease) in Prepaid Expense and Other Assets Financial Asset, Aging [Domain] Financial Asset, Aging [Domain] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Number of Properties Number of properties acquired Number Of Properties Acquired Number Of Properties Acquired Financing Receivable, Past Due [Line Items] Financing Receivable, Past Due [Line Items] Investments, All Other Investments [Abstract] Accounts and other receivables Increase (Decrease) in Accounts Receivable Dividends record date Dividends Payable, Date of Record Weighted Average Contractual Interest Rate Loans Receivable, Fixed Interest Rate Loans Receivable, Fixed Interest Rate Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Other loans receivable Other Loans Receivable [Member] Increase in dividends payable Increase Decrease In Dividends Payable Increase Decrease In Dividends Payable Investment in other loans receivable Payments to Acquire Loans Receivable Annual cash rent increase under amended lease Annual Cash Rent Increase Under Amended Lease Annual Cash Rent Increase Under Amended Lease Basic (in usd per share) (Loss) earnings per common share, basic (in dollars per share) Earnings Per Share, Basic Schedule of Real Estate Properties [Table] Schedule of Real Estate Properties [Table] Unvested, beginning balance (shares) Unvested, ending balance (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Lease termination revenue Gain (Loss) on Termination of Lease Lease Expiration October 2034, Next option 2026 Properties With Purchase Option, Lease Expiration October 2034, Next Option 2026 [Member] Properties With Purchase Option, Lease Expiration October 2034, Next Option 2026 Eduro amended triple-net master lease Eduro Amended Triple-Net Master Lease [Member] Eduro Amended Triple-Net Master Lease Straight-line rent Lease Income, Straight Line Rent [Member] Lease Income, Straight Line Rent [Member] Real estate investments Real Estate Investment Property, at Cost Geographic concentration risk Geographic Concentration Risk [Member] Number of Beds/Units Number Of Beds Or Units In Properties Acquired Number Of Beds Or Units In Properties Acquired Fair Value Measurement [Domain] Fair Value Measurement [Domain] Number of shares authorized for awards Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Ensign amended triple-net master lease Ensign Amended Triple-Net Master Lease [Member] Ensign Amended Triple-Net Master Lease 2027 Lessor, Operating Lease, Payment to be Received, Year Five Catch-up depreciation Other Depreciation and Amortization Principal Amount Outstanding amounts Long-term Debt, Gross Period prior to March 30 2028 Debt Instrument, Redemption, Period Two [Member] Schedule of Interest and Other Income Interest and Other Income [Table Text Block] Assets: Assets, Fair Value Disclosure [Abstract] Carrying Value Long-term Debt Level 1 Fair Value, Inputs, Level 1 [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Entity Small Business Entity Small Business Current Cash Rent Lessor, Annualized Cash Revenue For Contracts In Place Lessor, Annualized Cash Revenue For Contracts In Place Base Rate Base Rate [Member] Financial liabilities: Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract] Total liabilities and equity Liabilities and Equity Accounts and other receivables Accounts Receivable, after Allowance for Credit Loss Total Lessor, Operating Lease, Payments to be Received Metron Metron [Member] Metron Held for sale Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member] Cumulative Distributions in Excess of Earnings Accumulated Distributions in Excess of Net Income [Member] Number of properties impaired Number Of Real Estate Properties With Impairment Number Of Real Estate Properties With Impairment Concentration Risk [Line Items] Concentration Risk [Line Items] Liabilities and Equity: Liabilities and Equity [Abstract] (Loss) Earnings Per Common Share Earnings Per Share [Text Block] Initial lease term (in years) Lessor, Operating Lease, Term of Contract Expenses: Operating Expenses [Abstract] Entity Interactive Data Current Entity Interactive Data Current Property operating expenses Cost of Other Property Operating Expense Minimum Minimum [Member] Summary of Investment in Owned Properties Schedule of Real Estate Properties [Table Text Block] Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Unsecured revolving credit facility Borrowings outstanding Long-term Line of Credit Schedule of Total Future Contractual Minimum Rental Income Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block] Summary of the At-The-Market Offering Program Schedule of Stock by Class [Table Text Block] Deferred financing costs, net Debt Issuance Costs, Net Preferred stock, authorized (shares) Preferred Stock, Shares Authorized Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Address, State or Province Entity Address, State or Province 2023 Lessor, Operating Lease, Payment to be Received, Year One Receivable [Domain] Receivable [Domain] Issuance of common stock, net Stock Issued During Period, Value, New Issues Ensign and Pennant Ensign And Pennant [Member] Ensign And Pennant General and administrative General and Administrative Expense Debt Debt Disclosure [Text Block] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Stock-Based Compensation Share-based Payment Arrangement [Text Block] Notes payable Senior Notes [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Dividends paid on common stock Payments of Ordinary Dividends, Common Stock Ensign Ensign [Member] Ensign [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Commissions paid on stock issuance Payments of Stock Issuance Costs Issuance of common stock, net, (in shares) Number of shares Stock Issued During Period, Shares, New Issues Mezzanine loan receivable Mezzanine Loan [Member] Mezzanine Loan 2026 Lessor, Operating Lease, Payment to be Received, Year Four Aggregate required financing of capital expenditures as percentage of initial investment in property (percent) Aggregate Required Financing Of Capital Expenditures As Percentage Of Initial Investment In Property Aggregate Required Financing Of Capital Expenditures As Percentage Of Initial Investment In Property Document Transition Report Document Transition Report Property taxes Real Estate Tax Expense Common stock, $0.01 par value; 500,000,000 shares authorized, 96,487,066 and 96,296,673 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Customer concentration risk Customer Concentration Risk [Member] Unvested, beginning balance (usd per share) Unvested, ending balance (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Commitments and contingencies Commitments and Contingencies Summary of Face Value, Carrying Amount and Fair Value of Financial Instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Entity Emerging Growth Company Entity Emerging Growth Company SNF Skilled nursing facility Skilled Nursing Facility [Member] Skilled Nursing Facility [Member] Net proceeds from issuance Proceeds from Debt, Net of Issuance Costs RSAs Restricted Stock [Member] Other Commitments [Table] Other Commitments [Table] Summary of Restricted Stock Award and Performance Award Activity Share-based Payment Arrangement, Activity [Table Text Block] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Cover [Abstract] Cover [Abstract] Diluted market condition stock awards (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Total expenses Costs and Expenses CA CALIFORNIA Straight-line rental income Straight-line rent Straight Line Rent Common dividends (in usd per share) Dividends declared per share Common Stock, Dividends, Per Share, Declared Schedule of Dividends on Common Stock Dividends Declared [Table Text Block] Future Contractual Minimum Rental Income Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract] Equity [Abstract] Equity [Abstract] Carrying Amount Reported Value Measurement [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Document Quarterly Report Document Quarterly Report Common Stock Common Stock [Member] Variable Rate [Axis] Variable Rate [Axis] Financial Asset, Aging [Axis] Financial Asset, Aging [Axis] Certain capital improvements at triple-net leased facilities Capital Improvements At Triple Net Leased Facilities [Member] Capital Improvements At Triple Net Leased Facilities Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Lease Expiration March 2029, Next option 2022 Properties With Purchase Option, Lease Expiration March 2029, Next Option 2022 [Member] Properties With Purchase Option, Lease Expiration March 2029, Next Option 2022 Assets held for sale, net Assets Held-for-sale, Not Part of Disposal Group Variable Rate [Domain] Variable Rate [Domain] Additional Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Other real estate investments Real Estate Investments, Joint Ventures Loan receivable Financing Receivable, after Allowance for Credit Loss Percentage of principal amount (percent) Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Total liabilities Liabilities Award Type [Axis] Award Type [Axis] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Total equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Common stock, issued (shares) Common Stock, Shares, Issued Preferred stock, issued (shares) Preferred Stock, Shares Issued City Area Code City Area Code Financing Receivable, Allowance for Credit Loss [Table] Financing Receivable, Allowance for Credit Loss [Table] Accounts payable, accrued liabilities and deferred rent liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Entity Address, City or Town Entity Address, City or Town Equity: Stockholders' Equity Attributable to Parent [Abstract] Land Land Measurement Frequency [Domain] Measurement Frequency [Domain] Senior unsecured notes payable - face value Debt instrument face amount Debt Instrument, Face Amount Interest expense Interest Expense Lease Expiration October 2034, Next option 2022 Properties With Purchase Option, Lease Expiration October 2034, Next Option 2022 [Member] Properties With Purchase Option, Lease Expiration October 2034, Next Option 2022 Short-term lease Short Term Lease, Term Under One Year [Member] Short Term Lease, Term Under One Year Discontinued Operations and Disposal Groups [Abstract] Other Real Estate Investments, Net Other Real Estate Investments [Text Block] Other Real Estate Investments Loan loss recovery Financing Receivable, Allowance for Credit Loss, Recovery Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Entity Filer Category Entity Filer Category Unfunded loan commitment Unfunded Loan Commitment Unfunded Loan Commitment Business Acquisition [Line Items] Business Acquisition [Line Items] Principal payments received on real estate mortgage and other loans receivable Proceeds from Collection of Loans Receivable Income Statement [Abstract] Income Statement [Abstract] Concentration Risk [Table] Concentration Risk [Table] Interest and other income Interest and Other Income Senior unsecured notes payable 3.875% Senior Notes due 2028 Three Point Eight Seven Five Senior Notes Due 2028 [Member] Three Point Eight Seven Five Senior Notes Due 2028 Fair Value Estimate of Fair Value Measurement [Member] Entity Registrant Name Entity Registrant Name Prepaid expenses and other assets, net Prepaid Expense and Other Assets ATM Program At-The-Market Offering Program [Member] At-The-Market Offering Program [Member] Senior unsecured notes payable Notes Payable, Fair Value Disclosure Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Other Commitments [Domain] Other Commitments [Domain] Amendment Flag Amendment Flag Equity Components [Axis] Equity Components [Axis] Entity Tax Identification Number Entity Tax Identification Number Number of renewal options Lessor, Operating Lease, Number Of Renewal Options Lessor, Operating Lease, Number Of Renewal Options Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Concentration Risk Type [Domain] Concentration Risk Type [Domain] Sale of Stock [Domain] Sale of Stock [Domain] Forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Contractual rent due Operating Lease, Lease Income, Lease Payments Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Contractual cash rent attributable to properties held for sale and repurposed (percent) Contractual Cash Rent, Attributable To Properties Held For Sale And Repurposed, Percentage Contractual Cash Rent, Attributable To Properties Held For Sale And Repurposed, Percentage Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Less: Net income allocated to participating securities Undistributed Earnings (Loss) Allocated to Participating Securities, Basic Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Gross proceeds from issuance Proceeds from Issuance of Unsecured Debt Product and Service [Axis] Product and Service [Axis] Portion of funding commitment subject to rent increase at time of funding Portion Of Commitment Subject To Rent Increase At Time Of Funding Portion Of Commitment Subject To Rent Increase At Time Of Funding Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] ALF Assisted living Assisted Living Facility [Member] Assisted Living Facility [Member] Net proceeds from sales of real estate Proceeds from sale Proceeds from Sale of Real Estate Held-for-investment Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Rental revenue Revenue Benchmark [Member] Valuation, market approach Valuation, Market Approach [Member] Equity Component [Domain] Equity Component [Domain] Financing Receivable, Allowance for Credit Loss [Line Items] Financing Receivable, Allowance for Credit Loss [Line Items] Period after March 30 2028 Debt Instrument, Redemption, Period Three [Member] Disposal Group Name [Domain] Disposal Group Name [Domain] 2022 (nine months) Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year Lease renewal term (in years) Lessor, Operating Lease, Renewal Term Accounts payable, accrued liabilities and deferred rent liabilities Accounts Payable and Other Accrued Liabilities SNF / Campus Skilled Nursing And Campus Facilities [Member] Skilled Nursing And Campus Facilities Deferred Loan Fees Debt Issuance Costs, Gross Statement [Line Items] Statement [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Funding commitment Other Commitment Counterparty Name [Domain] Counterparty Name [Domain] Prices per unit input Price Per Unit, Value, Measurement Input Price Per Unit, Value, Measurement Input Debt Disclosure [Abstract] Debt Disclosure [Abstract] Weighted average Weighted Average [Member] Transfer of pre-acquisition costs to acquired assets Transfer Of Preacquisition Costs To Acquired Assets Transfer Of Preacquisition Costs To Acquired Assets Level 2 Fair Value, Inputs, Level 2 [Member] Various other operators Various Other Operators [Member] Various Other Operators Priority Management Group Priority Management Group LLC [Member] Priority Management Group LLC Senior unsecured notes payable, net Unsecured Long-term Debt, Noncurrent Redemption price, percentage upon change of control (percent) Debt Instrument Redemption Price Upon Change Of Control As Percentage Of Principal Amount Debt instrument redemption price upon change of control as percentage of principal amount. Customer [Axis] Customer [Axis] Accumulated depreciation and amortization Real Estate Investment Property, Accumulated Depreciation Senior unsecured term loan, net Loans Payable, Noncurrent Lease Expiration October 2032, Next option 2023 Properties With Purchase Option, Lease Expiration October 2032, Next Option 2023 [Member] Properties With Purchase Option, Lease Expiration October 2032, Next Option 2023 Reconciliation of Weighted-Average Common Shares Outstanding Used in Calculation of Basic EPS to Diluted EPS Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Stock-Based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Disposed of by sale Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Title of 12(b) Security Title of 12(b) Security Number of extension options Line Of Credit Facility, Number Of Extension Options Line Of Credit Facility, Number Of Extension Options Proceeds from the issuance of common stock, net Gross proceeds Proceeds from Issuance of Common Stock Total assets Assets Common stock, authorized (shares) Common Stock, Shares Authorized Dividends payment date Dividends Payable, Date to be Paid Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Geographical [Domain] Geographical [Domain] Numerator for basic and diluted earnings available to common stockholders Net Income (Loss) Available to Common Stockholders, Diluted Numerator: Net Income (Loss) Attributable to Parent [Abstract] Buildings and improvements Investment Building and Building Improvements Numerator for basic earnings available to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Document Type Document Type Product and Service [Domain] Product and Service [Domain] Swingline loan Swingline Loan [Member] Swingline Loan [Member] Schedule Of Tenant Purchase Options Schedule Of Tenant Purchase Options [Table Text Block] Schedule Of Tenant Purchase Options 2024 Lessor, Operating Lease, Payment to be Received, Year Two Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Interest rate (percent) Debt Instrument, Interest Rate, Stated Percentage Cumulative distributions in excess of earnings Accumulated Distributions in Excess of Net Income Thereafter Lessor, Operating Lease, Payment to be Received, after Year Five Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Revolving credit facility Revolving Credit Facility [Member] Adjustments for collectibility Operating Lease, Lease Income, Adjustments For Collectibility Operating Lease, Lease Income, Adjustments For Collectibility Real Estate [Line Items] Real Estate [Line Items] WLC amended triple-net master lease WLC Management Firm Amended Triple-Net Master Lease [Member] WLC Management Firm Amended Triple-Net Master Lease Measurement Frequency [Axis] Measurement Frequency [Axis] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Gain (loss) on sale of real estate (Gain) loss on sale of real estate Gain on sale of real estate Gains (Losses) on Sales of Investment Real Estate Remaining offering amount available Securities Offering, Remaining Authorized Amount Securities Offering, Remaining Authorized Amount Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Facility fee on revolving commitment fee based on investment grade ratings (percent) Line Of Credit, Commitment Fee Based On Investment Grade Rating, Percentage Line Of Credit, Commitment Fee Based On Investment Grade Rating, Percentage Geographical [Axis] Geographical [Axis] Lease Contractual Term [Domain] Lease Contractual Term [Domain] Basic (in shares) Weighted-average basic common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in usd per share) (Loss) earnings per common share, diluted (in dollars per share) Earnings Per Share, Diluted Amortization of deferred financing costs Amortization of Debt Issuance Costs and Discounts Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Weighted-average number of common shares: Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Term loan Loans Payable [Member] Number of properties transferred Number Of Properties Transferred Number Of Properties Transferred Lease Arrangements [Axis] Lease Arrangements [Axis] Lease Arrangements Fair Value Measurements Fair Value Disclosures [Text Block] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Purchases of equipment, furniture and fixtures and improvements to real estate Payments To Acquire Equipment, Furniture And Fixtures And Develop Real Estate Assets Payments To Acquire Equipment, Furniture And Fixtures And Develop Real Estate Assets Depreciation and amortization (including below-market ground leases) Depreciation, Depletion and Amortization Common dividends Dividends, Common Stock Schedule of Items Measured at Fair Value on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Borrowings under unsecured revolving credit facility Proceeds from Long-term Lines of Credit Common stock, outstanding (shares) Common Stock, Shares, Outstanding Dividends payable Dividends Payable Number of operational beds and units in facilities Number Of Operational Beds And Units In Facilities Number Of Operational Beds And Units In Facilities Revenues: Revenues [Abstract] Document Period End Date Document Period End Date Expected credit loss recognized Provision for Loan, Lease, and Other Losses ALF/ILF Assisted and Independent Living Properties [Member] Assisted and Independent Living Properties [Member] Lease Contractual Term [Axis] Lease Contractual Term [Axis] Entity Central Index Key Entity Central Index Key Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] TX TEXAS Operating expense reimbursements Lease Income, Operating Expense Reimbursements [Member] Lease Income, Operating Expense Reimbursements Financing Receivable, Past Due [Table] Financing Receivable, Past Due [Table] Supplemental schedule of noncash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Real estate investments, net Real estate investments, net Real Estate Investment Property, Net Lessor, Lease, Description [Line Items] Lessor, Lease, Description [Line Items] Concentration of Risk Concentration Risk Disclosure [Text Block] Skilled nursing Skilled Nursing Properties [Member] Skilled Nursing Properties [Member] Shares repurchased (in shares) Treasury Stock, Shares, Acquired Schedule of Debt Instruments Schedule of Long-term Debt Instruments [Table Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Trading Symbol Trading Symbol (Loss) earnings per common share: Earnings Per Share [Abstract] Impairment of real estate investments Impairment Losses Related to Real Estate Partnerships Weighted-average remaining vesting period (in years) Share-Based Compensation Arrangement By Share-Based Payment Award, Weighted Average Remaining Award Vesting Period Share-Based Compensation Arrangement By Share-Based Payment Award, Weighted Average Remaining Award Vesting Period Mezzanine loan receivable Mezzanine Loan Receivable [Member] Mezzanine Loan Receivable Lease Expiration November 2030, Next option 2022 Properties With Purchase Option, Lease Expiration November 2030, Next Option 2022 [Member] Properties With Purchase Option, Lease Expiration November 2030, Next Option 2022 Lease Expiration November 2034, Next option 2024 Properties With Purchase Option, Lease Expiration November 2034, Next Option 2024 [Member] Properties With Purchase Option, Lease Expiration November 2034, Next Option 2024 Senior unsecured term loan Senior Unsecured Term Loan [Member] Senior Unsecured Term Loan [Member] Extension option term (in months) Line Of Credit Facility Extension Option Term Line of credit facility extension option term. Total revenues Revenues Vesting of restricted common stock, net of shares withheld for employee taxes Restricted Stock, Value, Shares Issued Net of Tax Withholdings Line of Credit Facility [Table] Line of Credit Facility [Table] Purchase Price Asset Acquisition, Consideration Transferred Other Commitments [Line Items] Other Commitments [Line Items] RSAs and PSAs Restricted Stock And Performance Shares [Member] Restricted Stock And Performance Shares [Member] Amortization of stock-based compensation Stock-based compensation expense Share-based Payment Arrangement, Expense Entity Current Reporting Status Entity Current Reporting Status Weighted Average Share Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Number of Beds/Units Number Of Units And Beds In Facilities Number Of Units And Beds In Facilities Counterparty Name [Axis] Counterparty Name [Axis] Cash and cash equivalents as of the beginning of period Cash and cash equivalents as of the end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Schedules of Concentration of Risk Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Period prior to June 30 2024 Debt Instrument, Redemption, Period One [Member] Identified intangible assets Finite-Lived Intangible Assets, Gross Real Estate [Table] Real Estate [Table] LIBOR London Interbank Offered Rate (LIBOR) [Member] Vesting of restricted common stock, net of shares withheld for employee taxes (in shares) Restricted Stock, Shares Issued Net of Shares for Tax Withholdings Disposal Group Classification [Domain] Disposal Group Classification [Domain] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Diluted (in shares) Weighted-average diluted common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Recurring Fair Value, Recurring [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Basis spread on variable rate (percent) Debt Instrument, Basis Spread on Variable Rate Real Estate [Abstract] Real Estate [Abstract] Equity Stockholders' Equity Note Disclosure [Text Block] Measurement Basis [Axis] Measurement Basis [Axis] Rental Income Operating Lease, Lease Income [Abstract] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Other income (loss): Nonoperating Income (Expense) [Abstract] Class of Stock [Line Items] Class of Stock [Line Items] Mezzanine loan receivable Loans Receivable, Fair Value Disclosure Name of Property [Axis] Name of Property [Axis] Credit Facility [Axis] Credit Facility [Axis] Entity Address, Address Line One Entity Address, Address Line One Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Entity Address, Address Line Two Entity Address, Address Line Two Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Change in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Number of operational beds Number Of Operational Beds Number Of Operational Beds Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Vested (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Entity Shell Company Entity Shell Company Properties Number Of Properties With Tenant Purchase Option Number Of Properties With Tenant Purchase Option Net-settle adjustment on restricted stock Payment, Tax Withholding, Share-based Payment Arrangement Credit facility borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Current Fiscal Year End Date Current Fiscal Year End Date Book value Mortgage loan receivable Financing Receivable, before Allowance for Credit Loss Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Statement [Table] Statement [Table] Shares Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Schedule of Loans Receivable and Other Investments Investment [Table Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Other Commitments [Axis] Other Commitments [Axis] Unamortized stock-based compensation expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Statistical Measurement [Axis] Statistical Measurement [Axis] Contractual rent Lease Income, Contractual Rent [Member] Lease Income, Contractual Rent [Member] Real Estate Investments, Net Real Estate Disclosure [Text Block] Expected credit loss Expected credit loss Financing Receivable, Allowance for Credit Loss Number of facilities Number of properties Number of Real Estate Properties Multi-service campuses Campus Multi-Service Campus Properties [Member] Multi-Service Campus Properties [Member] 2025 Lessor, Operating Lease, Payment to be Received, Year Three Name of Property [Domain] Name of Property [Domain] Adjustments to reconcile net (loss) income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Number of properties to be repurposed Number Of Real Estate Properties To Be Repurposed Number Of Real Estate Properties To Be Repurposed Subfacility capacity as percentage of available revolving commitments (percent) Line Of Credit, Subfacility, Capacity As Percentage Of Available Revolving Commitments Line Of Credit, Subfacility, Capacity As Percentage Of Available Revolving Commitments Amount transferred out of assets held-for-sale Transferred Out Of Assets Held-For-Sale, Not Part Of Disposal Group Transferred Out Of Assets Held-For-Sale, Not Part Of Disposal Group EX-101.PRE 9 ctre-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover - shares
3 Months Ended
Mar. 31, 2022
May 04, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2022  
Document Transition Report false  
Entity File Number 001-36181  
Entity Registrant Name CareTrust REIT, Inc.  
Entity Incorporation, State or Country Code MD  
Entity Tax Identification Number 46-3999490  
Entity Address, Address Line One 905 Calle Amanecer  
Entity Address, Address Line Two Suite 300  
Entity Address, City or Town San Clemente  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92673  
City Area Code 949  
Local Phone Number 542-3130  
Title of 12(b) Security Common Stock, par value $0.01 per share  
Trading Symbol CTRE  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Central Index Key 0001590717  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   97,028,742
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Assets:    
Real estate investments, net $ 1,402,889 $ 1,589,971
Other real estate investments 15,155 15,155
Assets held for sale, net 141,716 4,835
Cash and cash equivalents 26,586 19,895
Accounts and other receivables 1,110 2,418
Prepaid expenses and other assets, net 5,668 7,512
Deferred financing costs, net 817 1,062
Total assets 1,593,941 1,640,848
Liabilities and Equity:    
Senior unsecured notes payable, net 394,484 394,262
Senior unsecured term loan, net 199,189 199,136
Unsecured revolving credit facility 105,000 80,000
Accounts payable, accrued liabilities and deferred rent liabilities 23,785 25,408
Dividends payable 26,900 26,285
Total liabilities 749,358 725,091
Commitments and contingencies
Equity:    
Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued and outstanding as of March 31, 2022 and December 31, 2021 0 0
Common stock, $0.01 par value; 500,000,000 shares authorized, 96,487,066 and 96,296,673 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively 965 963
Additional paid-in capital 1,195,586 1,196,839
Cumulative distributions in excess of earnings (351,968) (282,045)
Total equity 844,583 915,757
Total liabilities and equity $ 1,593,941 $ 1,640,848
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred stock, par value (in usd per share) $ 0.01 $ 0.01
Preferred stock, authorized (shares) 100,000,000 100,000,000
Preferred stock, issued (shares) 0 0
Preferred stock, outstanding (shares) 0 0
Common stock, par value (in usd per share) $ 0.01 $ 0.01
Common stock, authorized (shares) 500,000,000 500,000,000
Common stock, issued (shares) 96,487,066 96,296,673
Common stock, outstanding (shares) 96,487,066 96,296,673
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenues:    
Rental income $ 46,007 $ 45,246
Interest and other income 469 505
Total revenues 46,476 45,751
Expenses:    
Depreciation and amortization 13,575 13,473
Interest expense 5,742 5,762
Property taxes 1,420 696
Impairment of real estate investments 59,683 0
Provision for loan losses, net 3,844 0
Property operating expenses 447 0
General and administrative 5,215 5,142
Total expenses 89,926 25,073
Other income (loss):    
Gain (loss) on sale of real estate 186 (192)
Net (loss) income $ (43,264) $ 20,486
(Loss) earnings per common share:    
Basic (in usd per share) $ (0.45) $ 0.21
Diluted (in usd per share) $ (0.45) $ 0.21
Weighted-average number of common shares:    
Basic (in shares) 96,410 95,378
Diluted (in shares) 96,410 95,385
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Cumulative Distributions in Excess of Earnings
Beginning balance at Dec. 31, 2020 $ 914,142 $ 952 $ 1,164,402 $ (251,212)
Beginning balance (in shares) at Dec. 31, 2020   95,215,797    
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common stock, net 16,191 $ 7 16,184  
Issuance of common stock, net, (in shares)   702,000    
Vesting of restricted common stock, net of shares withheld for employee taxes (1,330) $ 1 (1,331)  
Vesting of restricted common stock, net of shares withheld for employee taxes (in shares)   63,265    
Amortization of stock-based compensation 1,585   1,585  
Common dividends (25,633)     (25,633)
Net (loss) income 20,486     20,486
Ending balance at Mar. 31, 2021 925,441 $ 960 1,180,840 (256,359)
Ending balance (in shares) at Mar. 31, 2021   95,981,062    
Beginning balance at Dec. 31, 2021 915,757 $ 963 1,196,839 (282,045)
Beginning balance (in shares) at Dec. 31, 2021   96,296,673    
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Vesting of restricted common stock, net of shares withheld for employee taxes (2,772) $ 2 (2,774)  
Vesting of restricted common stock, net of shares withheld for employee taxes (in shares)   190,393    
Amortization of stock-based compensation 1,521   1,521  
Common dividends (26,659)     (26,659)
Net (loss) income (43,264)     (43,264)
Ending balance at Mar. 31, 2022 $ 844,583 $ 965 $ 1,195,586 $ (351,968)
Ending balance (in shares) at Mar. 31, 2022   96,487,066    
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Equity (Parenthetical) - $ / shares
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Statement of Stockholders' Equity [Abstract]    
Common dividends (in usd per share) $ 0.275 $ 0.265
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities:    
Net (loss) income $ (43,264) $ 20,486
Adjustments to reconcile net (loss) income to net cash provided by operating activities:    
Depreciation and amortization (including below-market ground leases) 13,594 13,486
Amortization of deferred financing costs 520 487
Amortization of stock-based compensation 1,521 1,585
Straight-line rental income (6) (12)
Adjustment for collectibility of rental income 977 0
(Gain) loss on sale of real estate (186) 192
Impairment of real estate investments 59,683 0
Provision for loan losses, net 3,844 0
Change in operating assets and liabilities:    
Accounts and other receivables 337 (100)
Prepaid expenses and other assets, net (404) 278
Accounts payable, accrued liabilities and deferred rent liabilities (2,037) (2,453)
Net cash provided by operating activities 34,579 33,949
Cash flows from investing activities:    
Acquisitions of real estate, net of deposits applied (21,915) (138,151)
Purchases of equipment, furniture and fixtures and improvements to real estate (1,918) (1,319)
Investment in other loans receivable (2,086) (700)
Principal payments received on real estate mortgage and other loans receivable 888 56
Net proceeds from sales of real estate 959 6,814
Net cash used in investing activities (24,072) (133,300)
Cash flows from financing activities:    
Proceeds from the issuance of common stock, net 0 16,191
Borrowings under unsecured revolving credit facility 25,000 120,000
Net-settle adjustment on restricted stock (2,772) (1,330)
Dividends paid on common stock (26,044) (23,960)
Net cash (used in) provided by financing activities (3,816) 110,901
Net increase in cash and cash equivalents 6,691 11,550
Cash and cash equivalents as of the beginning of period 19,895 18,919
Cash and cash equivalents as of the end of period 26,586 30,469
Supplemental disclosures of cash flow information:    
Interest paid 1,355 1,325
Supplemental schedule of noncash investing and financing activities:    
Increase in dividends payable 615 1,673
Transfer of pre-acquisition costs to acquired assets $ 7 $ 358
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Organization
3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization ORGANIZATION
Description of Business—CareTrust REIT, Inc.’s (“CareTrust REIT” or the “Company”) primary business consists of acquiring, financing, developing and owning real property to be leased to third-party tenants in the healthcare sector. As of March 31, 2022, the Company owned and leased to independent operators, 228 skilled nursing facilities (“SNFs”), multi-service campuses, assisted living facilities (“ALFs”) and independent living facilities (“ILFs”) consisting of 23,834 operational beds and units located in 29 states with the highest concentration of properties by rental income located in California, Texas, Louisiana, Idaho and Arizona. As of March 31, 2022, the Company also had other real estate investments consisting of one mezzanine loan receivable with a carrying value of $15.2 million.
COVID-19—The COVID-19 pandemic has had and may continue to have an adverse impact on the economy generally and the Company’s business, results of operations and financial condition. The duration and extent of the COVID-19 pandemic’s effect on the Company’s operational and financial performance, and the operational and financial performance of the Company’s tenants, will depend on future developments, which are highly uncertain and cannot be predicted at this time, including the rate of public acceptance and usage of vaccines and the effectiveness of vaccines in limiting the spread of COVID-19 and its variants, resurgences of COVID-19 and, in particular, new and more contagious and/or vaccine resistant variants, actions taken to contain the spread of COVID-19 and how quickly and to what extent normal economic and operating conditions can resume. The adverse impact of the COVID-19 pandemic on the Company’s business, results of operations and financial condition could be material.
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation—The accompanying condensed consolidated financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, the condensed consolidated financial statements do not include all of the disclosures required by GAAP for a complete set of annual audited financial statements. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. In the opinion of management, all adjustments which are of a normal and recurring nature and considered necessary for a fair presentation of the results of the interim periods presented have been included. The results of operations for the interim periods are not necessarily indicative of results for the full year. All intercompany transactions and account balances within the Company have been eliminated.
 Recent Accounting Pronouncements—In March 2020, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), that provides optional relief to applying reference rate reform to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”). For U.S. Dollar LIBOR, the overnight, one-month, three-month, six-month and one-year LIBOR rates will be discontinued in June 2023, while other U.S. Dollar LIBOR rates were discontinued at the end of 2021. The amendments in this update are effective immediately and may be applied through December 31, 2022. Adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Real Estate Investments, Net
3 Months Ended
Mar. 31, 2022
Real Estate [Abstract]  
Real Estate Investments, Net REAL ESTATE INVESTMENTS, NET
The following table summarizes the Company’s real estate properties held for investment at March 31, 2022 and December 31, 2021 (dollars in thousands):
March 31, 2022December 31, 2021
Land$236,986 $251,787 
Buildings and improvements1,431,631 1,622,019 
Integral equipment, furniture and fixtures95,997 104,722 
Identified intangible assets2,658 1,257 
Real estate investments1,767,272 1,979,785 
Accumulated depreciation and amortization(364,383)(389,814)
Real estate investments, net$1,402,889 $1,589,971 
As of March 31, 2022, 226 of the Company’s 228 facilities were leased to various operators under triple-net leases. All of these leases contain annual escalators based on the percentage change in the Consumer Price Index (“CPI”) (but not less than zero), some of which are subject to a cap, or fixed rent escalators. Two of the Company’s 228 facilities are non-operational and are leased under a short term lease with an expected term of less than one year as of March 31, 2022. As of March 31, 2022, 27 facilities were held for sale.
As of March 31, 2022, the Company’s total future contractual minimum rental income for all of its tenants, excluding operating expense reimbursements, was (dollars in thousands):
YearAmount
2022 (nine months)$146,848 
2023195,547 
2024194,202 
2025194,173 
2026194,278 
2027191,589 
Thereafter998,873 
Total$2,115,510 
Tenant Purchase Options
Certain of the Company’s operators hold purchase options allowing them to acquire properties they currently lease from the Company. A summary of these purchase options is presented below (dollars in thousands):
Asset TypePropertiesLease ExpirationNext Option Open Date
Option Type(1)
Current Cash Rent(2)
ALF7October 20341/1/2022
(3)
A$3,383 
SNF11November 20301/1/2022
(3)
C4,944 
SNF1March 20294/1/2022
(4)
B / C(5)
779 
SNF / Campus2October 20321/1/2023
(3)
B1,065 
SNF4November 203412/1/2024
(4)
B3,796 
ALF2October 20341/1/2026
(3)
A1,598 
(1) Option type includes:
A - Fixed base price plus a specified share on any appreciation.
B - Fixed base price.
C - Fixed capitalization rate on lease revenue.
(2) Based on annualized cash revenue for contracts in place as of March 31, 2022.
(3) Option window is open for six months.
(4) Option window is open until the expiration of the lease term.
(5) Purchase option reflects two option types.
Rental Income
The following table summarizes components of the Company’s rental income (dollars in thousands):
For the Three Months Ended March 31,
Rental Income20222021
Contractual rent due(1)
$46,978 $45,171 
Straight-line rent12 
Adjustment for collectibility(2)
(977)— 
Lease termination revenue(3)
— 63 
Total$46,007 $45,246 
(1) Includes initial cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received.
(2)    During the three months ended March 31, 2022, and in accordance with Accounting Standards Codification 842, the Company evaluated the collectibility of lease payments through maturity and determined that it was not probable that the Company would collect substantially all of the contractual obligations from four existing and former operators. As such, the Company reversed $0.7 million of operating expense reimbursements, $0.2 million of contractual rent and $0.1 million of straight-line rent during the three months ended March 31, 2022. If lease payments are subsequently deemed probable of collection, the Company will increase rental income for such recoveries.
(3) During the three months ended March 31, 2021, in connection with the agreement to terminate its lease agreements with Metron Integrated Health Systems (“Metron”) and to sell the facilities to a third party, the Company received approximately $0.1 million in lease termination revenue from Metron affiliates.
Recent Real Estate Acquisitions
The following table summarizes the Company’s acquisitions for the three months ended March 31, 2022 (dollars in thousands):
Type of Property
Purchase Price(1)
Initial Annual Cash RentNumber of Properties
Number of Beds/Units(2)
Skilled nursing$8,918 $815 135 
Multi-service campuses13,003 1,235 130 
Total$21,921 $2,050 265 
(1) Purchase price includes capitalized acquisition costs.
(2) The number of beds/units includes operating beds at the acquisition date.
Lease Amendments
Pennant Partial Lease Termination and Amended Ensign Master Lease. On March 1, 2022, operations at one ALF in Arizona operated by affiliates of The Pennant Group, Inc. (“Pennant”) were transferred to affiliates of The Ensign Group, Inc. (“Ensign”). In connection with the transfer, the Company amended the Pennant master lease to reflect the removal of the ALF and amended an existing triple-net master lease with Ensign to include the one ALF. The applicable Ensign master lease has a remaining term of approximately 11 years, with two five-year renewal options and CPI-based rent escalators. Annual cash rent under the applicable Ensign master lease, as amended, increased by approximately $0.3 million and annual cash rent under the Pennant master lease, as amended, decreased by the same amount.
Amended Eduro Master Lease. On February 1, 2022, the Company acquired one SNF. In conjunction with the acquisition, the Company amended its existing triple-net master lease with affiliates of Eduro Healthcare, LLC (“Eduro”) to include the one SNF and extended the initial lease term. The Eduro master lease, as amended, has a remaining term of approximately 12 years, with two five-year renewal options and CPI-based rent escalators. Annual cash rent under the Eduro master lease, as amended, increased by approximately $0.8 million.
Amended WLC Master Lease. On March 1, 2022, the Company acquired one multi-service campus. In conjunction with the acquisition, the Company amended its existing triple-net master lease with affiliates of WLC Management Firm, LLC (“WLC”) to include the one multi-service campus. The WLC master lease, as amended, has a remaining term of approximately 12 years, with two five-year renewal options and CPI-based rent escalators. Annual cash rent under the WLC master lease, as amended, increased by approximately $1.2 million.
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Impairment of Real Estate Investments, Assets Held for Sale, Net and Asset Sales
3 Months Ended
Mar. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]  
Impairment of Real Estate Investments, Assets Held for Sale, Net and Asset Sales IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE, NET AND ASSET SALES
In connection with the Company’s ongoing review and monitoring of its investment portfolio and the performance of its tenants, the Company determined to pursue the sale of 27 properties and repurposing three properties representing an aggregate of approximately 10% of contractual cash rent as of March 31, 2022. As of March 31, 2022, the Company determined that these 27 properties met the criteria to be classified as assets held for sale and, in connection with this determination, the Company recognized an aggregate impairment charge of $59.7 million related to 20 of the 27 held for sale properties, which is reported in impairment of real estate investments in the condensed consolidated statements of operations for the three months ended March 31, 2022. The impairment charge was recognized to write down the properties’ aggregate carrying value to their aggregate fair value, less estimated costs to sell. As of March 31, 2022, the net book value of these 27 properties was $141.7 million, which is comprised of the real estate assets.
The fair value of the assets held for sale was based on estimated sales prices, which are considered to be Level 3 measurements within the fair value hierarchy. Estimated sales prices were determined using a market approach (comparable sales model), which relies on certain assumptions by management, including: (i) comparable market transactions, (ii) estimated prices per unit, and (iii) negotiations with prospective buyers. There are inherent uncertainties in making these assumptions. For the Company’s impairment calculations, the Company’s fair value estimates primarily relied on a market approach and utilized prices per unit ranging from $40,000 to $175,000, with a weighted average price per unit of $91,000.
During the first quarter of 2022, the Company determined that one ALF that was classified as held for sale at December 31, 2021 no longer met the held for sale criteria. The Company reclassified this ALF’s carrying value of $4.8 million out of assets held for sale and recorded catch-up depreciation of approximately $0.1 million during the three months ended March 31, 2022.
On February 22, 2022, the Company closed on the sale of one SNF, operated by affiliates of Cascadia Healthcare, LLC (“Cascadia”), consisting of 83 beds located in Washington with a carrying value of $0.8 million, for net sales proceeds of $1.0 million. During the three months ended March 31, 2022, the Company recorded a gain of $0.2 million in connection with the sale. There was no rent reduction under the Cascadia master lease in connection with the sale.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Other Real Estate Investments, Net
3 Months Ended
Mar. 31, 2022
Investments, All Other Investments [Abstract]  
Other Real Estate Investments, Net OTHER REAL ESTATE INVESTMENTS
As of March 31, 2022 and December 31, 2021, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):
As of March 31, 2022
InvestmentFinancial Statement Line Item
Principal Balance as of March 31, 2022
Book Value as of March 31, 2022
Book Value as of December 31, 2021
Weighted Average Contractual Interest RateMaturity Date
Mezzanine loan receivableOther real estate investments$15,000 $15,155 $15,155 12.0 %11/30/2025
Other loans receivablePrepaid expenses and other assets, net5,516 5,523 3,161 8.0 %9/1/2023 - 12/31/2023
Expected credit lossPrepaid expenses and other assets, net(4,594)(4,594)— 
Total$15,922 $16,084 $18,316 
Expected credit losses and recoveries are recorded in provision for loan losses, net in the condensed consolidated statements of operations. During the three months ended March 31, 2022, the Company recorded a $4.6 million expected credit loss related to two other loans receivable that were placed on non-accrual status, including an unfunded loan commitment of $0.4 million, net of a loan loss recovery of $0.8 million related to a loan previously written-off. As of December 31, 2021, the Company had no expected credit loss and did not consider any loan receivable investments to be impaired.
The following table summarizes the interest and other income recognized from the Company’s loans receivable and other investments during the quarter ended March 31, 2022 and 2021 (dollars in thousands):
For the Three Months Ended March 31,
Investment20222021
Mezzanine loan receivable$450 $450 
Other19 55 
Total$469 $505 
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements
3 Months Ended
Mar. 31, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements FAIR VALUE MEASUREMENTS
The Company determines fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment. GAAP guidance defines three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.

Level 3 – Unobservable inputs reflect the entity’s own assumptions about the assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.

The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and, depending on various factors, it is possible that an asset or
liability may be classified differently from quarter to quarter. Changes in the type of inputs may result in a reclassification for certain assets. The Company does not expect that changes in classifications between levels will be frequent.
Items Measured at Fair Value on a Recurring Basis
The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021, aggregated by the level in the fair value hierarchy within which those instruments fall (dollars in thousands):
Level 1Level 2Level 3
Balance as of March 31, 2022
Assets:
Mezzanine loan receivable$— $— $15,155 $15,155 
Level 1Level 2Level 3
Balance as of December 31, 2021
Assets:
Mezzanine loan receivable$— $— $15,155 $15,155 

Mezzanine loan receivable: The fair value of the mezzanine loan receivable was estimated using an internal valuation model that considered the expected future cash flows of the investment, the underlying collateral value, market interest rates and other credit enhancements. As such, the Company classifies the instrument as Level 3 due to the significant unobservable inputs used in determining market interest rates for investments with similar terms. Future changes in market interest rates could materially impact the estimated discounted cash flows. As of March 31, 2022 and December 31, 2021, the Company did not have any loans measured at fair value that were 90 days or more past due.
For the three months ended March 31, 2022, there were no classification changes in assets and liabilities with Level 3 inputs in the fair value hierarchy.

Items Disclosed at Fair Value

Considerable judgment is necessary to estimate the fair value disclosure of financial instruments. The estimates of fair value presented herein are not necessarily indicative of the amounts that could be realized upon disposition of the financial instruments. A summary of the face value, carrying amount and fair value of the Notes (as defined in Note 7, Debt, below) as of March 31, 2022 and December 31, 2021 using Level 2 inputs is as follows (dollars in thousands):  
 March 31, 2022December 31, 2021
 LevelFace
Value
Carrying
Amount
Fair
Value
Face
Value
Carrying
Amount
Fair
Value
Financial liabilities:
Senior unsecured notes payable2$400,000 $394,484 $377,000 $400,000 $394,262 $410,500 

Cash and cash equivalents, accounts and other receivables, accounts payable, and accrued liabilities: The carrying value for these instruments approximate their fair values due to the short-term nature of these instruments.

Senior unsecured notes payable: The fair value of the Notes was determined using third-party quotes derived from orderly trades.

Unsecured revolving credit facility and senior unsecured term loan: The fair values approximate their carrying values as the interest rates are variable and approximate prevailing market interest rates for similar debt arrangements.
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Debt
3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
Debt DEBT
The following table summarizes the balance of the Company’s indebtedness as of March 31, 2022 and December 31, 2021 (dollars in thousands):
March 31, 2022December 31, 2021
Principal AmountDeferred Loan FeesCarrying ValuePrincipal AmountDeferred Loan FeesCarrying Value
Senior unsecured notes payable$400,000 $(5,516)$394,484 $400,000 $(5,738)$394,262 
Senior unsecured term loan200,000 (811)199,189 200,000 (864)199,136 
Unsecured revolving credit facility105,000 — 105,000 80,000 — 80,000 
$705,000 $(6,327)$698,673 $680,000 $(6,602)$673,398 

Senior Unsecured Notes Payable
2028 Senior Notes. On June 17, 2021, the Company’s wholly owned subsidiary, CTR Partnership, L.P. (the “Operating Partnership”), and its wholly owned subsidiary, CareTrust Capital Corp. (together with the Operating Partnership, the “Issuers”) completed a private offering of $400.0 million aggregate principal amount of 3.875% Senior Notes due 2028 (the “Notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended. The Notes were issued at par, resulting in gross proceeds of $400.0 million and net proceeds of approximately $393.8 million after deducting underwriting fees and other offering expenses. The Notes mature on June 30, 2028. The Notes accrue interest at a rate of 3.875% per annum payable semiannually in arrears on June 30 and December 30 of each year, commencing on December 30, 2021.
The Issuers may redeem some or all of the Notes at any time prior to March 30, 2028 at a price equal to 100% of the principal amount of the Notes redeemed plus accrued and unpaid interest on the Notes, if any, to, but not including, the redemption date, plus a “make-whole” premium. At any time on or after March 30, 2028, the Issuers may redeem some or all of the Notes at a redemption price equal to 100% of the principal amount of the Notes redeemed plus accrued interest on the Notes, if any, to, but not including, the redemption date. In addition, at any time on or prior to June 30, 2024, up to 40% of the aggregate principal amount of the Notes may be redeemed with the net proceeds of certain equity offerings at a redemption price of 103.875% of the aggregate principal amount of Notes to be redeemed plus accrued and unpaid interest on the Notes, if any, to, but not including, the redemption date. If certain changes of control of the Company occur, the Issuers will be required to make an offer to holders of the Notes to repurchase their Notes at a price of 101% of their principal amount plus accrued and unpaid interest, if any, to, but not including, the repurchase date.
The obligations under the Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by the Company and all of CareTrust’s existing and future subsidiaries (other than the Issuers) that guarantee obligations under the Amended Credit Facility (as defined below); provided, however, that such guarantees are subject to automatic release under certain customary circumstances.
The indenture governing the Notes contains customary covenants such as limiting the ability of the Company and its restricted subsidiaries to: incur or guarantee additional indebtedness; incur or guarantee secured indebtedness; pay dividends or distributions on, or redeem or repurchase, capital stock; make certain investments or other restricted payments; sell assets; enter into transactions with affiliates; merge or consolidate or sell all or substantially all of their assets; and create restrictions on the ability of the Issuers and their restricted subsidiaries to pay dividends or other amounts to the Issuers. The indenture governing the Notes also requires the Company and its restricted subsidiaries to maintain a specified ratio of unencumbered assets to unsecured indebtedness. These covenants are subject to a number of important and significant limitations, qualifications and exceptions. The indenture governing the Notes also contains customary events of default.
As of March 31, 2022, the Company was in compliance with all applicable financial covenants under the indenture governing the Notes.

Unsecured Revolving Credit Facility and Term Loan
On February 8, 2019, the Operating Partnership, as the borrower, the Company, as guarantor, CareTrust GP, LLC, and certain of the Operating Partnership’s wholly owned subsidiaries entered into an amended and restated credit and guaranty
agreement with KeyBank National Association, as administrative agent, an issuing bank and swingline lender, and the lenders party thereto (the “Amended Credit Agreement”). The Amended Credit Agreement, which amended and restated the Company’s prior credit agreement, provides for: (i) an unsecured revolving credit facility (the “Revolving Facility”) with revolving commitments in an aggregate principal amount of $600.0 million, including a letter of credit subfacility for 10% of the then available revolving commitments and a swingline loan subfacility for 10% of the then available revolving commitments and (ii) an unsecured term loan credit facility (the “Term Loan” and, together with the Revolving Facility, the “Amended Credit Facility”) in an aggregate principal amount of $200.0 million. Borrowing availability under the Revolving Facility is subject to no default or event of default under the Amended Credit Agreement having occurred at the time of borrowing. Future borrowings under the Amended Credit Facility will be used for working capital purposes, for capital expenditures, to fund acquisitions and for general corporate purposes.
The interest rates applicable to loans under the Revolving Facility are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.10% to 0.55% per annum or LIBOR plus a margin ranging from 1.10% to 1.55% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). The interest rates applicable to loans under the Term Loan are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.50% to 1.20% per annum or LIBOR plus a margin ranging from 1.50% to 2.20% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). In addition, the Operating Partnership will pay a facility fee on the revolving commitments under the Revolving Facility ranging from 0.15% to 0.35% per annum, based on the debt to asset value ratio of the Company and its consolidated subsidiaries (unless the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt and the Operating Partnership elects to decrease the applicable margin as described above, in which case the Operating Partnership will pay a facility fee on the revolving commitments ranging from 0.125% to 0.30% per annum based on the credit ratings of the Company’s senior long-term unsecured debt). As of March 31, 2022, the Operating Partnership had $200.0 million of borrowings outstanding under the Term Loan and $105.0 million outstanding under the Revolving Facility.
The Revolving Facility has a maturity date of February 8, 2023, and includes, at the sole discretion of the Operating Partnership, two, six-month extension options. The Term Loan has a maturity date of February 8, 2026.
The Amended Credit Facility is guaranteed, jointly and severally, by the Company and its wholly owned subsidiaries that are party to the Amended Credit Agreement (other than the Operating Partnership). The Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend organizational documents and pay certain dividends and other restricted payments. The Amended Credit Agreement requires the Company to comply with financial maintenance covenants to be tested quarterly, consisting of a maximum debt to asset value ratio, a minimum fixed charge coverage ratio, a minimum tangible net worth, a maximum cash distributions to operating income ratio, a maximum secured debt to asset value ratio, a maximum secured recourse debt to asset value ratio, a maximum unsecured debt to unencumbered properties asset value ratio, a minimum unsecured interest coverage ratio and a minimum rent coverage ratio. The Amended Credit Agreement also contains certain customary events of default, including the failure to make timely payments under the Amended Credit Facility or other material indebtedness, the failure to satisfy certain covenants (including the financial maintenance covenants), the occurrence of change of control and specified events of bankruptcy and insolvency.
As of March 31, 2022, the Company was in compliance with all applicable financial covenants under the Amended Credit Agreement.
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Equity
3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Equity EQUITY
Common Stock
At-The-Market Offering—On March 10, 2020, the Company entered into a new equity distribution agreement to issue and sell, from time to time, up to $500.0 million in aggregate offering price of its common stock through an “at-the-market” equity offering program (the “ATM Program”).
There was no ATM Program activity for the three months ended March 31, 2022. The following table summarizes the ATM Program activity for the three months ended March 31, 2021 (in thousands, except per share amounts).
For the Three Months Ended
March 31, 2021
Number of shares702 
Average sales price per share$23.62 
Gross proceeds(1)
$16,579 
(1) Total gross proceeds is before $0.2 million of commissions paid to the sales agents during the three months ended March 31, 2021 under the ATM Program.
As of March 31, 2022, the Company had $476.5 million available for future issuances under the ATM Program.
Share Repurchase Program—On March 20, 2020, the Company’s Board of Directors authorized a share repurchase program for up to $150.0 million of outstanding shares of the Company’s common stock (the “Repurchase Program”). Repurchases under the Repurchase Program, which expires on March 31, 2023, may be made through open market purchases, privately negotiated transactions, structured or derivative transactions, including accelerated share repurchase transactions, or other methods of acquiring shares, in each case subject to market conditions and at such times as shall be permitted by applicable securities laws and determined by management. Repurchases under the Repurchase Program may also be made pursuant to a plan adopted under Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. The Company expects to finance any share repurchases under the Repurchase Program using available cash and may also use short-term borrowings under the Revolving Facility. Through March 31, 2022, the Company has not repurchased any shares of common stock under the Repurchase Program. As of March 31, 2022, $150.0 million remained available under the Repurchase Program. The Repurchase Program may be modified, discontinued or suspended at any time.
Dividends on Common Stock—The following table summarizes the cash dividends per share of common stock declared by the Company’s Board of Directors for the first quarter of 2022 (dollars in thousands, except per share amounts):
For the Three Months Ended
March 31, 2022
Dividends declared per share$0.275 
Dividends payment dateApril 15, 2022
Dividends payable as of record date$26,691 
Dividends record dateMarch 31, 2022
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation
3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation STOCK-BASED COMPENSATION
All stock-based awards are subject to the terms of the CareTrust REIT, Inc. and CTR Partnership, L.P. Incentive Award Plan (the “Plan”). The Plan provides for the granting of stock-based compensation, including stock options, restricted stock, performance awards, restricted stock units, relative total stockholder return based stock awards (“TSR Awards”) and other incentive awards to officers, employees and directors in connection with their employment with or services provided to the Company. Under the Plan, 5,000,000 shares have been authorized for awards.
Under the Plan, restricted stock awards (“RSAs”) granted in fiscal 2022 vest in equal annual installments beginning on the first anniversary of the grant date over a three year period.
The following table summarizes the RSAs and performance award activity for the three months ended March 31, 2022:
SharesWeighted Average Share Price
Unvested balance at December 31, 2021891,333 $20.91 
Granted:
RSAs9,684 17.56 
Vested(329,080)20.10 
Forfeited(1,900)21.50 
Unvested balance at March 31, 2022570,037 $21.32 
As of March 31, 2022, the weighted-average remaining vesting period of such awards was 1.6 years.
The following table summarizes the stock-based compensation expense recognized (dollars in thousands):
 For the Three Months Ended March 31,
 20222021
Stock-based compensation expense$1,521 $1,585 
As of March 31, 2022, there was $10.0 million of unamortized stock-based compensation expense related to the unvested RSAs, performance stock awards and TSR Awards.
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.22.1
(Loss) Earnings Per Common Share
3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
(Loss) Earnings Per Common Share EARNINGS PER COMMON SHARE
The following table presents the calculation of basic and diluted (loss) earnings per common share (“EPS”) for the Company’s common stock for the three months ended March 31, 2022 and 2021, and reconciles the weighted-average common shares outstanding used in the calculation of basic EPS to the weighted-average common shares outstanding used in the calculation of diluted EPS (amounts in thousands, except per share amounts):
 
 For the Three Months Ended March 31,
 20222021
Numerator:
Net (loss) income$(43,264)$20,486 
Less: Net income allocated to participating securities(117)(119)
Numerator for basic and diluted earnings available to common stockholders$(43,381)$20,367 
Denominator:
Weighted-average basic common shares outstanding96,410 95,378 
Dilutive performance stock awards— 
Weighted-average diluted common shares outstanding96,410 95,385 
(Loss) earnings per common share, basic$(0.45)$0.21 
(Loss) earnings per common share, diluted$(0.45)$0.21 
Antidilutive unvested RSAs, performance awards and TSR Awards excluded from the computation534 446 
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies COMMITMENTS AND CONTINGENCIES
The Company and its subsidiaries are and may become from time to time a party to various claims and lawsuits arising in the ordinary course of business, which are not individually or in the aggregate anticipated to have a material adverse effect on the Company’s results of operations, financial condition or cash flows. Claims and lawsuits may include matters involving general or professional liability asserted against the Company’s tenants, which are the responsibility of the Company’s tenants and for which the Company is entitled to be indemnified by its tenants under the insurance and indemnification provisions in the applicable leases.
Capital expenditures for each property leased under the Company’s triple-net leases are generally the responsibility of the tenant, except that, for the facilities leased to subsidiaries of Ensign and Pennant, the tenant will have an option to require the Company to finance certain capital expenditures up to an aggregate of 20% of the Company’s initial investment in such property, subject to a corresponding rent increase at the time of funding. For the Company’s other triple-net master leases, the tenants also have the option to request capital expenditure funding that would generally be subject to a corresponding rent increase at the time of funding, which are subject to tenant compliance with the conditions to the Company’s approval and funding of their requests. As of March 31, 2022, the Company had committed to fund expansions, construction and capital improvements at certain triple-net leased facilities totaling $5.5 million, of which $4.4 million is subject to rent increase at the time of funding.
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Concentration of Risk
3 Months Ended
Mar. 31, 2022
Risks and Uncertainties [Abstract]  
Concentration of Risk CONCENTRATION OF RISK
Concentrations of credit risk arise when one or more tenants, operators, or obligors related to the Company’s investments are engaged in similar business activities or activities in the same geographic region, or have similar economic features that would cause their ability to meet contractual obligations, including those to the Company, to be similarly affected by changes in economic conditions.
Major operator concentration - The Company has operators from which it derived 10% or more of its rental revenue for the three months ended March 31, 2022 and 2021. The following table sets forth information regarding the Company’s major operators as of March 31, 2022 and 2021:
 Number of FacilitiesNumber of Beds/Units
Percentage of Total Revenue(1)
Operator(2)
SNFCampusALF/ILFSNFCampusALF/ILF
March 31, 2022
Ensign83 88,756 997495 34 %
Priority Management Group13 2— 1,742 402— 16 %
March 31, 2021
Ensign77 88,129 1,027 395 32 %
Priority Management Group13 2— 1,742 402 — 16 %
(1)    The Company’s rental income, exclusive of operating expense reimbursements.
(2)    Ensign is subject to the registration and reporting requirements of the SEC and is required to file with the SEC annual reports containing audited financial information and quarterly reports containing unaudited financial information. Ensign’s financial statements, as filed with the SEC, can be found at http://www.sec.gov. The Company has not verified this information through an independent investigation or otherwise.
Major geographic concentration – The following table provides information regarding the Company’s concentrations with respect to certain states, from which the Company derived 10% or more of its rental revenue for the three months ended March 31, 2022:
 Number of FacilitiesNumber of Beds/Units
Percentage of Total Revenue(1)
StateSNFCampusALF/ILFSNFCampusALF/ILF
CA27 83,048 1,359 449 26 %
TX38 34,829 536242 22 %
(1)    The Company’s rental income, exclusive of operating expense reimbursements.
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation Basis of Presentation—The accompanying condensed consolidated financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, the condensed consolidated financial statements do not include all of the disclosures required by GAAP for a complete set of annual audited financial statements. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. In the opinion of management, all adjustments which are of a normal and recurring nature and considered necessary for a fair presentation of the results of the interim periods presented have been included. The results of operations for the interim periods are not necessarily indicative of results for the full year. All intercompany transactions and account balances within the Company have been eliminated.
Recent Accounting Pronouncements Recent Accounting Pronouncements—In March 2020, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), that provides optional relief to applying reference rate reform to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”). For U.S. Dollar LIBOR, the overnight, one-month, three-month, six-month and one-year LIBOR rates will be discontinued in June 2023, while other U.S. Dollar LIBOR rates were discontinued at the end of 2021. The amendments in this update are effective immediately and may be applied through December 31, 2022. Adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.
Fair Value Measurements
The Company determines fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment. GAAP guidance defines three levels of inputs that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.

Level 3 – Unobservable inputs reflect the entity’s own assumptions about the assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.

The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and, depending on various factors, it is possible that an asset or
liability may be classified differently from quarter to quarter. Changes in the type of inputs may result in a reclassification for certain assets. The Company does not expect that changes in classifications between levels will be frequent.
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Real Estate Investments, Net (Tables)
3 Months Ended
Mar. 31, 2022
Real Estate [Abstract]  
Summary of Investment in Owned Properties The following table summarizes the Company’s real estate properties held for investment at March 31, 2022 and December 31, 2021 (dollars in thousands):
March 31, 2022December 31, 2021
Land$236,986 $251,787 
Buildings and improvements1,431,631 1,622,019 
Integral equipment, furniture and fixtures95,997 104,722 
Identified intangible assets2,658 1,257 
Real estate investments1,767,272 1,979,785 
Accumulated depreciation and amortization(364,383)(389,814)
Real estate investments, net$1,402,889 $1,589,971 
Schedule of Total Future Contractual Minimum Rental Income As of March 31, 2022, the Company’s total future contractual minimum rental income for all of its tenants, excluding operating expense reimbursements, was (dollars in thousands):
YearAmount
2022 (nine months)$146,848 
2023195,547 
2024194,202 
2025194,173 
2026194,278 
2027191,589 
Thereafter998,873 
Total$2,115,510 
Schedule Of Tenant Purchase Options
Certain of the Company’s operators hold purchase options allowing them to acquire properties they currently lease from the Company. A summary of these purchase options is presented below (dollars in thousands):
Asset TypePropertiesLease ExpirationNext Option Open Date
Option Type(1)
Current Cash Rent(2)
ALF7October 20341/1/2022
(3)
A$3,383 
SNF11November 20301/1/2022
(3)
C4,944 
SNF1March 20294/1/2022
(4)
B / C(5)
779 
SNF / Campus2October 20321/1/2023
(3)
B1,065 
SNF4November 203412/1/2024
(4)
B3,796 
ALF2October 20341/1/2026
(3)
A1,598 
(1) Option type includes:
A - Fixed base price plus a specified share on any appreciation.
B - Fixed base price.
C - Fixed capitalization rate on lease revenue.
(2) Based on annualized cash revenue for contracts in place as of March 31, 2022.
(3) Option window is open for six months.
(4) Option window is open until the expiration of the lease term.
(5) Purchase option reflects two option types.
Schedule of Rental Income
The following table summarizes components of the Company’s rental income (dollars in thousands):
For the Three Months Ended March 31,
Rental Income20222021
Contractual rent due(1)
$46,978 $45,171 
Straight-line rent12 
Adjustment for collectibility(2)
(977)— 
Lease termination revenue(3)
— 63 
Total$46,007 $45,246 
(1) Includes initial cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received.
(2)    During the three months ended March 31, 2022, and in accordance with Accounting Standards Codification 842, the Company evaluated the collectibility of lease payments through maturity and determined that it was not probable that the Company would collect substantially all of the contractual obligations from four existing and former operators. As such, the Company reversed $0.7 million of operating expense reimbursements, $0.2 million of contractual rent and $0.1 million of straight-line rent during the three months ended March 31, 2022. If lease payments are subsequently deemed probable of collection, the Company will increase rental income for such recoveries.
(3) During the three months ended March 31, 2021, in connection with the agreement to terminate its lease agreements with Metron Integrated Health Systems (“Metron”) and to sell the facilities to a third party, the Company received approximately $0.1 million in lease termination revenue from Metron affiliates.
Schedule of Real Estate Acquisitions
The following table summarizes the Company’s acquisitions for the three months ended March 31, 2022 (dollars in thousands):
Type of Property
Purchase Price(1)
Initial Annual Cash RentNumber of Properties
Number of Beds/Units(2)
Skilled nursing$8,918 $815 135 
Multi-service campuses13,003 1,235 130 
Total$21,921 $2,050 265 
(1) Purchase price includes capitalized acquisition costs.
(2) The number of beds/units includes operating beds at the acquisition date.
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Other Real Estate Investments, Net (Tables)
3 Months Ended
Mar. 31, 2022
Investments, All Other Investments [Abstract]  
Schedule of Loans Receivable and Other Investments
As of March 31, 2022 and December 31, 2021, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):
As of March 31, 2022
InvestmentFinancial Statement Line Item
Principal Balance as of March 31, 2022
Book Value as of March 31, 2022
Book Value as of December 31, 2021
Weighted Average Contractual Interest RateMaturity Date
Mezzanine loan receivableOther real estate investments$15,000 $15,155 $15,155 12.0 %11/30/2025
Other loans receivablePrepaid expenses and other assets, net5,516 5,523 3,161 8.0 %9/1/2023 - 12/31/2023
Expected credit lossPrepaid expenses and other assets, net(4,594)(4,594)— 
Total$15,922 $16,084 $18,316 
Schedule of Interest and Other Income
The following table summarizes the interest and other income recognized from the Company’s loans receivable and other investments during the quarter ended March 31, 2022 and 2021 (dollars in thousands):
For the Three Months Ended March 31,
Investment20222021
Mezzanine loan receivable$450 $450 
Other19 55 
Total$469 $505 
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2022
Fair Value Disclosures [Abstract]  
Schedule of Items Measured at Fair Value on a Recurring Basis
The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021, aggregated by the level in the fair value hierarchy within which those instruments fall (dollars in thousands):
Level 1Level 2Level 3
Balance as of March 31, 2022
Assets:
Mezzanine loan receivable$— $— $15,155 $15,155 
Level 1Level 2Level 3
Balance as of December 31, 2021
Assets:
Mezzanine loan receivable$— $— $15,155 $15,155 
Summary of Face Value, Carrying Amount and Fair Value of Financial Instruments A summary of the face value, carrying amount and fair value of the Notes (as defined in Note 7, Debt, below) as of March 31, 2022 and December 31, 2021 using Level 2 inputs is as follows (dollars in thousands):  
 March 31, 2022December 31, 2021
 LevelFace
Value
Carrying
Amount
Fair
Value
Face
Value
Carrying
Amount
Fair
Value
Financial liabilities:
Senior unsecured notes payable2$400,000 $394,484 $377,000 $400,000 $394,262 $410,500 
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Debt (Tables)
3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
Schedule of Debt Instruments The following table summarizes the balance of the Company’s indebtedness as of March 31, 2022 and December 31, 2021 (dollars in thousands):
March 31, 2022December 31, 2021
Principal AmountDeferred Loan FeesCarrying ValuePrincipal AmountDeferred Loan FeesCarrying Value
Senior unsecured notes payable$400,000 $(5,516)$394,484 $400,000 $(5,738)$394,262 
Senior unsecured term loan200,000 (811)199,189 200,000 (864)199,136 
Unsecured revolving credit facility105,000 — 105,000 80,000 — 80,000 
$705,000 $(6,327)$698,673 $680,000 $(6,602)$673,398 
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Equity (Tables)
3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Summary of the At-The-Market Offering Program The following table summarizes the ATM Program activity for the three months ended March 31, 2021 (in thousands, except per share amounts).
For the Three Months Ended
March 31, 2021
Number of shares702 
Average sales price per share$23.62 
Gross proceeds(1)
$16,579 
(1) Total gross proceeds is before $0.2 million of commissions paid to the sales agents during the three months ended March 31, 2021 under the ATM Program.
Schedule of Dividends on Common Stock The following table summarizes the cash dividends per share of common stock declared by the Company’s Board of Directors for the first quarter of 2022 (dollars in thousands, except per share amounts):
For the Three Months Ended
March 31, 2022
Dividends declared per share$0.275 
Dividends payment dateApril 15, 2022
Dividends payable as of record date$26,691 
Dividends record dateMarch 31, 2022
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
Summary of Restricted Stock Award and Performance Award Activity The following table summarizes the RSAs and performance award activity for the three months ended March 31, 2022:
SharesWeighted Average Share Price
Unvested balance at December 31, 2021891,333 $20.91 
Granted:
RSAs9,684 17.56 
Vested(329,080)20.10 
Forfeited(1,900)21.50 
Unvested balance at March 31, 2022570,037 $21.32 
Schedule of Stock-Based Compensation Expense The following table summarizes the stock-based compensation expense recognized (dollars in thousands):
 For the Three Months Ended March 31,
 20222021
Stock-based compensation expense$1,521 $1,585 
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.22.1
(Loss) Earnings Per Common Share (Tables)
3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
Reconciliation of Weighted-Average Common Shares Outstanding Used in Calculation of Basic EPS to Diluted EPS
The following table presents the calculation of basic and diluted (loss) earnings per common share (“EPS”) for the Company’s common stock for the three months ended March 31, 2022 and 2021, and reconciles the weighted-average common shares outstanding used in the calculation of basic EPS to the weighted-average common shares outstanding used in the calculation of diluted EPS (amounts in thousands, except per share amounts):
 
 For the Three Months Ended March 31,
 20222021
Numerator:
Net (loss) income$(43,264)$20,486 
Less: Net income allocated to participating securities(117)(119)
Numerator for basic and diluted earnings available to common stockholders$(43,381)$20,367 
Denominator:
Weighted-average basic common shares outstanding96,410 95,378 
Dilutive performance stock awards— 
Weighted-average diluted common shares outstanding96,410 95,385 
(Loss) earnings per common share, basic$(0.45)$0.21 
(Loss) earnings per common share, diluted$(0.45)$0.21 
Antidilutive unvested RSAs, performance awards and TSR Awards excluded from the computation534 446 
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Concentration of Risk (Tables)
3 Months Ended
Mar. 31, 2022
Risks and Uncertainties [Abstract]  
Schedules of Concentration of Risk
Major operator concentration - The Company has operators from which it derived 10% or more of its rental revenue for the three months ended March 31, 2022 and 2021. The following table sets forth information regarding the Company’s major operators as of March 31, 2022 and 2021:
 Number of FacilitiesNumber of Beds/Units
Percentage of Total Revenue(1)
Operator(2)
SNFCampusALF/ILFSNFCampusALF/ILF
March 31, 2022
Ensign83 88,756 997495 34 %
Priority Management Group13 2— 1,742 402— 16 %
March 31, 2021
Ensign77 88,129 1,027 395 32 %
Priority Management Group13 2— 1,742 402 — 16 %
(1)    The Company’s rental income, exclusive of operating expense reimbursements.
(2)    Ensign is subject to the registration and reporting requirements of the SEC and is required to file with the SEC annual reports containing audited financial information and quarterly reports containing unaudited financial information. Ensign’s financial statements, as filed with the SEC, can be found at http://www.sec.gov. The Company has not verified this information through an independent investigation or otherwise.
Major geographic concentration – The following table provides information regarding the Company’s concentrations with respect to certain states, from which the Company derived 10% or more of its rental revenue for the three months ended March 31, 2022:
 Number of FacilitiesNumber of Beds/Units
Percentage of Total Revenue(1)
StateSNFCampusALF/ILFSNFCampusALF/ILF
CA27 83,048 1,359 449 26 %
TX38 34,829 536242 22 %
(1)    The Company’s rental income, exclusive of operating expense reimbursements.
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Organization (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2022
USD ($)
state
facility
bed
Dec. 31, 2021
USD ($)
Real Estate Properties [Line Items]    
Number of states with properties | state 29  
Other real estate investments | $ $ 15,155 $ 15,155
Skilled nursing, multi-service campuses, assisted living and independent living facilities    
Real Estate Properties [Line Items]    
Number of facilities | facility 228  
Number of operational beds and units in facilities | bed 23,834  
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Real Estate Investments, Net - Narrative (Details)
Mar. 31, 2022
facility
Skilled nursing, multi-service campuses, assisted living and independent living facilities  
Real Estate [Line Items]  
Number of facilities 228
Triple-net leases | Various other operators | Skilled nursing, multi-service campuses, assisted living and independent living facilities  
Real Estate [Line Items]  
Number of facilities 226
Short-term lease  
Real Estate [Line Items]  
Number of facilities 2
Held for sale  
Real Estate [Line Items]  
Number of facilities 27
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Real Estate Investments, Net - Real Estate Properties Held for Investment (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Real Estate [Abstract]    
Land $ 236,986 $ 251,787
Buildings and improvements 1,431,631 1,622,019
Integral equipment, furniture and fixtures 95,997 104,722
Identified intangible assets 2,658 1,257
Real estate investments 1,767,272 1,979,785
Accumulated depreciation and amortization (364,383) (389,814)
Real estate investments, net $ 1,402,889 $ 1,589,971
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Real Estate Investments, Net - Future Contractual Minimum Rental Income (Details)
$ in Thousands
Mar. 31, 2022
USD ($)
Future Contractual Minimum Rental Income  
2022 (nine months) $ 146,848
2023 195,547
2024 194,202
2025 194,173
2026 194,278
2027 191,589
Thereafter 998,873
Total $ 2,115,510
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Real Estate Investments, Net - Tenant Purchase Options (Details)
$ in Thousands
Mar. 31, 2022
USD ($)
property
ALF | Lease Expiration October 2034, Next option 2022  
Lessor, Lease, Description [Line Items]  
Properties | property 7
Current Cash Rent | $ $ 3,383
ALF | Lease Expiration October 2034, Next option 2026  
Lessor, Lease, Description [Line Items]  
Properties | property 2
Current Cash Rent | $ $ 1,598
SNF | Lease Expiration November 2030, Next option 2022  
Lessor, Lease, Description [Line Items]  
Properties | property 11
Current Cash Rent | $ $ 4,944
SNF | Lease Expiration March 2029, Next option 2022  
Lessor, Lease, Description [Line Items]  
Properties | property 1
Current Cash Rent | $ $ 779
SNF | Lease Expiration November 2034, Next option 2024  
Lessor, Lease, Description [Line Items]  
Properties | property 4
Current Cash Rent | $ $ 3,796
SNF / Campus | Lease Expiration October 2032, Next option 2023  
Lessor, Lease, Description [Line Items]  
Properties | property 2
Current Cash Rent | $ $ 1,065
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Real Estate Investments, Net - Rental Income (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Rental Income    
Contractual rent due $ 46,978 $ 45,171
Straight-line rent 6 12
Adjustments for collectibility (977) 0
Lease termination revenue 0 63
Total 46,007 45,246
Operating expense reimbursements    
Rental Income    
Adjustments for collectibility (700)  
Contractual rent    
Rental Income    
Adjustments for collectibility (200)  
Straight-line rent    
Rental Income    
Adjustments for collectibility $ (100)  
Metron    
Rental Income    
Lease termination revenue   $ 100
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Real Estate Investments, Net - Recent Real Estate Acquisitions (Details)
$ in Thousands
3 Months Ended
Mar. 01, 2022
facility
Mar. 31, 2022
USD ($)
unit
property
Business Acquisition [Line Items]    
Purchase Price   $ 21,921
Initial Annual Cash Rent   $ 2,050
Number of Properties | property   2
Number of Beds/Units | unit   265
Skilled nursing    
Business Acquisition [Line Items]    
Purchase Price   $ 8,918
Initial Annual Cash Rent   $ 815
Number of Properties | property   1
Number of Beds/Units | unit   135
Multi-service campuses    
Business Acquisition [Line Items]    
Purchase Price   $ 13,003
Initial Annual Cash Rent   $ 1,235
Number of Properties 1 1
Number of Beds/Units | unit   130
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Real Estate Investments, Net - Lease Amendments Narrative (Details)
$ in Thousands
3 Months Ended
Mar. 01, 2022
USD ($)
facility
extension_option
Feb. 01, 2022
USD ($)
extension_option
facility
Mar. 31, 2022
property
Real Estate [Line Items]      
Number of properties acquired | property     2
Ensign amended triple-net master lease      
Real Estate [Line Items]      
Initial lease term (in years) 11 years    
Number of renewal options | extension_option 2    
Lease renewal term (in years) 5 years    
Annual cash rent increase under amended lease | $ $ 300    
Eduro amended triple-net master lease      
Real Estate [Line Items]      
Initial lease term (in years)   12 years  
Number of renewal options | extension_option   2  
Lease renewal term (in years)   5 years  
Annual cash rent increase under amended lease | $   $ 800  
WLC amended triple-net master lease      
Real Estate [Line Items]      
Initial lease term (in years) 12 years    
Number of renewal options | extension_option 2    
Lease renewal term (in years) 5 years    
Annual cash rent increase under amended lease | $ $ 1,200    
Skilled nursing facility      
Real Estate [Line Items]      
Number of properties acquired | facility   1  
Multi-service campuses      
Real Estate [Line Items]      
Number of properties acquired 1   1
Ensign | Assisted living      
Real Estate [Line Items]      
Number of properties transferred | facility 1    
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Impairment of Real Estate Investments, Assets Held for Sale, Net and Asset Sales (Details)
$ in Thousands
3 Months Ended
Feb. 22, 2022
USD ($)
bed
facility
Mar. 31, 2022
USD ($)
facility
Mar. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
facility
Real Estate [Line Items]        
Number of properties to be repurposed | facility   3    
Contractual cash rent attributable to properties held for sale and repurposed (percent)   10.00%    
Assets held for sale, net   $ 141,716   $ 4,835
Amount transferred out of assets held-for-sale   4,800    
Catch-up depreciation   100    
Real estate investments, net   1,402,889   $ 1,589,971
Proceeds from sale   959 $ 6,814  
Gain on sale of real estate   $ 186 $ (192)  
Held for sale        
Real Estate [Line Items]        
Number of properties | facility   27    
Impairment expense to reduce carrying value to fair value less costs to sell   $ 59,700    
Number of properties impaired | facility   20    
Held for sale | ALF        
Real Estate [Line Items]        
Number of properties | facility       1
Disposed of by sale | Skilled nursing facility        
Real Estate [Line Items]        
Number of properties | facility 1      
Number of operational beds | bed 83      
Real estate investments, net $ 800      
Proceeds from sale 1,000      
Gain on sale of real estate $ 200      
Valuation, market approach | Level 3 | Minimum        
Real Estate [Line Items]        
Prices per unit input   $ 40    
Valuation, market approach | Level 3 | Maximum        
Real Estate [Line Items]        
Prices per unit input   175    
Valuation, market approach | Level 3 | Weighted average        
Real Estate [Line Items]        
Prices per unit input   $ 91    
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Other Real Estate Investments, Net - Loans Receivable and Other Investments (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Real Estate Properties [Line Items]    
Principal Amount $ 15,922  
Expected credit loss (4,594) $ 0
Loan receivable 16,084 18,316
Mezzanine loan receivable    
Real Estate Properties [Line Items]    
Principal Amount 15,000  
Book value $ 15,155 15,155
Weighted Average Contractual Interest Rate 12.00%  
Other loans receivable    
Real Estate Properties [Line Items]    
Principal Amount $ 5,516  
Book value $ 5,523 $ 3,161
Weighted Average Contractual Interest Rate 8.00%  
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Other Real Estate Investments, Net - Interest and Other Income (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Real Estate Properties [Line Items]    
Interest and other income $ 469 $ 505
Mezzanine loan receivable    
Real Estate Properties [Line Items]    
Interest and other income 450 450
Other    
Real Estate Properties [Line Items]    
Interest and other income $ 19 $ 55
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Other Real Estate Investments, Net - Narrative (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2022
USD ($)
loan
Dec. 31, 2021
USD ($)
Financing Receivable, Allowance for Credit Loss [Line Items]    
Expected credit loss $ 4,594 $ 0
Other loans receivable    
Financing Receivable, Allowance for Credit Loss [Line Items]    
Expected credit loss recognized $ 4,600  
Number of loans receivable with provision | loan 2  
Unfunded loan commitment $ 400  
Loan loss recovery $ 800  
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements - Items Measured at Fair Value on Recurring Basis (Details) - Recurring - Mezzanine loan receivable - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Assets:    
Mezzanine loan receivable $ 15,155 $ 15,155
Level 1    
Assets:    
Mezzanine loan receivable 0 0
Level 2    
Assets:    
Mezzanine loan receivable 0 0
Level 3    
Assets:    
Mezzanine loan receivable $ 15,155 $ 15,155
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements - Narrative (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Greater than 90 days past due    
Financing Receivable, Past Due [Line Items]    
Mortgage loan receivable $ 0 $ 0
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements - Face Value, Carrying Amount and Fair Value of Financial Instruments (Details) - Notes payable - Senior unsecured notes payable - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Jun. 17, 2021
Financial liabilities:      
Senior unsecured notes payable - face value $ 400,000,000 $ 400,000,000 $ 400,000,000
Carrying Amount | Level 2      
Financial liabilities:      
Senior unsecured notes payable 394,484,000 394,262,000  
Fair Value | Level 2      
Financial liabilities:      
Senior unsecured notes payable $ 377,000,000 $ 410,500,000  
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.22.1
Debt - Schedule of Debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Debt Instrument [Line Items]    
Principal Amount $ 705,000 $ 680,000
Deferred Loan Fees (6,327) (6,602)
Carrying Value 698,673 673,398
Notes payable | Senior unsecured notes payable    
Debt Instrument [Line Items]    
Principal Amount 400,000 400,000
Deferred Loan Fees (5,516) (5,738)
Carrying Value 394,484 394,262
Term loan | Senior unsecured term loan    
Debt Instrument [Line Items]    
Principal Amount 200,000 200,000
Deferred Loan Fees (811) (864)
Carrying Value 199,189 199,136
Revolving credit facility    
Debt Instrument [Line Items]    
Principal Amount 105,000 80,000
Deferred Loan Fees 0 0
Carrying Value $ 105,000 $ 80,000
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.22.1
Debt - Senior Unsecured Notes Payable Narrative (Details) - Notes payable - 3.875% Senior Notes due 2028 - USD ($)
Jun. 17, 2021
Mar. 31, 2022
Dec. 31, 2021
Debt Instrument [Line Items]      
Debt instrument face amount $ 400,000,000 $ 400,000,000 $ 400,000,000
Interest rate (percent) 3.875%    
Gross proceeds from issuance $ 400,000,000    
Net proceeds from issuance $ 393,800,000    
Redemption price, percentage upon change of control (percent) 101.00%    
Period prior to March 30 2028      
Debt Instrument [Line Items]      
Redemption price of notes (percent) 100.00%    
Period after March 30 2028      
Debt Instrument [Line Items]      
Redemption price of notes (percent) 100.00%    
Period prior to June 30 2024      
Debt Instrument [Line Items]      
Redemption price of notes (percent) 103.875%    
Percentage of principal amount (percent) 40.00%    
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.22.1
Debt - Unsecured Revolving Credit Facility and Term Loan Narrative (Details)
Feb. 08, 2019
USD ($)
extension_option
Mar. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Line of Credit Facility [Line Items]      
Outstanding amounts   $ 705,000,000 $ 680,000,000
Borrowings outstanding   105,000,000 80,000,000
Revolving credit facility      
Line of Credit Facility [Line Items]      
Credit facility borrowing capacity $ 600,000,000    
Outstanding amounts   105,000,000 80,000,000
Borrowings outstanding   105,000,000  
Number of extension options | extension_option 2    
Extension option term (in months) 6 months    
Revolving credit facility | Minimum      
Line of Credit Facility [Line Items]      
Facility fee on revolving commitment fees (percent) 0.15%    
Facility fee on revolving commitment fee based on investment grade ratings (percent) 0.125%    
Revolving credit facility | Minimum | Base Rate      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (percent) 0.10%    
Revolving credit facility | Minimum | LIBOR      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (percent) 1.10%    
Revolving credit facility | Maximum      
Line of Credit Facility [Line Items]      
Facility fee on revolving commitment fees (percent) 0.35%    
Facility fee on revolving commitment fee based on investment grade ratings (percent) 0.30%    
Revolving credit facility | Maximum | Base Rate      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (percent) 0.55%    
Revolving credit facility | Maximum | LIBOR      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (percent) 1.55%    
Letter of credit      
Line of Credit Facility [Line Items]      
Subfacility capacity as percentage of available revolving commitments (percent) 10.00%    
Swingline loan      
Line of Credit Facility [Line Items]      
Subfacility capacity as percentage of available revolving commitments (percent) 10.00%    
Term loan | Senior unsecured term loan      
Line of Credit Facility [Line Items]      
Debt instrument face amount $ 200,000,000    
Outstanding amounts   $ 200,000,000 $ 200,000,000
Term loan | Senior unsecured term loan | Minimum | Base Rate      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (percent) 0.50%    
Term loan | Senior unsecured term loan | Minimum | LIBOR      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (percent) 1.50%    
Term loan | Senior unsecured term loan | Maximum | Base Rate      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (percent) 1.20%    
Term loan | Senior unsecured term loan | Maximum | LIBOR      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (percent) 2.20%    
XML 56 R47.htm IDEA: XBRL DOCUMENT v3.22.1
Equity - Narrative (Details) - USD ($)
3 Months Ended 24 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2022
Mar. 20, 2020
Mar. 10, 2020
Class of Stock [Line Items]          
Share repurchase program authorization       $ 150,000,000  
Shares repurchased (in shares)     0    
Remaining available authorization $ 150,000,000   $ 150,000,000    
ATM Program          
Class of Stock [Line Items]          
Issuance of common stock, net, (in shares) 0 702,000      
Remaining offering amount available $ 476,500,000   $ 476,500,000    
ATM Program | Maximum          
Class of Stock [Line Items]          
Authorized aggregate offering price of common stock         $ 500,000,000
XML 57 R48.htm IDEA: XBRL DOCUMENT v3.22.1
Equity - At-The-Market Offering (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Class of Stock [Line Items]    
Gross proceeds $ 0 $ 16,191
ATM Program    
Class of Stock [Line Items]    
Number of shares 0 702,000
Average sales price per share (usd per share)   $ 23.62
Gross proceeds   $ 16,579
Commissions paid on stock issuance   $ 200
XML 58 R49.htm IDEA: XBRL DOCUMENT v3.22.1
Equity - Dividends on Common Stock (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dividends on common stock    
Dividends declared per share $ 0.275 $ 0.265
Dividends payment date Apr. 15, 2022  
Dividends payable as of record date $ 26,691  
Dividends record date Mar. 31, 2022  
XML 59 R50.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation - Narrative (Details)
$ in Millions
3 Months Ended
Mar. 31, 2022
USD ($)
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of shares authorized for awards | shares 5,000,000
Unamortized stock-based compensation expense | $ $ 10.0
RSAs  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Vesting period (in years) 3 years
RSAs and PSAs  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Weighted-average remaining vesting period (in years) 1 year 7 months 6 days
XML 60 R51.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation - Restricted Stock and Performance Awards Activity (Details) - RSAs and PSAs
3 Months Ended
Mar. 31, 2022
$ / shares
shares
Shares  
Unvested, beginning balance (shares) | shares 891,333
Granted (shares) | shares 9,684
Vested (shares) | shares (329,080)
Forfeited (shares) | shares (1,900)
Unvested, ending balance (shares) | shares 570,037
Weighted Average Share Price  
Unvested, beginning balance (usd per share) | $ / shares $ 20.91
Granted (usd per share) | $ / shares 17.56
Vested (usd per share) | $ / shares 20.10
Forfeited (usd per share) | $ / shares 21.50
Unvested, ending balance (usd per share) | $ / shares $ 21.32
XML 61 R52.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]    
Stock-based compensation expense $ 1,521 $ 1,585
XML 62 R53.htm IDEA: XBRL DOCUMENT v3.22.1
(Loss) Earnings Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Numerator:    
Net income (loss) $ (43,264) $ 20,486
Less: Net income allocated to participating securities (117) (119)
Numerator for basic earnings available to common stockholders (43,381) 20,367
Numerator for basic and diluted earnings available to common stockholders $ (43,381) $ 20,367
Denominator:    
Weighted-average basic common shares outstanding (in shares) 96,410 95,378
Diluted market condition stock awards (in shares) 0 7
Weighted-average diluted common shares outstanding (in shares) 96,410 95,385
(Loss) earnings per common share, basic (in dollars per share) $ (0.45) $ 0.21
(Loss) earnings per common share, diluted (in dollars per share) $ (0.45) $ 0.21
Antidilutive unvested RSAs, performance awards and TSR Awards excluded from the computation 534 446
XML 63 R54.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies (Details)
$ in Millions
Mar. 31, 2022
USD ($)
Ensign and Pennant  
Other Commitments [Line Items]  
Aggregate required financing of capital expenditures as percentage of initial investment in property (percent) 20.00%
Certain capital improvements at triple-net leased facilities  
Other Commitments [Line Items]  
Funding commitment $ 5.5
Portion of funding commitment subject to rent increase at time of funding $ 4.4
XML 64 R55.htm IDEA: XBRL DOCUMENT v3.22.1
Concentration of Risk (Details)
3 Months Ended
Mar. 31, 2022
beds
facility
Mar. 31, 2021
beds
facility
Ensign | SNF    
Concentration Risk [Line Items]    
Number of Facilities | facility 83 77
Number of Beds/Units | beds 8,756 8,129
Ensign | Campus    
Concentration Risk [Line Items]    
Number of Facilities | facility 8 8
Number of Beds/Units | beds 997 1,027
Ensign | ALF/ILF    
Concentration Risk [Line Items]    
Number of Facilities | facility 5 4
Number of Beds/Units | beds 495 395
Ensign | Rental revenue | Customer concentration risk    
Concentration Risk [Line Items]    
Concentration risk (percent) 34.00% 32.00%
Priority Management Group | SNF    
Concentration Risk [Line Items]    
Number of Facilities | facility 13 13
Number of Beds/Units | beds 1,742 1,742
Priority Management Group | Campus    
Concentration Risk [Line Items]    
Number of Facilities | facility 2 2
Number of Beds/Units | beds 402 402
Priority Management Group | ALF/ILF    
Concentration Risk [Line Items]    
Number of Facilities | facility 0 0
Number of Beds/Units | beds 0 0
Priority Management Group | Rental revenue | Customer concentration risk    
Concentration Risk [Line Items]    
Concentration risk (percent) 16.00% 16.00%
CA | SNF    
Concentration Risk [Line Items]    
Number of Facilities | facility 27  
Number of Beds/Units | beds 3,048  
CA | Campus    
Concentration Risk [Line Items]    
Number of Facilities | facility 8  
Number of Beds/Units | beds 1,359  
CA | ALF/ILF    
Concentration Risk [Line Items]    
Number of Facilities | facility 5  
Number of Beds/Units | beds 449  
CA | Rental revenue | Geographic concentration risk    
Concentration Risk [Line Items]    
Concentration risk (percent) 26.00%  
TX | SNF    
Concentration Risk [Line Items]    
Number of Facilities | facility 38  
Number of Beds/Units | beds 4,829  
TX | Campus    
Concentration Risk [Line Items]    
Number of Facilities | facility 3  
Number of Beds/Units | beds 536  
TX | ALF/ILF    
Concentration Risk [Line Items]    
Number of Facilities | facility 3  
Number of Beds/Units | beds 242  
TX | Rental revenue | Geographic concentration risk    
Concentration Risk [Line Items]    
Concentration risk (percent) 22.00%  
XML 65 ctre-20220331_htm.xml IDEA: XBRL DOCUMENT 0001590717 2022-01-01 2022-03-31 0001590717 2022-05-04 0001590717 2022-03-31 0001590717 2021-12-31 0001590717 2021-01-01 2021-03-31 0001590717 us-gaap:CommonStockMember 2021-12-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2021-12-31 0001590717 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2022-01-01 2022-03-31 0001590717 us-gaap:CommonStockMember 2022-03-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2022-03-31 0001590717 us-gaap:CommonStockMember 2020-12-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2020-12-31 0001590717 2020-12-31 0001590717 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2021-01-01 2021-03-31 0001590717 us-gaap:CommonStockMember 2021-03-31 0001590717 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001590717 us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember 2021-03-31 0001590717 2021-03-31 0001590717 ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember 2022-03-31 0001590717 ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember 2022-01-01 2022-03-31 0001590717 ctre:VariousOtherOperatorsMember ctre:SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember ctre:TripleNetLeasesMember 2022-03-31 0001590717 ctre:ShortTermLeaseTermUnderOneYearMember 2022-03-31 0001590717 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember 2022-03-31 0001590717 ctre:AssistedLivingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2034NextOption2022Member 2022-03-31 0001590717 ctre:SkilledNursingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2030NextOption2022Member 2022-03-31 0001590717 ctre:SkilledNursingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationMarch2029NextOption2022Member 2022-03-31 0001590717 ctre:SkilledNursingAndCampusFacilitiesMember ctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2032NextOption2023Member 2022-03-31 0001590717 ctre:SkilledNursingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationNovember2034NextOption2024Member 2022-03-31 0001590717 ctre:AssistedLivingFacilityMember ctre:PropertiesWithPurchaseOptionLeaseExpirationOctober2034NextOption2026Member 2022-03-31 0001590717 ctre:LeaseIncomeOperatingExpenseReimbursementsMember 2022-01-01 2022-03-31 0001590717 ctre:LeaseIncomeContractualRentMember 2022-01-01 2022-03-31 0001590717 ctre:LeaseIncomeStraightLineRentMember 2022-01-01 2022-03-31 0001590717 ctre:MetronMember 2021-01-01 2021-03-31 0001590717 ctre:SkilledNursingPropertiesMember 2022-01-01 2022-03-31 0001590717 ctre:MultiServiceCampusPropertiesMember 2022-01-01 2022-03-31 0001590717 ctre:EnsignMember ctre:AssistedLivingFacilityMember 2022-03-01 0001590717 ctre:EnsignAmendedTripleNetMasterLeaseMember 2022-03-01 0001590717 ctre:SkilledNursingFacilityMember 2022-02-01 2022-02-01 0001590717 ctre:EduroAmendedTripleNetMasterLeaseMember 2022-02-01 0001590717 ctre:MultiServiceCampusPropertiesMember 2022-03-01 2022-03-01 0001590717 ctre:WLCManagementFirmAmendedTripleNetMasterLeaseMember 2022-03-01 0001590717 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember 2022-01-01 2022-03-31 0001590717 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:MarketApproachValuationTechniqueMember 2022-03-31 0001590717 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:MarketApproachValuationTechniqueMember 2022-03-31 0001590717 srt:WeightedAverageMember us-gaap:FairValueInputsLevel3Member us-gaap:MarketApproachValuationTechniqueMember 2022-03-31 0001590717 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember ctre:AssistedLivingFacilityMember 2021-12-31 0001590717 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ctre:SkilledNursingFacilityMember 2022-02-22 0001590717 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ctre:SkilledNursingFacilityMember 2022-02-22 2022-02-22 0001590717 ctre:MezzanineLoanReceivableMember 2022-03-31 0001590717 ctre:MezzanineLoanReceivableMember 2021-12-31 0001590717 us-gaap:LoansReceivableMember 2022-03-31 0001590717 us-gaap:LoansReceivableMember 2021-12-31 0001590717 us-gaap:LoansReceivableMember 2022-01-01 2022-03-31 0001590717 ctre:MezzanineLoanReceivableMember 2022-01-01 2022-03-31 0001590717 ctre:MezzanineLoanReceivableMember 2021-01-01 2021-03-31 0001590717 us-gaap:LoansReceivableMember 2021-01-01 2021-03-31 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001590717 ctre:MezzanineLoanMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001590717 us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember 2022-03-31 0001590717 us-gaap:FinancingReceivablesEqualToGreaterThan90DaysPastDueMember 2021-12-31 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:SeniorNotesMember 2022-03-31 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2022-03-31 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2022-03-31 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:SeniorNotesMember 2021-12-31 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SeniorNotesMember 2021-12-31 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SeniorNotesMember 2021-12-31 0001590717 ctre:SeniorUnsecuredTermLoanMember us-gaap:LoansPayableMember 2022-03-31 0001590717 ctre:SeniorUnsecuredTermLoanMember us-gaap:LoansPayableMember 2021-12-31 0001590717 us-gaap:RevolvingCreditFacilityMember 2022-03-31 0001590717 us-gaap:RevolvingCreditFacilityMember 2021-12-31 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:SeniorNotesMember 2021-06-17 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:SeniorNotesMember 2021-06-17 2021-06-17 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:SeniorNotesMember 2021-06-17 2021-06-17 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:DebtInstrumentRedemptionPeriodThreeMember us-gaap:SeniorNotesMember 2021-06-17 2021-06-17 0001590717 ctre:ThreePointEightSevenFiveSeniorNotesDue2028Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:SeniorNotesMember 2021-06-17 2021-06-17 0001590717 us-gaap:RevolvingCreditFacilityMember 2019-02-08 0001590717 us-gaap:LetterOfCreditMember 2019-02-08 0001590717 ctre:SwinglineLoanMember 2019-02-08 0001590717 ctre:SeniorUnsecuredTermLoanMember us-gaap:LoansPayableMember 2019-02-08 0001590717 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2019-02-08 2019-02-08 0001590717 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-02-08 2019-02-08 0001590717 srt:MinimumMember ctre:SeniorUnsecuredTermLoanMember us-gaap:LoansPayableMember us-gaap:BaseRateMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember ctre:SeniorUnsecuredTermLoanMember us-gaap:LoansPayableMember us-gaap:BaseRateMember 2019-02-08 2019-02-08 0001590717 srt:MinimumMember ctre:SeniorUnsecuredTermLoanMember us-gaap:LoansPayableMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember ctre:SeniorUnsecuredTermLoanMember us-gaap:LoansPayableMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-02-08 2019-02-08 0001590717 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember 2019-02-08 2019-02-08 0001590717 us-gaap:RevolvingCreditFacilityMember 2019-02-08 2019-02-08 0001590717 srt:MaximumMember ctre:AtTheMarketOfferingProgramMember 2020-03-10 0001590717 ctre:AtTheMarketOfferingProgramMember 2022-01-01 2022-03-31 0001590717 ctre:AtTheMarketOfferingProgramMember 2021-01-01 2021-03-31 0001590717 ctre:AtTheMarketOfferingProgramMember 2022-03-31 0001590717 2020-03-20 0001590717 2020-03-20 2022-03-31 0001590717 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001590717 ctre:RestrictedStockAndPerformanceSharesMember 2021-12-31 0001590717 ctre:RestrictedStockAndPerformanceSharesMember 2022-01-01 2022-03-31 0001590717 ctre:RestrictedStockAndPerformanceSharesMember 2022-03-31 0001590717 ctre:EnsignAndPennantMember 2022-03-31 0001590717 ctre:CapitalImprovementsAtTripleNetLeasedFacilitiesMember 2022-03-31 0001590717 ctre:EnsignMember ctre:SkilledNursingFacilityMember 2022-03-31 0001590717 ctre:EnsignMember ctre:MultiServiceCampusPropertiesMember 2022-03-31 0001590717 ctre:EnsignMember ctre:AssistedAndIndependentLivingPropertiesMember 2022-03-31 0001590717 ctre:EnsignMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001590717 ctre:PriorityManagementGroupLLCMember ctre:SkilledNursingFacilityMember 2022-03-31 0001590717 ctre:PriorityManagementGroupLLCMember ctre:MultiServiceCampusPropertiesMember 2022-03-31 0001590717 ctre:PriorityManagementGroupLLCMember ctre:AssistedAndIndependentLivingPropertiesMember 2022-03-31 0001590717 ctre:PriorityManagementGroupLLCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001590717 ctre:EnsignMember ctre:SkilledNursingFacilityMember 2021-03-31 0001590717 ctre:EnsignMember ctre:MultiServiceCampusPropertiesMember 2021-03-31 0001590717 ctre:EnsignMember ctre:AssistedAndIndependentLivingPropertiesMember 2021-03-31 0001590717 ctre:EnsignMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001590717 ctre:PriorityManagementGroupLLCMember ctre:SkilledNursingFacilityMember 2021-03-31 0001590717 ctre:PriorityManagementGroupLLCMember ctre:MultiServiceCampusPropertiesMember 2021-03-31 0001590717 ctre:PriorityManagementGroupLLCMember ctre:AssistedAndIndependentLivingPropertiesMember 2021-03-31 0001590717 ctre:PriorityManagementGroupLLCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001590717 ctre:SkilledNursingFacilityMember stpr:CA 2022-03-31 0001590717 ctre:MultiServiceCampusPropertiesMember stpr:CA 2022-03-31 0001590717 ctre:AssistedAndIndependentLivingPropertiesMember stpr:CA 2022-03-31 0001590717 stpr:CA us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-03-31 0001590717 ctre:SkilledNursingFacilityMember stpr:TX 2022-03-31 0001590717 ctre:MultiServiceCampusPropertiesMember stpr:TX 2022-03-31 0001590717 ctre:AssistedAndIndependentLivingPropertiesMember stpr:TX 2022-03-31 0001590717 stpr:TX us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-03-31 shares iso4217:USD iso4217:USD shares ctre:facility ctre:bed ctre:state ctre:property ctre:unit ctre:extension_option pure ctre:loan ctre:beds 0001590717 --12-31 2022 Q1 false P3Y 10-Q true 2022-03-31 false 001-36181 CareTrust REIT, Inc. MD 46-3999490 905 Calle Amanecer Suite 300 San Clemente CA 92673 949 542-3130 Common Stock, par value $0.01 per share CTRE NASDAQ Yes Yes Large Accelerated Filer false false false 97028742 1402889000 1589971000 15155000 15155000 141716000 4835000 26586000 19895000 1110000 2418000 5668000 7512000 817000 1062000 1593941000 1640848000 394484000 394262000 199189000 199136000 105000000 80000000 23785000 25408000 26900000 26285000 749358000 725091000 0.01 0.01 100000000 100000000 0 0 0 0 0 0 0.01 0.01 500000000 500000000 96487066 96487066 96296673 96296673 965000 963000 1195586000 1196839000 351968000 282045000 844583000 915757000 1593941000 1640848000 46007000 45246000 469000 505000 46476000 45751000 13575000 13473000 5742000 5762000 1420000 696000 59683000 0 3844000 0 447000 0 5215000 5142000 89926000 25073000 186000 -192000 -43264000 20486000 -0.45 0.21 -0.45 0.21 96410000 95378000 96410000 95385000 96296673 963000 1196839000 -282045000 915757000 190393 2000 -2774000 -2772000 1521000 1521000 0.275 26659000 26659000 -43264000 -43264000 96487066 965000 1195586000 -351968000 844583000 95215797 952000 1164402000 -251212000 914142000 702000 7000 16184000 16191000 63265 1000 -1331000 -1330000 1585000 1585000 0.265 25633000 25633000 20486000 20486000 95981062 960000 1180840000 -256359000 925441000 -43264000 20486000 13594000 13486000 520000 487000 1521000 1585000 6000 12000 977000 0 186000 -192000 59683000 0 3844000 0 -337000 100000 404000 -278000 -2037000 -2453000 34579000 33949000 21915000 138151000 1918000 1319000 2086000 700000 888000 56000 959000 6814000 -24072000 -133300000 0 16191000 25000000 120000000 2772000 1330000 26044000 23960000 -3816000 110901000 6691000 11550000 19895000 18919000 26586000 30469000 1355000 1325000 615000 1673000 7000 358000 ORGANIZATION<div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of Business—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CareTrust REIT, Inc.’s (“CareTrust REIT” or the “Company”) primary business consists of acquiring, financing, developing and owning real property to be leased to third-party tenants in the healthcare sector. As of March 31, 2022, the Company owned and leased to independent ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rators, 228 skilled nursing facilities (“SNFs”), multi-service campuses, assisted living facilities (“ALFs”) and independent living facilities (“ILFs”) consisting of 23,834 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operational beds and units located in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> states with the highest concentration of properties by rental income located i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n California, Texas, Louisiana, Idaho and Arizona. A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s of March 31, 2022, the Company also had other real estate investments consisting of one mezzanine loan receivable with a carrying value of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.2 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has had and may continue to have an adverse impact on the economy generally and the Company’s business, results of operations and financial condition. The duration and extent of the COVID-19 pandemic’s effect on the Company’s operational and financial performance, and the operational and financial performance of the Company’s tenants, will depend on future developments, which are highly uncertain and cannot be predicted at this time, including the rate of public acceptance and usage of vaccines and the effectiveness of vaccines in limiting the spread of COVID-19 and its variants, resurgences of COVID-19 and, in particular, new and more contagious and/or vaccine resistant variants, actions taken to contain the spread of COVID-19 and how quickly and to what extent normal economic and operating conditions can resume. The adverse impact of the COVID-19 pandemic on the Company’s business, results of operations and financial condition could be material.</span></div> 228 23834 29 15200000 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The accompanying condensed consolidated financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, the condensed consolidated financial statements do not include all of the disclosures required by GAAP for a complete set of annual audited financial statements. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. In the opinion of management, all adjustments which are of a normal and recurring nature and considered necessary for a fair presentation of the results of the interim periods presented have been included. The results of operations for the interim periods are not necessarily indicative of results for the full year. All intercompany transactions and account balances within the Company have been eliminated.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—In March 2020, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2020-04, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2020-04”), that provides optional relief to applying reference rate reform to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”). For U.S. Dollar LIBOR, the overnight, one-month, three-month, six-month and one-year LIBOR rates will be discontinued in June 2023, while other U.S. Dollar LIBOR rates were discontinued at the end of 2021. The amendments in this update are effective immediately and may be applied through December 31, 202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The accompanying condensed consolidated financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and Article 10 of Regulation S-X. Accordingly, the condensed consolidated financial statements do not include all of the disclosures required by GAAP for a complete set of annual audited financial statements. The condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. In the opinion of management, all adjustments which are of a normal and recurring nature and considered necessary for a fair presentation of the results of the interim periods presented have been included. The results of operations for the interim periods are not necessarily indicative of results for the full year. All intercompany transactions and account balances within the Company have been eliminated.</span> <span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—In March 2020, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2020-04, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2020-04”), that provides optional relief to applying reference rate reform to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”). For U.S. Dollar LIBOR, the overnight, one-month, three-month, six-month and one-year LIBOR rates will be discontinued in June 2023, while other U.S. Dollar LIBOR rates were discontinued at the end of 2021. The amendments in this update are effective immediately and may be applied through December 31, 202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Adoption of this ASU did not have a material impact on the Company’s consolidated financial statements.</span> REAL ESTATE INVESTMENTS, NET<div style="margin-bottom:9pt;margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s real estate properties held for investment at March 31, 2022 and December 31, 2021 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,986 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,787 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431,631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,622,019 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integral equipment, furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identified intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,767,272 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979,785 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(364,383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(389,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402,889 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,589,971 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 226 of the Company’s 228 facilities wer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e leased to various operators under triple-net leases. All of these leases contain annual escalators based on the percentage change in the Consumer Price Index (“CPI”) (but not less than zero), some of which are subject to a cap, or fixed rent escalators. Two of the Company’s </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">228</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> facilities are non-operational and are leased under a short term lease with an expected term of less than one year as of March 31, 2022. As of March 31, 2022, 27 facilities were held for sale.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the Company’s total future contractual minimum rental income for all of its tenants, excluding operating expense reimbursements, was (dollars in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,848 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998,873 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,115,510 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenant Purchase Options</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s operators hold purchase options allowing them to acquire properties they currently lease from the Company. A summary of these purchase options is presented below (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.571%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Type</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Properties</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Expiration</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Next Option Open Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Type</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current Cash Rent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALF</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2034</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,383 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,944 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/1/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B / C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF / Campus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2032</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2034</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/1/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2034</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Option type includes:</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A - Fixed base price plus a specified share on any appreciation.</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B - Fixed base price.</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C - Fixed capitalization rate on lease revenue.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Based on annualized cash revenue for contracts in place as of March 31, 2022.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Option window is open for six months.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Option window is open until the expiration of the lease term.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5) Purchase option reflects two option types.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rental Income</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes components of the Company’s rental income (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.960%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rental Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual rent due</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,978 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line rent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment for collectibility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(977)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease termination revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,007 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,246 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Includes initial cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2)    During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> months ended March 31, 2022, and in accordance with Accounting Standards Codification 842, the Company evaluated the collectibility of lease payments through maturity and determined that it was not probable that the Company would collect substantially all of the contractual obligations from four existing and former operators. As such, the Company reversed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$0.7 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of operating expense reimbursements, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$0.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of contractual rent and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$0.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of straight-line rent during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> months ended March 31, 2022. If lease payments are subsequently deemed probable of collection, the Company will increase rental income for such recoveries. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) During the three months ended March 31, 2021, in connection with the agreement to terminate its lease agreements with Metron Integrated Health Systems (“Metron”) and to sell the facilities to a third party, the Company received approximately $0.1 million in lease termination revenue from Metron affiliates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Real Estate Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s acquisitions for the three months ended March 31, 2022 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.350%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Property</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Initial Annual Cash Rent</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Properties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Beds/Units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled nursing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,918 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-service campuses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,003 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,921 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,050 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Purchase price includes capitalized acquisition costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) The number of beds/units includes operating beds at the acquisition date. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease Amendments</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pennant Partial Lease Termination and Amended Ensign Master Lease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2022, operations at one ALF in Arizona operated by affiliates of The Pennant Group, Inc. (“Pennant”) were transferred to affiliates of The Ensign Group, Inc. (“Ensign”). In connection with the transfer, the Company amended the Pennant master lease to reflect the removal of the ALF and amended an existing triple-net master lease with Ensign to include the one ALF. The applicable Ensign master lease has a remaining term of approximately 11 years, with two five-year renewal options and CPI-based rent escalators. Annual cash rent under the applicable Ensign master lease, as amended, increased by approximately $0.3 million and annual cash rent under the Pennant master lease, as amended, decreased by the same amount.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended Eduro Master Lease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2022, the Company acquired one SNF. In conjunction with the acquisition, the Company amended its existing triple-net master lease with affiliates of Eduro Healthcare, LLC (“Eduro”) to include the one SNF and extended the initial lease term. The Eduro master lease, as amended, has a remaining term of approximately 12 years, wit</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h two five-year re</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">newal options and CPI-based rent escalators. Annual cash rent under the Eduro master lease, as amended, increased by approximately $0.8 million.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended WLC Master Lease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On March 1, 2022, the Company acquired one multi-service campus. In conjunction with the acquisition, the Company amended its existing triple-net master lease with affiliates of WLC Management Firm, LLC (“WLC”) to include the one multi-service campus. The WLC master lease, as amended, has a remaining term of approximately 12 years, with two five-year renewal options and CPI-based rent escalators. Annual cash rent under the WLC master lease, as amended, increased by approximately $1.2 million.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s real estate properties held for investment at March 31, 2022 and December 31, 2021 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,986 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,787 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431,631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,622,019 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integral equipment, furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identified intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,767,272 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979,785 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(364,383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(389,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402,889 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,589,971 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 236986000 251787000 1431631000 1622019000 95997000 104722000 2658000 1257000 1767272000 1979785000 364383000 389814000 1402889000 1589971000 226 228 2 228 27 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the Company’s total future contractual minimum rental income for all of its tenants, excluding operating expense reimbursements, was (dollars in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,848 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">998,873 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,115,510 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 146848000 195547000 194202000 194173000 194278000 191589000 998873000 2115510000 <div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s operators hold purchase options allowing them to acquire properties they currently lease from the Company. A summary of these purchase options is presented below (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.571%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset Type</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Properties</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Expiration</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Next Option Open Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Type</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current Cash Rent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALF</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2034</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,383 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,944 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/1/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B / C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF / Campus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2032</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,065 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SNF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2034</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/1/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2034</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/1/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Option type includes:</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A - Fixed base price plus a specified share on any appreciation.</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">B - Fixed base price.</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">C - Fixed capitalization rate on lease revenue.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Based on annualized cash revenue for contracts in place as of March 31, 2022.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Option window is open for six months.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Option window is open until the expiration of the lease term.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5) Purchase option reflects two option types.</span></div> 7 3383000 11 4944000 1 779000 2 1065000 4 3796000 2 1598000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes components of the Company’s rental income (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.960%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rental Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual rent due</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,978 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line rent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment for collectibility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(977)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease termination revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,007 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,246 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Includes initial cash rent and tenant operating expense reimbursements, as adjusted for applicable rental escalators and rent increases due to capital expenditures funded by the Company. For tenants on a cash basis, this represents the lesser of the amount that would be recognized on a straight-line basis or cash that has been received. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2)    During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> months ended March 31, 2022, and in accordance with Accounting Standards Codification 842, the Company evaluated the collectibility of lease payments through maturity and determined that it was not probable that the Company would collect substantially all of the contractual obligations from four existing and former operators. As such, the Company reversed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$0.7 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of operating expense reimbursements, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$0.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of contractual rent and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$0.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of straight-line rent during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> months ended March 31, 2022. If lease payments are subsequently deemed probable of collection, the Company will increase rental income for such recoveries. </span></div>(3) During the three months ended March 31, 2021, in connection with the agreement to terminate its lease agreements with Metron Integrated Health Systems (“Metron”) and to sell the facilities to a third party, the Company received approximately $0.1 million in lease termination revenue from Metron affiliates. 46978000 45171000 6000 12000 977000 0 0 63000 46007000 45246000 700000 200000 100000 100000 <div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s acquisitions for the three months ended March 31, 2022 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.350%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Type of Property</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Initial Annual Cash Rent</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Properties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Beds/Units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled nursing</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,918 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multi-service campuses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,003 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,921 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,050 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Purchase price includes capitalized acquisition costs.</span></div>(2) The number of beds/units includes operating beds at the acquisition date. 8918000 815000 1 135 13003000 1235000 1 130 21921000 2050000 2 265 1 1 P11Y 2 P5Y 300000 1 1 P12Y 2 P5Y 800000 1 1 P12Y 2 P5Y 1200000 IMPAIRMENT OF REAL ESTATE INVESTMENTS, ASSETS HELD FOR SALE, NET AND ASSET SALES<div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company’s ongoing review and monitoring of its investment portfolio and the performance of its tenants, the Company determined to pursue the sale of 27 properties and repurposing three properties representing an aggregate of approximately 10% of contractual cash rent as of March 31, 2022. As of March 31, 2022, the Company determined that these 27 properties met the criteria to be classified as assets held for sale and, in connection with this determination, the Company recognized an aggregate impairment charge of $59.7 million related to 20 of the 27 held for sale properties, which is reported in impairment of real estate investments in the condensed consolidated statements of operations for the three months ended March 31, 2022. The impairment charge was recognized to write down the properties’ aggregate carrying value to their aggregate fair value, less estimated costs to sell. As of March 31, 2022, the net book value of these 27 properties was $141.7 million, which is comprised of the real estate assets. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets held for sale was based on estimated sales prices, which are considered to be Level 3 measurements within the fair value hierarchy. Estimated sales prices were determined using a market approach (comparable sales model), which relies on certain assumptions by management, including: (i) comparable market transactions, (ii) estimated prices per unit, and (iii) negotiations with prospective buyers. There are inherent uncertainties in making these assumptions. For the Company’s impairment calculations, the Company’s fair value estimates primarily relied on a market approach and utilized prices per unit rangin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g from </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$40,000 to $175,000, with a weighted average price per unit of $91,000. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022, the Company determined that one ALF that was classified as held for sale at December 31, 2021 no longer met the held for sale criteria. The Company reclassified this ALF’s carrying value of $4.8 million out of assets held for sale and recorded catch-up depreciation of approximately $0.1 million during the three months ended March 31, 2022.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 22, 2022, the Company closed on the sale of one SNF, operated by affiliates of Cascadia Healthcare, LLC (“Cascadia”), consisting of 83 beds located in Washington with a carrying value of $0.8 million, for net sales proceeds of $1.0 million. During the three months ended March 31, 2022, the Company recorded a gain of $0.2 million in connection with the sale. There was no rent reduction under the Cascadia master lease in connection with the sale.</span></div> 27 3 0.10 27 59700000 20 27 27 141700000 40000 175000 91000 1 4800000 100000 1 83 800000 1000000 200000 OTHER REAL ESTATE INVESTMENTS<div style="margin-bottom:6pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December 31, 2021, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of March 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Statement Line Item</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Balance as of March 31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Book Value as of March 31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Book Value as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Contractual Interest Rate</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loan receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other real estate investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,155 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,155 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/30/2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loans receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,516 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,161 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/1/2023 - 12/31/2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected credit loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,594)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,594)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,922 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,084 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,316 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected credit losses and recoveries are recorded in provision for loan losses, net in the condensed consolidated statements of operations. During the three months ended March 31, 2022, the Company recorded a $4.6 million expected credit loss related to two other loans receivable that were placed on non-accrual status, including an unfunded loan commitment of $0.4 million, net of a loan loss recovery of $0.8 million related to a loan previously written-off. As of December 31, 2021, the Company had no expected credit loss and did not consider any loan receivable investments to be impaired.</span></div><div style="margin-bottom:6pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the interest and other income recognized from the Company’s loans receivable and other investments during the quarter ended March 31, 2022 and 2021 (dollars in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.960%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loan receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-bottom:6pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December 31, 2021, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of March 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Statement Line Item</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Balance as of March 31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Book Value as of March 31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Book Value as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Contractual Interest Rate</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loan receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other real estate investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,155 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,155 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/30/2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loans receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,516 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,161 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/1/2023 - 12/31/2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected credit loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,594)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,594)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,922 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,084 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,316 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div> 15000000 15155000 15155000 0.120 5516000 5523000 3161000 0.080 4594000 4594000 0 15922000 16084000 18316000 4600000 2 400000 800000 0 <div style="margin-bottom:6pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the interest and other income recognized from the Company’s loans receivable and other investments during the quarter ended March 31, 2022 and 2021 (dollars in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.960%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loan receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 450000 450000 19000 55000 469000 505000 FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment. GAAP guidance defines three levels of inputs that may be used to measure fair value:</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 – Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 – Unobservable inputs reflect the entity’s own assumptions about the assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and, depending on various factors, it is possible that an asset or </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liability may be classified differently from quarter to quarter. Changes in the type of inputs may result in a reclassification for certain assets. The Company does not expect that changes in classifications between levels will be frequent.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021, aggregated by the level in the fair value hierarchy within which those instruments fall (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loan receivable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,155 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loan receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mezzanine loan receivable:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of the mezzanine loan receivable was estimated using an internal valuation model that considered the expected future cash flows of the investment, the underlying collateral value, market interest rates and other credit enhancements. As such, the Company classifies the instrument as Level 3 due to the significant unobservable inputs used in determining market interest rates for investments with similar terms. Future changes in market interest rates could materially impact the estimated discounted cas</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h flows. As of March 31, 2022 and December 31, 2021, the Company did not have any loans measured at fair value that were 90 days or more past due.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, there were no classification changes in assets and liabilities with Level 3 inputs in the fair value hierarchy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Items Disclosed at Fair Value</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Considerable judgment is necessary to estimate the fair value disclosure of financial instruments. The estimates of fair value presented herein are not necessarily indicative of the amounts that could be realized upon disposition of the financial instruments. A summary of the face value, carrying amount and fair value of the Notes (as defined in Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below) as of March 31, 2022 and December 31, 2021 using Level 2 inputs is as follows (dollars in thousands): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.581%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Face<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Face<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior unsecured notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents, accounts and other receivables, accounts payable, and accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value for these instruments approximate their fair values due to the short-term nature of these instruments.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior unsecured notes payable:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value of the Notes was determined using third-party quotes derived from orderly trades.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unsecured revolving credit facility and senior unsecured term loan:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair values approximate their carrying values as the interest rates are variable and approximate prevailing market interest rates for similar debt arrangements.</span></div> <div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment. GAAP guidance defines three levels of inputs that may be used to measure fair value:</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 – Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 – Unobservable inputs reflect the entity’s own assumptions about the assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and, depending on various factors, it is possible that an asset or </span></div>liability may be classified differently from quarter to quarter. Changes in the type of inputs may result in a reclassification for certain assets. The Company does not expect that changes in classifications between levels will be frequent. <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021, aggregated by the level in the fair value hierarchy within which those instruments fall (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loan receivable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,155 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine loan receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 15155000 15155000 0 0 15155000 15155000 0 0 A summary of the face value, carrying amount and fair value of the Notes (as defined in Note 7, <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below) as of March 31, 2022 and December 31, 2021 using Level 2 inputs is as follows (dollars in thousands): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.581%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Face<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Face<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior unsecured notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 400000000 394484000 377000000 400000000 394262000 410500000 DEBT<div style="margin-top:6pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of the Company’s indebtedness as of March 31, 2022 and December 31, 2021 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.985%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.192%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Loan Fees</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Loan Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior unsecured notes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,516)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,484 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,738)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior unsecured term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(811)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(864)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unsecured revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,327)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698,673 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,602)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673,398 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes Payable</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2028 Senior Notes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On June 17, 2021, the Company’s wholly owned subsidiary, CTR Partnership, L.P. (the “Operating Partnership”), and its wholly owned subsidiary, CareTrust Capital Corp. (together with the Operating Partnership, the “Issuers”) completed a private offering of $400.0 million aggregate principal amount of 3.875% Senior Notes due 2028 (the “Notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended. The Notes were issued at par, resulting in gross proceeds of $400.0 million and net proceeds of approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$393.8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> after deducting underwriting fees and other offering expenses. The Notes mature on June 30, 2028. The Notes accrue interest at a rate of 3.875% per annum payable semiannually in arrears on June 30 and December 30 of each year, commencing on December 30, 2021.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Issuers may redeem some or all of the Notes at any time prior to March 30, 2028 at a price equal to 100% of the principal amount of the Notes redeemed plus accrued and unpaid interest on the Notes, if any, to, but not including, the redemption date, plus a “make-whole” premium. At any time on or after March 30, 2028, the Issuers may redeem some or all of the Notes at a redemption price equal to 100% of the principal amount of the Notes redeemed plus accrued interest on the Notes, if any, to, but not including, the redemption date. In addition, at any time on or prior to June 30, 2024, up to 40% of the aggregate principal amount of the Notes may be redeemed with the net proceeds of certain equity offerings at a redemption price of 103.875% of the aggregate principal amount of Notes to be redeemed plus accrued and unpaid interest on the Notes, if any, to, but not including, the redemption date. If certain changes of control of the Company occur, the Issuers will be required to make an offer to holders of the Notes to repurchase their Notes at a price of 101% of their principal amount plus accrued and unpaid interest, if any, to, but not including, the repurchase date.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations under the Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by the Company and all of CareTrust’s existing and future subsidiaries (other than the Issuers) that guarantee obligations under the Amended Credit Facility (as defined below); provided, however, that such guarantees are subject to automatic release under certain customary circumstances.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture governing the Notes contains customary covenants such as limiting the ability of the Company and its restricted subsidiaries to: incur or guarantee additional indebtedness; incur or guarantee secured indebtedness; pay dividends or distributions on, or redeem or repurchase, capital stock; make certain investments or other restricted payments; sell assets; enter into transactions with affiliates; merge or consolidate or sell all or substantially all of their assets; and create restrictions on the ability of the Issuers and their restricted subsidiaries to pay dividends or other amounts to the Issuers. The indenture governing the Notes also requires the Company and its restricted subsidiaries to maintain a specified ratio of unencumbered assets to unsecured indebtedness. These covenants are subject to a number of important and significant limitations, qualifications and exceptions. The indenture governing the Notes also contains customary events of default.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the Company was in compliance with all applicable financial covenants under the indenture governing the Notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unsecured Revolving Credit Facility and Term Loan</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2019, the Operating Partnership, as the borrower, the Company, as guarantor, CareTrust GP, LLC, and certain of the Operating Partnership’s wholly owned subsidiaries entered into an amended and restated credit and guaranty </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement with KeyBank National Association, as administrative agent, an issuing bank and swingline lender, and the lenders party thereto (the “Amended Credit Agreement”). The Amended Credit Agreement, which amended and restated the Company’s prior credit agreement, provides for: (i) an unsecured revolving credit facility (the “Revolving Facility”) with revolving commitments in an aggregate principal amount of $600.0 million, including a letter of credit subfacility for 10% of the then available revolving commitments and a swingline loan subfacility for 10% of the then available revolving commitments and (ii) an unsecured term loan credit facility (the “Term Loan” and, together with the Revolving Facility, the “Amended Credit Facility”) in an aggregate principal amount of $200.0 million. Borrowing availability under the Revolving Facility is subject to no default or event of default under the Amended Credit Agreement having occurred at the time of borrowing. Future borrowings under the Amended Credit Facility will be used for working capital purposes, for capital expenditures, to fund acquisitions and for general corporate purposes. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rates applicable to loans under the Revolving Facility are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.10% to 0.55% per annum or LIBOR plus a margin ranging from 1.10% to 1.55% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). The interest rates applicable to loans under the Term Loan are, at the Operating Partnership’s option, equal to either a base rate plus a margin ranging from 0.50% to 1.20% per annum or LIBOR plus a margin ranging from 1.50% to 2.20% per annum based on the debt to asset value ratio of the Company and its consolidated subsidiaries (subject to decrease at the Operating Partnership’s election if the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt). In addition, the Operating Partnership will pay a facility fee on the revolving commitments under the Revolving Facility ranging from 0.15% to 0.35% per annum, based on the debt to asset value ratio of the Company and its consolidated subsidiaries (unless the Company obtains certain specified investment grade ratings on its senior long-term unsecured debt and the Operating Partnership elects to decrease the applicable margin as described above, in which case the Operating Partnership will pay a facility fee on the revolving commitments ranging from 0.125% to 0.30% per annum based on the credit ratings of the Company’s senior long-term unsecured debt). As of March 31, 2022, the Operating Partnership had $200.0 million of borrowings outstanding under the Term Loan and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$105.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outstanding under the Revolving Facility. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Facility has a maturity date of February 8, 2023, and includes, at the sole discretion of the Operating Partnership, two, six-month extension options. The Term Loan has a maturity date of February 8, 2026.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Facility is guaranteed, jointly and severally, by the Company and its wholly owned subsidiaries that are party to the Amended Credit Agreement (other than the Operating Partnership). The Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend organizational documents and pay certain dividends and other restricted payments. The Amended Credit Agreement requires the Company to comply with financial maintenance covenants to be tested quarterly, consisting of a maximum debt to asset value ratio, a minimum fixed charge coverage ratio, a minimum tangible net worth, a maximum cash distributions to operating income ratio, a maximum secured debt to asset value ratio, a maximum secured recourse debt to asset value ratio, a maximum unsecured debt to unencumbered properties asset value ratio, a minimum unsecured interest coverage ratio and a minimum rent coverage ratio. The Amended Credit Agreement also contains certain customary events of default, including the failure to make timely payments under the Amended Credit Facility or other material indebtedness, the failure to satisfy certain covenants (including the financial maintenance covenants), the occurrence of change of control and specified events of bankruptcy and insolvency.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the Company was in compliance with all applicable financial covenants under the Amended Credit Agreement.</span></div> <span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of the Company’s indebtedness as of March 31, 2022 and December 31, 2021 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.985%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.192%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Loan Fees</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Loan Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior unsecured notes payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,516)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,484 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,738)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior unsecured term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(811)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(864)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unsecured revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,327)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698,673 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">680,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,602)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673,398 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 400000000 5516000 394484000 400000000 5738000 394262000 200000000 811000 199189000 200000000 864000 199136000 105000000 0 105000000 80000000 0 80000000 705000000 6327000 698673000 680000000 6602000 673398000 400000000 0.03875 400000000 393800000 0.03875 1 1 0.40 1.03875 1.01 600000000 0.10 0.10 200000000 0.0010 0.0055 0.0110 0.0155 0.0050 0.0120 0.0150 0.0220 0.0015 0.0035 0.00125 0.0030 200000000 105000000 2 P6M EQUITY<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-The-Market Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—On March 10, 2020, the Company entered into a new equity distribution agreement to issue and sell, from time to time, up to $500.0 million in aggregate offering price of its common stock through an “at-the-market” equity offering program (the “ATM Program”).</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no ATM Program activity for the three months ended March 31, 2022. The following table summarizes the ATM Program activity for the three months ended March 31, 2021 (in thousands, except per share amounts).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.361%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.855%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average sales price per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross proceeds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,579 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Total gross proceeds is before $0.2 million of commissions paid to the sales agents during the three months ended March 31, 2021 under the ATM Program. </span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the Company had $476.5 million available for future issuances under the ATM Program. </span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Share Repurchase Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">—On March 20, 2020, the Company’s Board of Directors authorized a share repurchase program for up to $150.0 million of outstanding shares of the Company’s common stock (the “Repurchase Program”). </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Repurchases under the Repurchase Program, which expires on March 31, 2023, may be made through open market purchases, privately negotiated transactions, structured or derivative transactions, including accelerated share repurchase transactions, or other methods of acquiring shares, in each case subject to market conditions and at such times as shall be permitted by applicable securities laws and determined by management. Repurchases under the Repurchase Program may also be made pursuant to a plan adopted under Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company expects to finance any share repurchases under the Repurchase Program using available cash and may also use short-term borrowings under the Revolving Facility. Through March 31, 2022, t</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">he Company has not repurchased any shares of common stock under the Repurchase Program. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 31, 2022</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$150.0 million </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">remained available under the Repurchase Program.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Repurchase Program may be modified, discontinued or suspended at any time.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends on Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The following table summarizes the cash dividends per share of common stock declared by the Company’s Board of Directors for the first quarter of 2022 (dollars in thousands, except per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payment date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 15, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable as of record date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends record date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 500000000 0 The following table summarizes the ATM Program activity for the three months ended March 31, 2021 (in thousands, except per share amounts).<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.361%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.855%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average sales price per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross proceeds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,579 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table>(1) Total gross proceeds is before $0.2 million of commissions paid to the sales agents during the three months ended March 31, 2021 under the ATM Program. 702000 23.62 16579000 200000 476500000 150000000 0 150000000 The following table summarizes the cash dividends per share of common stock declared by the Company’s Board of Directors for the first quarter of 2022 (dollars in thousands, except per share amounts):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends declared per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payment date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 15, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable as of record date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends record date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 0.275 2022-04-15 26691000 2022-03-31 STOCK-BASED COMPENSATION<div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based awards are subject to the terms of the CareTrust REIT, Inc. and CTR Partnership, L.P. Incentive Award Plan (the “Plan”). The Plan provides for the granting of stock-based compensation, including stock options, restricted stock, performance awards, restricted stock units, relative total stockholder return based stock awards (“TSR Awards”) and other incentive awards to officers, employees and directors in connection with their employment with or services provided to the Company. Under the Plan, 5,000,000 shares have been authorized for awards.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Plan, restricted stock awards (“RSAs”) granted in fiscal 2022 vest in equal annual installments beginning on the first anniversary of the grant date over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjE4M2Y1NThjNWEzODQ0YTNiYjRlOWVmNDAzOTQyOGQwL3NlYzoxODNmNTU4YzVhMzg0NGEzYmI0ZTllZjQwMzk0MjhkMF81Mi9mcmFnOjJlYjEyY2ZlN2ZkYTRhZTVhNTFkMGU1ZmMwYmM1YjA5L3RleHRyZWdpb246MmViMTJjZmU3ZmRhNGFlNWE1MWQwZTVmYzBiYzViMDlfMTA5OTUxMTY0NTQxMg_7a70b067-00b0-4942-8f7b-aa8ce81ed67b">three</span> year period.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSAs and performance award activity for the three months ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Share Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891,333 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.91 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570,037 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.32 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the weighted-average remaining vesting period of such awards was 1.6 years.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,585 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, there was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.0 million</span> of unamortized stock-based compensation expense related to the unvested RSAs, performance stock awards and TSR Awards. 5000000 <span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSAs and performance award activity for the three months ended March 31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Share Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891,333 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.91 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570,037 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.32 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 891333 20.91 9684 17.56 329080 20.10 1900 21.50 570037 21.32 P1Y7M6D <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,585 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 1521000 1585000 10000000 EARNINGS PER COMMON SHARE<div style="margin-top:6pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted (loss) earnings per common share (“EPS”) for the Company’s common stock for the three months ended March 31, 2022 and 2021, and reconciles the weighted-average common shares outstanding used in the calculation of basic EPS to the weighted-average common shares outstanding used in the calculation of diluted EPS (amounts in thousands, except per share amounts):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,264)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income allocated to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for basic and diluted earnings available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,381)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,367 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive performance stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,410 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,385 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) earnings per common share, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) earnings per common share, diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antidilutive unvested RSAs, performance awards and TSR Awards excluded from the computation</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-top:6pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted (loss) earnings per common share (“EPS”) for the Company’s common stock for the three months ended March 31, 2022 and 2021, and reconciles the weighted-average common shares outstanding used in the calculation of basic EPS to the weighted-average common shares outstanding used in the calculation of diluted EPS (amounts in thousands, except per share amounts):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,264)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income allocated to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for basic and diluted earnings available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,381)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,367 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive performance stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,410 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,385 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) earnings per common share, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) earnings per common share, diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.45)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antidilutive unvested RSAs, performance awards and TSR Awards excluded from the computation</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> -43264000 20486000 117000 119000 -43381000 -43381000 20367000 20367000 96410000 95378000 0 7000 96410000 95385000 -0.45 0.21 -0.45 0.21 534000 446000 COMMITMENTS AND CONTINGENCIES<div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are and may become from time to time a party to various claims and lawsuits arising in the ordinary course of business, which are not individually or in the aggregate anticipated to have a material adverse effect on the Company’s results of operations, financial condition or cash flows. Claims and lawsuits may include matters involving general or professional liability asserted against the Company’s tenants, which are the responsibility of the Company’s tenants and for which the Company is entitled to be indemnified by its tenants under the insurance and indemnification provisions in the applicable leases.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures for each property leased under the Company’s triple-net leases are generally the responsibility of the tenant, except that, for the facilities leased to subsidiaries of Ensign and Pennant, the tenant will have an option to require the Company to finance certain capital expenditures up to an aggregate of 20% of the Company’s initial investment in such property, subject to a corresponding rent increase at the time of funding. For the Company’s other triple-net master leases, the tenants also have the option to request capital expenditure funding that would generally be subject to a corresponding rent increase at the time of funding, which are subject to tenant compliance with the conditions to the Company’s approval and funding of their requests. As of March 31, 2022, the Company had committed to fund expansions, construction and capital improvements at certain triple-net leased facilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> totaling $5.5 million, of which $4.4 million is su</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bject to rent increase at the time of funding.</span></div> 0.20 5500000 4400000 CONCENTRATION OF RISK<div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrations of credit risk arise when one or more tenants, operators, or obligors related to the Company’s investments are engaged in similar business activities or activities in the same geographic region, or have similar economic features that would cause their ability to meet contractual obligations, including those to the Company, to be similarly affected by changes in economic conditions.</span></div><div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Major operator concentration - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operators from which it derived 10% or more of its rental revenue for the three months ended March 31, 2022 and 2021. The following table sets forth information regarding the Company’s major operators as of March 31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.214%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Facilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Beds/Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Total Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operator</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SNF</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Campus</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALF/ILF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SNF</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Campus</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALF/ILF</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ensign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,756 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority Management Group</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ensign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority Management Group</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    The Company’s rental income, exclusive of operating expense reimbursements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)    Ensign is subject to the registration and reporting requirements of the SEC and is required to file with the SEC annual reports containing audited financial information and quarterly reports containing unaudited financial information. Ensign’s financial statements, as filed with the SEC, can be found at http://www.sec.gov. The Company has not verified this information through an independent investigation or otherwise. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Major geographic concentration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> – The following table provides information regarding the Company’s concentrations with respect to certain states, from which the Company derived 10% or more of its rental revenue for the three months ended March 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.214%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Facilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Beds/Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Total Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SNF</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Campus</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALF/ILF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SNF</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Campus</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALF/ILF</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,048 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    The Company’s rental income, exclusive of operating expense reimbursements.</span></div> <div style="margin-top:6pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Major operator concentration - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operators from which it derived 10% or more of its rental revenue for the three months ended March 31, 2022 and 2021. The following table sets forth information regarding the Company’s major operators as of March 31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.214%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Facilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Beds/Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Total Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operator</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SNF</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Campus</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALF/ILF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SNF</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Campus</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALF/ILF</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ensign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,756 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority Management Group</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ensign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority Management Group</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    The Company’s rental income, exclusive of operating expense reimbursements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)    Ensign is subject to the registration and reporting requirements of the SEC and is required to file with the SEC annual reports containing audited financial information and quarterly reports containing unaudited financial information. Ensign’s financial statements, as filed with the SEC, can be found at http://www.sec.gov. The Company has not verified this information through an independent investigation or otherwise. </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Major geographic concentration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> – The following table provides information regarding the Company’s concentrations with respect to certain states, from which the Company derived 10% or more of its rental revenue for the three months ended March 31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.214%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Facilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Beds/Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Total Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SNF</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Campus</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALF/ILF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SNF</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Campus</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALF/ILF</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,048 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    The Company’s rental income, exclusive of operating expense reimbursements.</span></div> 83 8 5 8756 997 495 0.34 13 2 0 1742 402 0 0.16 77 8 4 8129 1027 395 0.32 13 2 0 1742 402 0 0.16 27 8 5 3048 1359 449 0.26 38 3 3 4829 536 242 0.22 EXCEL 66 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 67 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 68 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 69 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 139 240 1 false 69 0 false 12 false false R1.htm 0001001 - Document - Cover Sheet http://www.caretrustreit.com/role/Cover Cover Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Equity Sheet http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity Condensed Consolidated Statements of Equity Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Equity (Parenthetical) Sheet http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquityParenthetical Condensed Consolidated Statements of Equity (Parenthetical) Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101101 - Disclosure - Organization Sheet http://www.caretrustreit.com/role/Organization Organization Notes 8 false false R9.htm 2103102 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.caretrustreit.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2105103 - Disclosure - Real Estate Investments, Net Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNet Real Estate Investments, Net Notes 10 false false R11.htm 2114104 - Disclosure - Impairment of Real Estate Investments, Assets Held for Sale, Net and Asset Sales Sheet http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSales Impairment of Real Estate Investments, Assets Held for Sale, Net and Asset Sales Notes 11 false false R12.htm 2116105 - Disclosure - Other Real Estate Investments, Net Sheet http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNet Other Real Estate Investments, Net Notes 12 false false R13.htm 2121106 - Disclosure - Fair Value Measurements Sheet http://www.caretrustreit.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 2126107 - Disclosure - Debt Sheet http://www.caretrustreit.com/role/Debt Debt Notes 14 false false R15.htm 2131108 - Disclosure - Equity Sheet http://www.caretrustreit.com/role/Equity Equity Notes 15 false false R16.htm 2136109 - Disclosure - Stock-Based Compensation Sheet http://www.caretrustreit.com/role/StockBasedCompensation Stock-Based Compensation Notes 16 false false R17.htm 2141110 - Disclosure - (Loss) Earnings Per Common Share Sheet http://www.caretrustreit.com/role/LossEarningsPerCommonShare (Loss) Earnings Per Common Share Notes 17 false false R18.htm 2144111 - Disclosure - Commitments and Contingencies Sheet http://www.caretrustreit.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 18 false false R19.htm 2146112 - Disclosure - Concentration of Risk Sheet http://www.caretrustreit.com/role/ConcentrationofRisk Concentration of Risk Notes 19 false false R20.htm 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.caretrustreit.com/role/SummaryofSignificantAccountingPolicies 20 false false R21.htm 2306301 - Disclosure - Real Estate Investments, Net (Tables) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables Real Estate Investments, Net (Tables) Tables http://www.caretrustreit.com/role/RealEstateInvestmentsNet 21 false false R22.htm 2317302 - Disclosure - Other Real Estate Investments, Net (Tables) Sheet http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetTables Other Real Estate Investments, Net (Tables) Tables http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNet 22 false false R23.htm 2322303 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.caretrustreit.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.caretrustreit.com/role/FairValueMeasurements 23 false false R24.htm 2327304 - Disclosure - Debt (Tables) Sheet http://www.caretrustreit.com/role/DebtTables Debt (Tables) Tables http://www.caretrustreit.com/role/Debt 24 false false R25.htm 2332305 - Disclosure - Equity (Tables) Sheet http://www.caretrustreit.com/role/EquityTables Equity (Tables) Tables http://www.caretrustreit.com/role/Equity 25 false false R26.htm 2337306 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.caretrustreit.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.caretrustreit.com/role/StockBasedCompensation 26 false false R27.htm 2342307 - Disclosure - (Loss) Earnings Per Common Share (Tables) Sheet http://www.caretrustreit.com/role/LossEarningsPerCommonShareTables (Loss) Earnings Per Common Share (Tables) Tables http://www.caretrustreit.com/role/LossEarningsPerCommonShare 27 false false R28.htm 2347308 - Disclosure - Concentration of Risk (Tables) Sheet http://www.caretrustreit.com/role/ConcentrationofRiskTables Concentration of Risk (Tables) Tables http://www.caretrustreit.com/role/ConcentrationofRisk 28 false false R29.htm 2402401 - Disclosure - Organization (Details) Sheet http://www.caretrustreit.com/role/OrganizationDetails Organization (Details) Details http://www.caretrustreit.com/role/Organization 29 false false R30.htm 2407402 - Disclosure - Real Estate Investments, Net - Narrative (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails Real Estate Investments, Net - Narrative (Details) Details 30 false false R31.htm 2408403 - Disclosure - Real Estate Investments, Net - Real Estate Properties Held for Investment (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetRealEstatePropertiesHeldforInvestmentDetails Real Estate Investments, Net - Real Estate Properties Held for Investment (Details) Details 31 false false R32.htm 2409404 - Disclosure - Real Estate Investments, Net - Future Contractual Minimum Rental Income (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails Real Estate Investments, Net - Future Contractual Minimum Rental Income (Details) Details 32 false false R33.htm 2410405 - Disclosure - Real Estate Investments, Net - Tenant Purchase Options (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails Real Estate Investments, Net - Tenant Purchase Options (Details) Details 33 false false R34.htm 2411406 - Disclosure - Real Estate Investments, Net - Rental Income (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails Real Estate Investments, Net - Rental Income (Details) Details 34 false false R35.htm 2412407 - Disclosure - Real Estate Investments, Net - Recent Real Estate Acquisitions (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails Real Estate Investments, Net - Recent Real Estate Acquisitions (Details) Details 35 false false R36.htm 2413408 - Disclosure - Real Estate Investments, Net - Lease Amendments Narrative (Details) Sheet http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails Real Estate Investments, Net - Lease Amendments Narrative (Details) Details 36 false false R37.htm 2415409 - Disclosure - Impairment of Real Estate Investments, Assets Held for Sale, Net and Asset Sales (Details) Sheet http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails Impairment of Real Estate Investments, Assets Held for Sale, Net and Asset Sales (Details) Details http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSales 37 false false R38.htm 2418410 - Disclosure - Other Real Estate Investments, Net - Loans Receivable and Other Investments (Details) Sheet http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetLoansReceivableandOtherInvestmentsDetails Other Real Estate Investments, Net - Loans Receivable and Other Investments (Details) Details 38 false false R39.htm 2419411 - Disclosure - Other Real Estate Investments, Net - Interest and Other Income (Details) Sheet http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetInterestandOtherIncomeDetails Other Real Estate Investments, Net - Interest and Other Income (Details) Details 39 false false R40.htm 2420412 - Disclosure - Other Real Estate Investments, Net - Narrative (Details) Sheet http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetNarrativeDetails Other Real Estate Investments, Net - Narrative (Details) Details 40 false false R41.htm 2423413 - Disclosure - Fair Value Measurements - Items Measured at Fair Value on Recurring Basis (Details) Sheet http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails Fair Value Measurements - Items Measured at Fair Value on Recurring Basis (Details) Details 41 false false R42.htm 2424414 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 42 false false R43.htm 2425415 - Disclosure - Fair Value Measurements - Face Value, Carrying Amount and Fair Value of Financial Instruments (Details) Sheet http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails Fair Value Measurements - Face Value, Carrying Amount and Fair Value of Financial Instruments (Details) Details 43 false false R44.htm 2428416 - Disclosure - Debt - Schedule of Debt (Details) Sheet http://www.caretrustreit.com/role/DebtScheduleofDebtDetails Debt - Schedule of Debt (Details) Details 44 false false R45.htm 2429417 - Disclosure - Debt - Senior Unsecured Notes Payable Narrative (Details) Notes http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails Debt - Senior Unsecured Notes Payable Narrative (Details) Details 45 false false R46.htm 2430418 - Disclosure - Debt - Unsecured Revolving Credit Facility and Term Loan Narrative (Details) Sheet http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails Debt - Unsecured Revolving Credit Facility and Term Loan Narrative (Details) Details 46 false false R47.htm 2433419 - Disclosure - Equity - Narrative (Details) Sheet http://www.caretrustreit.com/role/EquityNarrativeDetails Equity - Narrative (Details) Details 47 false false R48.htm 2434420 - Disclosure - Equity - At-The-Market Offering (Details) Sheet http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails Equity - At-The-Market Offering (Details) Details 48 false false R49.htm 2435421 - Disclosure - Equity - Dividends on Common Stock (Details) Sheet http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails Equity - Dividends on Common Stock (Details) Details 49 false false R50.htm 2438422 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 50 false false R51.htm 2439423 - Disclosure - Stock-Based Compensation - Restricted Stock and Performance Awards Activity (Details) Sheet http://www.caretrustreit.com/role/StockBasedCompensationRestrictedStockandPerformanceAwardsActivityDetails Stock-Based Compensation - Restricted Stock and Performance Awards Activity (Details) Details 51 false false R52.htm 2440424 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details) Sheet http://www.caretrustreit.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails Stock-Based Compensation - Stock-Based Compensation Expense (Details) Details 52 false false R53.htm 2443425 - Disclosure - (Loss) Earnings Per Common Share (Details) Sheet http://www.caretrustreit.com/role/LossEarningsPerCommonShareDetails (Loss) Earnings Per Common Share (Details) Details http://www.caretrustreit.com/role/LossEarningsPerCommonShareTables 53 false false R54.htm 2445426 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.caretrustreit.com/role/CommitmentsandContingencies 54 false false R55.htm 2448427 - Disclosure - Concentration of Risk (Details) Sheet http://www.caretrustreit.com/role/ConcentrationofRiskDetails Concentration of Risk (Details) Details http://www.caretrustreit.com/role/ConcentrationofRiskTables 55 false false All Reports Book All Reports ctre-20220331.htm ctre-20220331.xsd ctre-20220331_cal.xml ctre-20220331_def.xml ctre-20220331_lab.xml ctre-20220331_pre.xml ctre20220331q1ex311.htm ctre20220331q1ex312.htm ctre20220331q1ex321.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 72 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ctre-20220331.htm": { "axisCustom": 1, "axisStandard": 27, "contextCount": 139, "dts": { "calculationLink": { "local": [ "ctre-20220331_cal.xml" ] }, "definitionLink": { "local": [ "ctre-20220331_def.xml" ] }, "inline": { "local": [ "ctre-20220331.htm" ] }, "labelLink": { "local": [ "ctre-20220331_lab.xml" ] }, "presentationLink": { "local": [ "ctre-20220331_pre.xml" ] }, "schema": { "local": [ "ctre-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 433, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 1, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 6 }, "keyCustom": 39, "keyStandard": 201, "memberCustom": 34, "memberStandard": 32, "nsprefix": "ctre", "nsuri": "http://www.caretrustreit.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.caretrustreit.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RealEstateDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105103 - Disclosure - Real Estate Investments, Net", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNet", "shortName": "Real Estate Investments, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RealEstateDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114104 - Disclosure - Impairment of Real Estate Investments, Assets Held for Sale, Net and Asset Sales", "role": "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSales", "shortName": "Impairment of Real Estate Investments, Assets Held for Sale, Net and Asset Sales", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "ctre:OtherRealEstateInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116105 - Disclosure - Other Real Estate Investments, Net", "role": "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNet", "shortName": "Other Real Estate Investments, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "ctre:OtherRealEstateInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121106 - Disclosure - Fair Value Measurements", "role": "http://www.caretrustreit.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126107 - Disclosure - Debt", "role": "http://www.caretrustreit.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131108 - Disclosure - Equity", "role": "http://www.caretrustreit.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2136109 - Disclosure - Stock-Based Compensation", "role": "http://www.caretrustreit.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2141110 - Disclosure - (Loss) Earnings Per Common Share", "role": "http://www.caretrustreit.com/role/LossEarningsPerCommonShare", "shortName": "(Loss) Earnings Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2144111 - Disclosure - Commitments and Contingencies", "role": "http://www.caretrustreit.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2146112 - Disclosure - Concentration of Risk", "role": "http://www.caretrustreit.com/role/ConcentrationofRisk", "shortName": "Concentration of Risk", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "if4aa0185d3e940b8bb25d5eb1afb282e_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RealEstateInvestmentPropertyNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "if4aa0185d3e940b8bb25d5eb1afb282e_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Real Estate Investments, Net (Tables)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables", "shortName": "Real Estate Investments, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317302 - Disclosure - Other Real Estate Investments, Net (Tables)", "role": "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetTables", "shortName": "Other Real Estate Investments, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322303 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.caretrustreit.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327304 - Disclosure - Debt (Tables)", "role": "http://www.caretrustreit.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2332305 - Disclosure - Equity (Tables)", "role": "http://www.caretrustreit.com/role/EquityTables", "shortName": "Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2337306 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.caretrustreit.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2342307 - Disclosure - (Loss) Earnings Per Common Share (Tables)", "role": "http://www.caretrustreit.com/role/LossEarningsPerCommonShareTables", "shortName": "(Loss) Earnings Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2347308 - Disclosure - Concentration of Risk (Tables)", "role": "http://www.caretrustreit.com/role/ConcentrationofRiskTables", "shortName": "Concentration of Risk (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "if4aa0185d3e940b8bb25d5eb1afb282e_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfStatesInWhichEntityOperates", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Organization (Details)", "role": "http://www.caretrustreit.com/role/OrganizationDetails", "shortName": "Organization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "if4aa0185d3e940b8bb25d5eb1afb282e_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfStatesInWhichEntityOperates", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "if4aa0185d3e940b8bb25d5eb1afb282e_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "if4aa0185d3e940b8bb25d5eb1afb282e_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i8a4eae05ae5a441b984830effac81e64_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unitRef": "facility", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Real Estate Investments, Net - Narrative (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails", "shortName": "Real Estate Investments, Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i82326ad932434092a42ca734561b289f_I20220331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unique": true, "unitRef": "facility", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "if4aa0185d3e940b8bb25d5eb1afb282e_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Real Estate Investments, Net - Real Estate Properties Held for Investment (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRealEstatePropertiesHeldforInvestmentDetails", "shortName": "Real Estate Investments, Net - Real Estate Properties Held for Investment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "if4aa0185d3e940b8bb25d5eb1afb282e_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "if4aa0185d3e940b8bb25d5eb1afb282e_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Real Estate Investments, Net - Future Contractual Minimum Rental Income (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails", "shortName": "Real Estate Investments, Net - Future Contractual Minimum Rental Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "if4aa0185d3e940b8bb25d5eb1afb282e_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfTenantPurchaseOptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i836e9c96ae5245b7aad41423af435763_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ctre:NumberOfPropertiesWithTenantPurchaseOption", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Real Estate Investments, Net - Tenant Purchase Options (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails", "shortName": "Real Estate Investments, Net - Tenant Purchase Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfTenantPurchaseOptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i836e9c96ae5245b7aad41423af435763_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ctre:NumberOfPropertiesWithTenantPurchaseOption", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411406 - Disclosure - Real Estate Investments, Net - Rental Income (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails", "shortName": "Real Estate Investments, Net - Rental Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfAssetsAcquisitionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412407 - Disclosure - Real Estate Investments, Net - Recent Real Estate Acquisitions (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails", "shortName": "Real Estate Investments, Net - Recent Real Estate Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfAssetsAcquisitionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ctre:ScheduleOfAssetsAcquisitionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ctre:NumberOfPropertiesAcquired", "reportCount": 1, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413408 - Disclosure - Real Estate Investments, Net - Lease Amendments Narrative (Details)", "role": "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "shortName": "Real Estate Investments, Net - Lease Amendments Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "iee6064791ca04d8189c526bcfcb48eb6_I20220301", "decimals": null, "lang": "en-US", "name": "us-gaap:LessorOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "if4aa0185d3e940b8bb25d5eb1afb282e_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ctre:NumberOfRealEstatePropertiesToBeRepurposed", "reportCount": 1, "unique": true, "unitRef": "facility", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415409 - Disclosure - Impairment of Real Estate Investments, Assets Held for Sale, Net and Asset Sales (Details)", "role": "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails", "shortName": "Impairment of Real Estate Investments, Assets Held for Sale, Net and Asset Sales (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "if4aa0185d3e940b8bb25d5eb1afb282e_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ctre:NumberOfRealEstatePropertiesToBeRepurposed", "reportCount": 1, "unique": true, "unitRef": "facility", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "if4aa0185d3e940b8bb25d5eb1afb282e_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "ctre:FinancingReceivablePrincipalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418410 - Disclosure - Other Real Estate Investments, Net - Loans Receivable and Other Investments (Details)", "role": "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetLoansReceivableandOtherInvestmentsDetails", "shortName": "Other Real Estate Investments, Net - Loans Receivable and Other Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "if4aa0185d3e940b8bb25d5eb1afb282e_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "ctre:FinancingReceivablePrincipalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestAndOtherIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestAndOtherIncome", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419411 - Disclosure - Other Real Estate Investments, Net - Interest and Other Income (Details)", "role": "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetInterestandOtherIncomeDetails", "shortName": "Other Real Estate Investments, Net - Interest and Other Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestAndOtherIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i341005b01afd4bec8b67d8b43fc79934_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:InterestAndOtherIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncome", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations", "role": "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "if4aa0185d3e940b8bb25d5eb1afb282e_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420412 - Disclosure - Other Real Estate Investments, Net - Narrative (Details)", "role": "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetNarrativeDetails", "shortName": "Other Real Estate Investments, Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i259ddafaa2cc4697b21280b43a3eaa52_D20220101-20220331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ProvisionForLoanLeaseAndOtherLosses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i3dccbad9bc7642b0856447713c7bd3a0_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LoansReceivableFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423413 - Disclosure - Fair Value Measurements - Items Measured at Fair Value on Recurring Basis (Details)", "role": "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails", "shortName": "Fair Value Measurements - Items Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i3dccbad9bc7642b0856447713c7bd3a0_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LoansReceivableFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i89a37c40a2b844f6aff9492a670a20c2_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NotesReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424414 - Disclosure - Fair Value Measurements - Narrative (Details)", "role": "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails", "shortName": "Fair Value Measurements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i89a37c40a2b844f6aff9492a670a20c2_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NotesReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i211f6a0954e741b8a3b8917343700ce0_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425415 - Disclosure - Fair Value Measurements - Face Value, Carrying Amount and Fair Value of Financial Instruments (Details)", "role": "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "shortName": "Fair Value Measurements - Face Value, Carrying Amount and Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i4befa0c4471144f688d3449bcf639e1e_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NotesPayableFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "if4aa0185d3e940b8bb25d5eb1afb282e_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428416 - Disclosure - Debt - Schedule of Debt (Details)", "role": "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "shortName": "Debt - Schedule of Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "if4aa0185d3e940b8bb25d5eb1afb282e_I20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "ibfa61a70930f40308c8cdef1b13df1fd_I20210617", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429417 - Disclosure - Debt - Senior Unsecured Notes Payable Narrative (Details)", "role": "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "shortName": "Debt - Senior Unsecured Notes Payable Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "ibfa61a70930f40308c8cdef1b13df1fd_I20210617", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "if4aa0185d3e940b8bb25d5eb1afb282e_I20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430418 - Disclosure - Debt - Unsecured Revolving Credit Facility and Term Loan Narrative (Details)", "role": "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "shortName": "Debt - Unsecured Revolving Credit Facility and Term Loan Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i46ae8b49609048ff83d72f5139f39d87_I20190208", "decimals": "-5", "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "id52c9c410aff4f1885138b66b4fb2162_I20200320", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433419 - Disclosure - Equity - Narrative (Details)", "role": "http://www.caretrustreit.com/role/EquityNarrativeDetails", "shortName": "Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "id52c9c410aff4f1885138b66b4fb2162_I20200320", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434420 - Disclosure - Equity - At-The-Market Offering (Details)", "role": "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "shortName": "Equity - At-The-Market Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "ibc7222ce6382452caf3f9352c02ec9ba_D20210101-20210331", "decimals": "2", "lang": "en-US", "name": "ctre:SharesIssuedDuringPeriodAveragePricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435421 - Disclosure - Equity - Dividends on Common Stock (Details)", "role": "http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails", "shortName": "Equity - Dividends on Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "lang": "en-US", "name": "us-gaap:DividendPayableDateToBePaidDayMonthAndYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "ic218218237f94e1fa3c6e23abbf0be80_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Equity", "role": "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity", "shortName": "Condensed Consolidated Statements of Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "ic218218237f94e1fa3c6e23abbf0be80_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "if4aa0185d3e940b8bb25d5eb1afb282e_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438422 - Disclosure - Stock-Based Compensation - Narrative (Details)", "role": "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails", "shortName": "Stock-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "if4aa0185d3e940b8bb25d5eb1afb282e_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "ice565178a0174b809a9faf491657e27b_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439423 - Disclosure - Stock-Based Compensation - Restricted Stock and Performance Awards Activity (Details)", "role": "http://www.caretrustreit.com/role/StockBasedCompensationRestrictedStockandPerformanceAwardsActivityDetails", "shortName": "Stock-Based Compensation - Restricted Stock and Performance Awards Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "ice565178a0174b809a9faf491657e27b_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440424 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)", "role": "http://www.caretrustreit.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails", "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443425 - Disclosure - (Loss) Earnings Per Common Share (Details)", "role": "http://www.caretrustreit.com/role/LossEarningsPerCommonShareDetails", "shortName": "(Loss) Earnings Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i1b07407152f14adc863d444f9806c523_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ctre:AggregateRequiredFinancingOfCapitalExpendituresAsPercentageOfInitialInvestmentInProperty", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445426 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i1b07407152f14adc863d444f9806c523_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ctre:AggregateRequiredFinancingOfCapitalExpendituresAsPercentageOfInitialInvestmentInProperty", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "ie8a511d99602423f8ba5d875f2ae9b2b_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ctre:NumberOfFacilities", "reportCount": 1, "unique": true, "unitRef": "facility", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448427 - Disclosure - Concentration of Risk (Details)", "role": "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "shortName": "Concentration of Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "ie8a511d99602423f8ba5d875f2ae9b2b_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "ctre:NumberOfFacilities", "reportCount": 1, "unique": true, "unitRef": "facility", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Equity (Parenthetical)", "role": "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquityParenthetical", "shortName": "Condensed Consolidated Statements of Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization", "role": "http://www.caretrustreit.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctre-20220331.htm", "contextRef": "i6e66a5c3a8c14fa1bda8b02440f132d7_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 69, "tag": { "ctre_AggregateRequiredFinancingOfCapitalExpendituresAsPercentageOfInitialInvestmentInProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate Required Financing Of Capital Expenditures As Percentage Of Initial Investment In Property", "label": "Aggregate Required Financing Of Capital Expenditures As Percentage Of Initial Investment In Property", "terseLabel": "Aggregate required financing of capital expenditures as percentage of initial investment in property (percent)" } } }, "localname": "AggregateRequiredFinancingOfCapitalExpendituresAsPercentageOfInitialInvestmentInProperty", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "ctre_AnnualCashRentIncreaseUnderAmendedLease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Annual Cash Rent Increase Under Amended Lease", "label": "Annual Cash Rent Increase Under Amended Lease", "terseLabel": "Annual cash rent increase under amended lease" } } }, "localname": "AnnualCashRentIncreaseUnderAmendedLease", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ctre_AssistedAndIndependentLivingPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assisted and Independent Living Properties [Member]", "label": "Assisted and Independent Living Properties [Member]", "verboseLabel": "ALF/ILF" } } }, "localname": "AssistedAndIndependentLivingPropertiesMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "ctre_AssistedLivingFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assisted Living Facility [Member]", "label": "Assisted Living Facility [Member]", "terseLabel": "Assisted living", "verboseLabel": "ALF" } } }, "localname": "AssistedLivingFacilityMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_AtTheMarketOfferingProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At-The-Market Offering Program [Member]", "label": "At-The-Market Offering Program [Member]", "terseLabel": "ATM Program" } } }, "localname": "AtTheMarketOfferingProgramMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_CapitalImprovementsAtTripleNetLeasedFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital Improvements At Triple Net Leased Facilities", "label": "Capital Improvements At Triple Net Leased Facilities [Member]", "terseLabel": "Certain capital improvements at triple-net leased facilities" } } }, "localname": "CapitalImprovementsAtTripleNetLeasedFacilitiesMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "ctre_ContractualCashRentAttributableToPropertiesHeldForSaleAndRepurposedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual Cash Rent, Attributable To Properties Held For Sale And Repurposed, Percentage", "label": "Contractual Cash Rent, Attributable To Properties Held For Sale And Repurposed, Percentage", "terseLabel": "Contractual cash rent attributable to properties held for sale and repurposed (percent)" } } }, "localname": "ContractualCashRentAttributableToPropertiesHeldForSaleAndRepurposedPercentage", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "percentItemType" }, "ctre_DebtInstrumentRedemptionPriceUponChangeOfControlAsPercentageOfPrincipalAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument redemption price upon change of control as percentage of principal amount.", "label": "Debt Instrument Redemption Price Upon Change Of Control As Percentage Of Principal Amount", "terseLabel": "Redemption price, percentage upon change of control (percent)" } } }, "localname": "DebtInstrumentRedemptionPriceUponChangeOfControlAsPercentageOfPrincipalAmount", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "percentItemType" }, "ctre_EduroAmendedTripleNetMasterLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eduro Amended Triple-Net Master Lease", "label": "Eduro Amended Triple-Net Master Lease [Member]", "terseLabel": "Eduro amended triple-net master lease" } } }, "localname": "EduroAmendedTripleNetMasterLeaseMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_EnsignAmendedTripleNetMasterLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ensign Amended Triple-Net Master Lease", "label": "Ensign Amended Triple-Net Master Lease [Member]", "terseLabel": "Ensign amended triple-net master lease" } } }, "localname": "EnsignAmendedTripleNetMasterLeaseMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_EnsignAndPennantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ensign And Pennant", "label": "Ensign And Pennant [Member]", "terseLabel": "Ensign and Pennant" } } }, "localname": "EnsignAndPennantMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "ctre_EnsignMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ensign [Member]", "label": "Ensign [Member]", "terseLabel": "Ensign" } } }, "localname": "EnsignMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_FinancingReceivableAllowanceForCreditLossesNumberOfLoans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Allowance For Credit Losses, Number Of Loans", "label": "Financing Receivable, Allowance For Credit Losses, Number Of Loans", "terseLabel": "Number of loans receivable with provision" } } }, "localname": "FinancingReceivableAllowanceForCreditLossesNumberOfLoans", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_FinancingReceivablePrincipalAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing Receivable, Principal Amount", "label": "Financing Receivable, Principal Amount", "terseLabel": "Principal Amount" } } }, "localname": "FinancingReceivablePrincipalAmount", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetLoansReceivableandOtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "ctre_IncreaseDecreaseInDividendsPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase Decrease In Dividends Payable", "label": "Increase Decrease In Dividends Payable", "terseLabel": "Increase in dividends payable" } } }, "localname": "IncreaseDecreaseInDividendsPayable", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ctre_LeaseArrangementsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Arrangements", "label": "Lease Arrangements [Axis]", "terseLabel": "Lease Arrangements [Axis]" } } }, "localname": "LeaseArrangementsAxis", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "ctre_LeaseArrangementsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Arrangements", "label": "Lease Arrangements [Domain]", "terseLabel": "Lease Arrangements [Domain]" } } }, "localname": "LeaseArrangementsDomain", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_LeaseIncomeContractualRentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Income, Contractual Rent [Member]", "label": "Lease Income, Contractual Rent [Member]", "terseLabel": "Contractual rent" } } }, "localname": "LeaseIncomeContractualRentMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "domainItemType" }, "ctre_LeaseIncomeOperatingExpenseReimbursementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Income, Operating Expense Reimbursements", "label": "Lease Income, Operating Expense Reimbursements [Member]", "terseLabel": "Operating expense reimbursements" } } }, "localname": "LeaseIncomeOperatingExpenseReimbursementsMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "domainItemType" }, "ctre_LeaseIncomeStraightLineRentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Income, Straight Line Rent [Member]", "label": "Lease Income, Straight Line Rent [Member]", "terseLabel": "Straight-line rent" } } }, "localname": "LeaseIncomeStraightLineRentMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "domainItemType" }, "ctre_LessorAnnualizedCashRevenueForContractsInPlace": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessor, Annualized Cash Revenue For Contracts In Place", "label": "Lessor, Annualized Cash Revenue For Contracts In Place", "terseLabel": "Current Cash Rent" } } }, "localname": "LessorAnnualizedCashRevenueForContractsInPlace", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "monetaryItemType" }, "ctre_LessorOperatingLeaseNumberOfRenewalOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessor, Operating Lease, Number Of Renewal Options", "label": "Lessor, Operating Lease, Number Of Renewal Options", "terseLabel": "Number of renewal options" } } }, "localname": "LessorOperatingLeaseNumberOfRenewalOptions", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_LineOfCreditCommitmentFeeBasedOnInvestmentGradeRatingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line Of Credit, Commitment Fee Based On Investment Grade Rating, Percentage", "label": "Line Of Credit, Commitment Fee Based On Investment Grade Rating, Percentage", "terseLabel": "Facility fee on revolving commitment fee based on investment grade ratings (percent)" } } }, "localname": "LineOfCreditCommitmentFeeBasedOnInvestmentGradeRatingPercentage", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "percentItemType" }, "ctre_LineOfCreditFacilityExtensionOptionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line of credit facility extension option term.", "label": "Line Of Credit Facility Extension Option Term", "terseLabel": "Extension option term (in months)" } } }, "localname": "LineOfCreditFacilityExtensionOptionTerm", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "durationItemType" }, "ctre_LineOfCreditFacilityNumberOfExtensionOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line Of Credit Facility, Number Of Extension Options", "label": "Line Of Credit Facility, Number Of Extension Options", "terseLabel": "Number of extension options" } } }, "localname": "LineOfCreditFacilityNumberOfExtensionOptions", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_LineOfCreditSubfacilityCapacityAsPercentageOfAvailableRevolvingCommitments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line Of Credit, Subfacility, Capacity As Percentage Of Available Revolving Commitments", "label": "Line Of Credit, Subfacility, Capacity As Percentage Of Available Revolving Commitments", "terseLabel": "Subfacility capacity as percentage of available revolving commitments (percent)" } } }, "localname": "LineOfCreditSubfacilityCapacityAsPercentageOfAvailableRevolvingCommitments", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "percentItemType" }, "ctre_LoansReceivableFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loans Receivable, Fixed Interest Rate", "label": "Loans Receivable, Fixed Interest Rate", "verboseLabel": "Weighted Average Contractual Interest Rate" } } }, "localname": "LoansReceivableFixedInterestRate", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetLoansReceivableandOtherInvestmentsDetails" ], "xbrltype": "percentItemType" }, "ctre_MetronMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Metron", "label": "Metron [Member]", "terseLabel": "Metron" } } }, "localname": "MetronMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "domainItemType" }, "ctre_MezzanineLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mezzanine Loan", "label": "Mezzanine Loan [Member]", "terseLabel": "Mezzanine loan receivable" } } }, "localname": "MezzanineLoanMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "ctre_MezzanineLoanReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mezzanine Loan Receivable", "label": "Mezzanine Loan Receivable [Member]", "terseLabel": "Mezzanine loan receivable" } } }, "localname": "MezzanineLoanReceivableMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetInterestandOtherIncomeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetLoansReceivableandOtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "ctre_MultiServiceCampusPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Multi-Service Campus Properties [Member]", "label": "Multi-Service Campus Properties [Member]", "terseLabel": "Multi-service campuses", "verboseLabel": "Campus" } } }, "localname": "MultiServiceCampusPropertiesMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "ctre_NumberOfBedsOrUnitsInPropertiesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Beds Or Units In Properties Acquired", "label": "Number Of Beds Or Units In Properties Acquired", "terseLabel": "Number of Beds/Units" } } }, "localname": "NumberOfBedsOrUnitsInPropertiesAcquired", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Facilities", "label": "Number of Facilities", "terseLabel": "Number of Facilities" } } }, "localname": "NumberOfFacilities", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfOperationalBeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Operational Beds", "label": "Number Of Operational Beds", "terseLabel": "Number of operational beds" } } }, "localname": "NumberOfOperationalBeds", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfOperationalBedsAndUnitsInFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Operational Beds And Units In Facilities", "label": "Number Of Operational Beds And Units In Facilities", "terseLabel": "Number of operational beds and units in facilities" } } }, "localname": "NumberOfOperationalBedsAndUnitsInFacilities", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/OrganizationDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfPropertiesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Properties Acquired", "label": "Number Of Properties Acquired", "terseLabel": "Number of Properties", "verboseLabel": "Number of properties acquired" } } }, "localname": "NumberOfPropertiesAcquired", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfPropertiesTransferred": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Properties Transferred", "label": "Number Of Properties Transferred", "terseLabel": "Number of properties transferred" } } }, "localname": "NumberOfPropertiesTransferred", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfPropertiesWithTenantPurchaseOption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Properties With Tenant Purchase Option", "label": "Number Of Properties With Tenant Purchase Option", "terseLabel": "Properties" } } }, "localname": "NumberOfPropertiesWithTenantPurchaseOption", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfRealEstatePropertiesToBeRepurposed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Real Estate Properties To Be Repurposed", "label": "Number Of Real Estate Properties To Be Repurposed", "terseLabel": "Number of properties to be repurposed" } } }, "localname": "NumberOfRealEstatePropertiesToBeRepurposed", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfRealEstatePropertiesWithImpairment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Real Estate Properties With Impairment", "label": "Number Of Real Estate Properties With Impairment", "terseLabel": "Number of properties impaired" } } }, "localname": "NumberOfRealEstatePropertiesWithImpairment", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "integerItemType" }, "ctre_NumberOfUnitsAndBedsInFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Units And Beds In Facilities", "label": "Number Of Units And Beds In Facilities", "terseLabel": "Number of Beds/Units" } } }, "localname": "NumberOfUnitsAndBedsInFacilities", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "integerItemType" }, "ctre_OperatingLeaseLeaseIncomeAdjustmentsForCollectibility": { "auth_ref": [], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeaseLeaseIncome", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Lease, Lease Income, Adjustments For Collectibility", "label": "Operating Lease, Lease Income, Adjustments For Collectibility", "negatedTerseLabel": "Adjustments for collectibility" } } }, "localname": "OperatingLeaseLeaseIncomeAdjustmentsForCollectibility", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ctre_OperatingLeasesAnticipatedInitialAnnualLeaseRevenues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Leases, Anticipated Initial Annual Lease Revenues", "label": "Operating Leases, Anticipated Initial Annual Lease Revenues", "terseLabel": "Initial Annual Cash Rent" } } }, "localname": "OperatingLeasesAnticipatedInitialAnnualLeaseRevenues", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "ctre_OtherRealEstateInvestmentsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Real Estate Investments", "label": "Other Real Estate Investments [Text Block]", "terseLabel": "Other Real Estate Investments, Net" } } }, "localname": "OtherRealEstateInvestmentsTextBlock", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNet" ], "xbrltype": "textBlockItemType" }, "ctre_PaymentsToAcquireEquipmentFurnitureAndFixturesAndDevelopRealEstateAssets": { "auth_ref": [], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Equipment, Furniture And Fixtures And Develop Real Estate Assets", "label": "Payments To Acquire Equipment, Furniture And Fixtures And Develop Real Estate Assets", "negatedTerseLabel": "Purchases of equipment, furniture and fixtures and improvements to real estate" } } }, "localname": "PaymentsToAcquireEquipmentFurnitureAndFixturesAndDevelopRealEstateAssets", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ctre_PortionOfCommitmentSubjectToRentIncreaseAtTimeOfFunding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Portion Of Commitment Subject To Rent Increase At Time Of Funding", "label": "Portion Of Commitment Subject To Rent Increase At Time Of Funding", "terseLabel": "Portion of funding commitment subject to rent increase at time of funding" } } }, "localname": "PortionOfCommitmentSubjectToRentIncreaseAtTimeOfFunding", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "ctre_PricePerUnitValueMeasurementInput": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Price Per Unit, Value, Measurement Input", "label": "Price Per Unit, Value, Measurement Input", "terseLabel": "Prices per unit input" } } }, "localname": "PricePerUnitValueMeasurementInput", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "monetaryItemType" }, "ctre_PriorityManagementGroupLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Priority Management Group LLC", "label": "Priority Management Group LLC [Member]", "terseLabel": "Priority Management Group" } } }, "localname": "PriorityManagementGroupLLCMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationMarch2029NextOption2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Properties With Purchase Option, Lease Expiration March 2029, Next Option 2022", "label": "Properties With Purchase Option, Lease Expiration March 2029, Next Option 2022 [Member]", "terseLabel": "Lease Expiration March 2029, Next option 2022" } } }, "localname": "PropertiesWithPurchaseOptionLeaseExpirationMarch2029NextOption2022Member", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationNovember2030NextOption2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Properties With Purchase Option, Lease Expiration November 2030, Next Option 2022", "label": "Properties With Purchase Option, Lease Expiration November 2030, Next Option 2022 [Member]", "terseLabel": "Lease Expiration November 2030, Next option 2022" } } }, "localname": "PropertiesWithPurchaseOptionLeaseExpirationNovember2030NextOption2022Member", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationNovember2034NextOption2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Properties With Purchase Option, Lease Expiration November 2034, Next Option 2024", "label": "Properties With Purchase Option, Lease Expiration November 2034, Next Option 2024 [Member]", "terseLabel": "Lease Expiration November 2034, Next option 2024" } } }, "localname": "PropertiesWithPurchaseOptionLeaseExpirationNovember2034NextOption2024Member", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationOctober2032NextOption2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Properties With Purchase Option, Lease Expiration October 2032, Next Option 2023", "label": "Properties With Purchase Option, Lease Expiration October 2032, Next Option 2023 [Member]", "terseLabel": "Lease Expiration October 2032, Next option 2023" } } }, "localname": "PropertiesWithPurchaseOptionLeaseExpirationOctober2032NextOption2023Member", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationOctober2034NextOption2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Properties With Purchase Option, Lease Expiration October 2034, Next Option 2022", "label": "Properties With Purchase Option, Lease Expiration October 2034, Next Option 2022 [Member]", "terseLabel": "Lease Expiration October 2034, Next option 2022" } } }, "localname": "PropertiesWithPurchaseOptionLeaseExpirationOctober2034NextOption2022Member", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_PropertiesWithPurchaseOptionLeaseExpirationOctober2034NextOption2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Properties With Purchase Option, Lease Expiration October 2034, Next Option 2026", "label": "Properties With Purchase Option, Lease Expiration October 2034, Next Option 2026 [Member]", "terseLabel": "Lease Expiration October 2034, Next option 2026" } } }, "localname": "PropertiesWithPurchaseOptionLeaseExpirationOctober2034NextOption2026Member", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_RestrictedStockAndPerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock And Performance Shares [Member]", "label": "Restricted Stock And Performance Shares [Member]", "terseLabel": "RSAs and PSAs" } } }, "localname": "RestrictedStockAndPerformanceSharesMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails", "http://www.caretrustreit.com/role/StockBasedCompensationRestrictedStockandPerformanceAwardsActivityDetails" ], "xbrltype": "domainItemType" }, "ctre_ScheduleOfAssetsAcquisitionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Assets Acquisitions [Table Text Block]", "label": "Schedule Of Assets Acquisitions [Table Text Block]", "terseLabel": "Schedule of Real Estate Acquisitions" } } }, "localname": "ScheduleOfAssetsAcquisitionsTableTextBlock", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "ctre_ScheduleOfTenantPurchaseOptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Tenant Purchase Options", "label": "Schedule Of Tenant Purchase Options [Table Text Block]", "terseLabel": "Schedule Of Tenant Purchase Options" } } }, "localname": "ScheduleOfTenantPurchaseOptionsTableTextBlock", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "ctre_SecuritiesOfferingAuthorizedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Securities Offering, Authorized Amount", "label": "Securities Offering, Authorized Amount", "terseLabel": "Authorized aggregate offering price of common stock" } } }, "localname": "SecuritiesOfferingAuthorizedAmount", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ctre_SecuritiesOfferingRemainingAuthorizedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Securities Offering, Remaining Authorized Amount", "label": "Securities Offering, Remaining Authorized Amount", "terseLabel": "Remaining offering amount available" } } }, "localname": "SecuritiesOfferingRemainingAuthorizedAmount", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ctre_SeniorUnsecuredTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Unsecured Term Loan [Member]", "label": "Senior Unsecured Term Loan [Member]", "terseLabel": "Senior unsecured term loan" } } }, "localname": "SeniorUnsecuredTermLoanMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingAwardVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Weighted Average Remaining Award Vesting Period", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Weighted Average Remaining Award Vesting Period", "terseLabel": "Weighted-average remaining vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingAwardVestingPeriod", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "ctre_SharesIssuedDuringPeriodAveragePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Issued During Period, Average Price Per Share", "label": "Shares Issued During Period, Average Price Per Share", "terseLabel": "Average sales price per share (usd per share)" } } }, "localname": "SharesIssuedDuringPeriodAveragePricePerShare", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails" ], "xbrltype": "perShareItemType" }, "ctre_ShortTermLeaseTermUnderOneYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short Term Lease, Term Under One Year", "label": "Short Term Lease, Term Under One Year [Member]", "terseLabel": "Short-term lease" } } }, "localname": "ShortTermLeaseTermUnderOneYearMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_SkilledNursingAndCampusFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Nursing And Campus Facilities", "label": "Skilled Nursing And Campus Facilities [Member]", "verboseLabel": "SNF / Campus" } } }, "localname": "SkilledNursingAndCampusFacilitiesMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_SkilledNursingFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Nursing Facility [Member]", "label": "Skilled Nursing Facility [Member]", "terseLabel": "Skilled nursing facility", "verboseLabel": "SNF" } } }, "localname": "SkilledNursingFacilityMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "ctre_SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Nursing, Multi Service Campuses, Assisted Living, and Independent Living Facilities", "label": "Skilled Nursing, Multi Service Campuses, Assisted Living, and Independent Living Facilities [Member]", "terseLabel": "Skilled nursing, multi-service campuses, assisted living and independent living facilities" } } }, "localname": "SkilledNursingMultiServiceCampusesAssistedLivingAndIndependentLivingFacilitiesMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/OrganizationDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_SkilledNursingPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Nursing Properties [Member]", "label": "Skilled Nursing Properties [Member]", "terseLabel": "Skilled nursing" } } }, "localname": "SkilledNursingPropertiesMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "ctre_SwinglineLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Swingline Loan [Member]", "label": "Swingline Loan [Member]", "terseLabel": "Swingline loan" } } }, "localname": "SwinglineLoanMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_ThreePointEightSevenFiveSeniorNotesDue2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point Eight Seven Five Senior Notes Due 2028", "label": "Three Point Eight Seven Five Senior Notes Due 2028 [Member]", "terseLabel": "Senior unsecured notes payable", "verboseLabel": "3.875% Senior Notes due 2028" } } }, "localname": "ThreePointEightSevenFiveSeniorNotesDue2028Member", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "ctre_TransferOfPreacquisitionCostsToAcquiredAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Transfer Of Preacquisition Costs To Acquired Assets", "label": "Transfer Of Preacquisition Costs To Acquired Assets", "terseLabel": "Transfer of pre-acquisition costs to acquired assets" } } }, "localname": "TransferOfPreacquisitionCostsToAcquiredAssets", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ctre_TransferredOutOfAssetsHeldForSaleNotPartOfDisposalGroup": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Transferred Out Of Assets Held-For-Sale, Not Part Of Disposal Group", "label": "Transferred Out Of Assets Held-For-Sale, Not Part Of Disposal Group", "terseLabel": "Amount transferred out of assets held-for-sale" } } }, "localname": "TransferredOutOfAssetsHeldForSaleNotPartOfDisposalGroup", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "monetaryItemType" }, "ctre_TripleNetLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Triple-Net Leases", "label": "Triple-Net Leases [Member]", "terseLabel": "Triple-net leases" } } }, "localname": "TripleNetLeasesMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_UnfundedLoanCommitment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unfunded Loan Commitment", "label": "Unfunded Loan Commitment", "terseLabel": "Unfunded loan commitment" } } }, "localname": "UnfundedLoanCommitment", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ctre_VariousOtherOperatorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Various Other Operators", "label": "Various Other Operators [Member]", "terseLabel": "Various other operators" } } }, "localname": "VariousOtherOperatorsMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "ctre_WLCManagementFirmAmendedTripleNetMasterLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "WLC Management Firm Amended Triple-Net Master Lease", "label": "WLC Management Firm Amended Triple-Net Master Lease [Member]", "terseLabel": "WLC amended triple-net master lease" } } }, "localname": "WLCManagementFirmAmendedTripleNetMasterLeaseMember", "nsuri": "http://www.caretrustreit.com/20220331", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.caretrustreit.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r33", "r35", "r75", "r76", "r206", "r244" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r146", "r266", "r269", "r418" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r205", "r243", "r280", "r282", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r415", "r419", "r442", "r444" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails", "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r205", "r243", "r280", "r282", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r415", "r419", "r442", "r444" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r146", "r266", "r269", "r418" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r143", "r266", "r267", "r380", "r414", "r416" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r143", "r266", "r267", "r380", "r414", "r416" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r205", "r243", "r270", "r280", "r282", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r415", "r419", "r442", "r444" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails", "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r205", "r243", "r270", "r280", "r282", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r415", "r419", "r442", "r444" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails", "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r438" ], "lang": { "en-us": { "role": { "label": "Name of Property [Axis]", "terseLabel": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "http://www.caretrustreit.com/role/OrganizationDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [ "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r438" ], "lang": { "en-us": { "role": { "label": "Name of Property [Domain]", "terseLabel": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails", "http://www.caretrustreit.com/role/OrganizationDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r34", "r35", "r75", "r76", "r206", "r244" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r144", "r145", "r266", "r268", "r417", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r144", "r145", "r266", "r268", "r417", "r425", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "stringItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r373", "r375", "r378", "r442", "r444" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted average" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "domainItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CALIFORNIA", "terseLabel": "CA" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "stpr_TX": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TEXAS", "terseLabel": "TX" } } }, "localname": "TX", "nsuri": "http://xbrl.sec.gov/stpr/2021", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Information by type of receivable.", "label": "Receivable Type [Axis]", "terseLabel": "Receivable Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.", "label": "Accounts Payable and Other Accrued Liabilities", "terseLabel": "Accounts payable, accrued liabilities and deferred rent liabilities" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r15", "r400", "r426" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, after Allowance for Credit Loss", "terseLabel": "Accounts and other receivables" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDistributionsInExcessOfNetIncome": { "auth_ref": [ "r424" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount as of the balance sheet date by which cumulative distributions to shareholders (or partners) exceed retained earnings (or accumulated earnings).", "label": "Accumulated Distributions in Excess of Net Income", "negatedLabel": "Cumulative distributions in excess of earnings" } } }, "localname": "AccumulatedDistributionsInExcessOfNetIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDistributionsInExcessOfNetIncomeMember": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Cumulative distributions to shareholders (or partners) in excess of retained earnings (or accumulated earnings).", "label": "Accumulated Distributions in Excess of Net Income [Member]", "terseLabel": "Cumulative Distributions in Excess of Earnings" } } }, "localname": "AccumulatedDistributionsInExcessOfNetIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r16" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r79", "r80", "r81", "r302", "r303", "r304", "r323" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r283", "r285", "r306", "r307" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Amortization of stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net (loss) income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r285", "r299", "r305" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Amortization of stock-based compensation", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r64", "r225", "r234", "r235", "r354" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of deferred financing costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive unvested RSAs, performance awards and TSR Awards excluded from the computation" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/LossEarningsPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "auth_ref": [ "r314", "r315", "r316", "r317" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Purchase Price" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r74", "r132", "r135", "r141", "r158", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r318", "r320", "r343", "r367", "r369", "r382", "r401" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup": { "auth_ref": [ "r177" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets held-for-sale that are not part of a disposal group.", "label": "Assets Held-for-sale, Not Part of Disposal Group", "terseLabel": "Assets held for sale, net" } } }, "localname": "AssetsHeldForSaleNotPartOfDisposalGroup", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets", "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r286", "r301" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails", "http://www.caretrustreit.com/role/StockBasedCompensationRestrictedStockandPerformanceAwardsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r338", "r339" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Amount" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r5", "r20", "r66" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r60", "r66", "r69" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents as of the end of period", "periodStartLabel": "Cash and cash equivalents as of the beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r60", "r344" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental schedule of noncash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r29", "r188", "r388", "r405" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r185", "r186", "r187", "r189", "r428" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Common dividends (in usd per share)", "verboseLabel": "Dividends declared per share" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquityParenthetical", "http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r79", "r80", "r323" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r257" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding (shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14", "r369" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.01 par value; 500,000,000 shares authorized, 96,487,066 and 96,296,673 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r124", "r125", "r146", "r340", "r341", "r427" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r124", "r125", "r146", "r340", "r341", "r423", "r427" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r124", "r125", "r146", "r340", "r341", "r423", "r427" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Concentration of Risk" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRisk" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r124", "r125", "r146", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk (percent)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r121", "r124", "r125", "r126", "r340", "r342", "r427" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r124", "r125", "r146", "r340", "r341", "r427" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfOtherPropertyOperatingExpense": { "auth_ref": [ "r48" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations": { "order": 6.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other operating costs incurred during the reporting period and may include amounts paid to maintain the property.", "label": "Cost of Other Property Operating Expense", "terseLabel": "Property operating expenses" } } }, "localname": "CostOfOtherPropertyOperatingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r47" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r122", "r146" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer concentration risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r70", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r219", "r226", "r227", "r229", "r236" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r8", "r9", "r10", "r73", "r77", "r202", "r203", "r204", "r205", "r206", "r207", "r209", "r215", "r216", "r217", "r218", "r220", "r221", "r222", "r223", "r224", "r225", "r232", "r233", "r234", "r235", "r355", "r383", "r385", "r399" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate (percent)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r10", "r230", "r385", "r399" ], "calculation": { "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Principal Amount", "verboseLabel": "Outstanding amounts" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r202", "r232", "r233", "r353", "r355", "r356" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument face amount", "verboseLabel": "Senior unsecured notes payable - face value" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r27", "r203" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate (percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r28", "r73", "r77", "r202", "r203", "r204", "r205", "r206", "r207", "r209", "r215", "r216", "r217", "r218", "r220", "r221", "r222", "r223", "r224", "r225", "r232", "r233", "r234", "r235", "r355" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period One [Member]", "terseLabel": "Period prior to June 30 2024" } } }, "localname": "DebtInstrumentRedemptionPeriodOneMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Three [Member]", "terseLabel": "Period after March 30 2028" } } }, "localname": "DebtInstrumentRedemptionPeriodThreeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Two [Member]", "terseLabel": "Period prior to March 30 2028" } } }, "localname": "DebtInstrumentRedemptionPeriodTwoMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption price of notes (percent)" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of principal amount of debt redeemed.", "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed", "terseLabel": "Percentage of principal amount (percent)" } } }, "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r28", "r73", "r77", "r202", "r203", "r204", "r205", "r206", "r207", "r209", "r215", "r216", "r217", "r218", "r220", "r221", "r222", "r223", "r224", "r225", "r228", "r232", "r233", "r234", "r235", "r258", "r261", "r262", "r263", "r352", "r353", "r355", "r356", "r398" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r354" ], "calculation": { "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "negatedTerseLabel": "Deferred Loan Fees" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r22", "r215", "r354" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Deferred financing costs, net" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r64", "r180" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r64", "r131" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization (including below-market ground leases)" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r179", "r183" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposed of by sale" } } }, "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r178", "r179", "r183" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Held for sale" } } }, "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": { "auth_ref": [ "r64", "r179", "r182" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down", "terseLabel": "Impairment expense to reduce carrying value to fair value less costs to sell" } } }, "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r3", "r184" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Impairment of Real Estate Investments, Assets Held for Sale, Net and Asset Sales" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSales" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r279", "r281" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendPayableDateToBePaidDayMonthAndYear": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Date the declared dividend will be paid, in YYYY-MM-DD format.", "label": "Dividends Payable, Date to be Paid", "terseLabel": "Dividends payment date" } } }, "localname": "DividendPayableDateToBePaidDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DividendsCommonStock": { "auth_ref": [ "r264", "r396" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Common Stock", "negatedLabel": "Common dividends" } } }, "localname": "DividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCommonStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dividends, Common Stock [Abstract]", "terseLabel": "Dividends on common stock" } } }, "localname": "DividendsCommonStockAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsDeclaredTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.", "label": "Dividends Declared [Table Text Block]", "terseLabel": "Schedule of Dividends on Common Stock" } } }, "localname": "DividendsDeclaredTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r7", "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends Payable, Current", "terseLabel": "Dividends payable as of record date" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r9", "r11", "r384", "r402" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividends Payable", "verboseLabel": "Dividends payable" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableDateOfRecordDayMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format.", "label": "Dividends Payable, Date of Record", "terseLabel": "Dividends record date" } } }, "localname": "DividendsPayableDateOfRecordDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityDividendsonCommonStockDetails" ], "xbrltype": "dateItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "(Loss) earnings per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r44", "r84", "r85", "r86", "r87", "r88", "r92", "r95", "r106", "r109", "r110", "r114", "r115", "r324", "r325", "r392", "r409" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in usd per share)", "verboseLabel": "(Loss) earnings per common share, basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations", "http://www.caretrustreit.com/role/LossEarningsPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r44", "r84", "r85", "r86", "r87", "r88", "r95", "r106", "r109", "r110", "r114", "r115", "r324", "r325", "r392", "r409" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in usd per share)", "verboseLabel": "(Loss) earnings per common share, diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations", "http://www.caretrustreit.com/role/LossEarningsPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r111", "r112", "r113", "r116" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "(Loss) Earnings Per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/LossEarningsPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r300" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unamortized stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r38", "r39", "r40", "r79", "r80", "r81", "r83", "r89", "r91", "r118", "r161", "r257", "r264", "r302", "r303", "r304", "r310", "r311", "r323", "r345", "r346", "r347", "r348", "r349", "r350", "r420", "r421", "r422", "r466" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r217", "r232", "r233", "r337" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r326", "r327", "r328", "r333" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Items Measured at Fair Value on a Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r326", "r338", "r339" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r326", "r338" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Summary of Face Value, Carrying Amount and Fair Value of Financial Instruments" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r217", "r232", "r233", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r327", "r370", "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails", "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r217", "r232", "r233", "r326", "r334" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r326", "r327", "r330", "r331", "r335" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r217", "r232", "r233" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r217", "r271", "r272", "r277", "r278", "r327", "r370" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r217", "r232", "r233", "r271", "r272", "r277", "r278", "r327", "r371" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r217", "r232", "r233", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r327", "r372" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails", "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r217", "r232", "r233", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r370", "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails", "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r332", "r335" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]", "terseLabel": "Financial liabilities:" } } }, "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLosses": { "auth_ref": [ "r148", "r162", "r163", "r166", "r387", "r460", "r462", "r464" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.", "label": "Financing Receivable, Allowance for Credit Loss", "negatedTerseLabel": "Expected credit loss", "terseLabel": "Expected credit loss" } } }, "localname": "FinancingReceivableAllowanceForCreditLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetLoansReceivableandOtherInvestmentsDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Financing Receivable, Allowance for Credit Loss [Line Items]", "terseLabel": "Financing Receivable, Allowance for Credit Loss [Line Items]" } } }, "localname": "FinancingReceivableAllowanceForCreditLossesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivableAllowanceForCreditLossesRecovery": { "auth_ref": [ "r150", "r165", "r174" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in allowance for credit loss on financing receivable from recovery.", "label": "Financing Receivable, Allowance for Credit Loss, Recovery", "terseLabel": "Loan loss recovery" } } }, "localname": "FinancingReceivableAllowanceForCreditLossesRecovery", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis": { "auth_ref": [ "r151", "r152", "r153", "r168", "r169", "r171", "r172", "r173", "r174", "r175", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464" ], "lang": { "en-us": { "role": { "documentation": "Information by class of financing receivable determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk.", "label": "Class of Financing Receivable [Axis]", "terseLabel": "Class of Financing Receivable [Axis]" } } }, "localname": "FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetInterestandOtherIncomeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetLoansReceivableandOtherInvestmentsDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain": { "auth_ref": [ "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464" ], "lang": { "en-us": { "role": { "documentation": "Financing receivables determined on the basis of initial measurement attribute, risk characteristics and method of monitoring and assessing credit risk.", "label": "Class of Financing Receivable [Domain]", "terseLabel": "Class of Financing Receivable [Domain]" } } }, "localname": "FinancingReceivableRecordedInvestmentClassOfFinancingReceivableDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetInterestandOtherIncomeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetLoansReceivableandOtherInvestmentsDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Financing Receivable, Past Due [Line Items]", "terseLabel": "Financing Receivable, Past Due [Line Items]" } } }, "localname": "FinancingReceivableRecordedInvestmentPastDueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivablesEqualToGreaterThan90DaysPastDueMember": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "Financial asset equal to or greater than 90 days past due.", "label": "Financial Asset, Equal to or Greater than 90 Days Past Due [Member]", "terseLabel": "Greater than 90 days past due" } } }, "localname": "FinancingReceivablesEqualToGreaterThan90DaysPastDueMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancingReceivablesPeriodPastDueAxis": { "auth_ref": [ "r153", "r168", "r175" ], "lang": { "en-us": { "role": { "documentation": "Information by period in which financial asset is past due or not past due.", "label": "Financial Asset, Aging [Axis]", "terseLabel": "Financial Asset, Aging [Axis]" } } }, "localname": "FinancingReceivablesPeriodPastDueAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivablesPeriodPastDueDomain": { "auth_ref": [ "r153", "r168", "r175" ], "lang": { "en-us": { "role": { "documentation": "Period in which financial asset is past due or not past due. For past due, element name and standard label in Financial Asset, [numeric lower end] to [numeric higher end] [date measure] Past Due [Member] or Financial Asset, Greater than [low end numeric value] [date measure] Past Due [Member] or Financial Asset, Less than [high end numeric value] [date measure] Past Due [Member] formats.", "label": "Financial Asset, Aging [Domain]", "terseLabel": "Financial Asset, Aging [Domain]" } } }, "localname": "FinancingReceivablesPeriodPastDueDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r176", "r381" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRealEstatePropertiesHeldforInvestmentDetails": { "order": 4.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Identified intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRealEstatePropertiesHeldforInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FixturesAndEquipmentGross": { "auth_ref": [], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRealEstatePropertiesHeldforInvestmentDetails": { "order": 3.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines.", "label": "Fixtures and Equipment, Gross", "terseLabel": "Integral equipment, furniture and fixtures" } } }, "localname": "FixturesAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRealEstatePropertiesHeldforInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnTerminationOfLease": { "auth_ref": [ "r357" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingLeaseLeaseIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.", "label": "Gain (Loss) on Termination of Lease", "terseLabel": "Lease termination revenue" } } }, "localname": "GainLossOnTerminationOfLease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnSalesOfInvestmentRealEstate": { "auth_ref": [ "r45", "r46", "r64", "r390", "r410", "r411", "r412", "r413" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net gain (loss) resulting from sales and other disposals of real estate owned for investment purposes.", "label": "Gains (Losses) on Sales of Investment Real Estate", "negatedTerseLabel": "(Gain) loss on sale of real estate", "terseLabel": "Gain (loss) on sale of real estate", "verboseLabel": "Gain on sale of real estate" } } }, "localname": "GainsLossesOnSalesOfInvestmentRealEstate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations", "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r50" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations": { "order": 7.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r123", "r427" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic concentration risk" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentLossesRelatedToRealEstatePartnerships": { "auth_ref": [ "r65", "r181" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Impairment losses measured as the amount by which the carrying amount of the business or real estate partnerships exceeds the fair value of the business or partnership.", "label": "Impairment Losses Related to Real Estate Partnerships", "terseLabel": "Impairment of real estate investments" } } }, "localname": "ImpairmentLossesRelatedToRealEstatePartnerships", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r279", "r281" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r63" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued liabilities and deferred rent liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r63" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts and other receivables" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r63" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets, net" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r96", "r97", "r98", "r110" ], "calculation": { "http://www.caretrustreit.com/role/LossEarningsPerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Diluted market condition stock awards (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/LossEarningsPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestAndOtherIncome": { "auth_ref": [], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).", "label": "Interest and Other Income", "terseLabel": "Interest and other income" } } }, "localname": "InterestAndOtherIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetInterestandOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndOtherIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest income and income classified as other.", "label": "Interest and Other Income [Table Text Block]", "terseLabel": "Schedule of Interest and Other Income" } } }, "localname": "InterestAndOtherIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r41", "r130", "r351", "r354", "r394" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r59", "r61", "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentBuildingAndBuildingImprovements": { "auth_ref": [ "r407" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRealEstatePropertiesHeldforInvestmentDetails": { "order": 2.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate of the carrying amounts as of the balance sheet date of investments in building and building improvements.", "label": "Investment Building and Building Improvements", "terseLabel": "Buildings and improvements" } } }, "localname": "InvestmentBuildingAndBuildingImprovements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRealEstatePropertiesHeldforInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTableTextBlock": { "auth_ref": [ "r156", "r157", "r159", "r160" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment.", "label": "Investment [Table Text Block]", "terseLabel": "Schedule of Loans Receivable and Other Investments" } } }, "localname": "InvestmentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, All Other Investments [Abstract]" } } }, "localname": "InvestmentsAllOtherInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_Land": { "auth_ref": [ "r6", "r21" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRealEstatePropertiesHeldforInvestmentDetails": { "order": 1.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRealEstatePropertiesHeldforInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LessorLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessor, Lease, Description [Line Items]", "terseLabel": "Lessor, Lease, Description [Line Items]" } } }, "localname": "LessorLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorLeaseDescriptionTable": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessor's leases.", "label": "Lessor, Lease, Description [Table]", "terseLabel": "Lessor, Lease, Description [Table]" } } }, "localname": "LessorLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTenantPurchaseOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]", "terseLabel": "Future Contractual Minimum Rental Income" } } }, "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r362" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "Lessor, Operating Lease, Payments to be Received", "totalLabel": "Total" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "auth_ref": [ "r362" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 6.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Five", "terseLabel": "2027" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "auth_ref": [ "r362" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 5.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "terseLabel": "2026" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.", "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of Total Future Contractual Minimum Rental Income" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r362" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "terseLabel": "2023" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": { "auth_ref": [ "r362" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year", "terseLabel": "2022 (nine months)" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": { "auth_ref": [ "r362" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 7.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r362" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 4.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "terseLabel": "2025" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r362" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "terseLabel": "2024" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetFutureContractualMinimumRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeaseRenewalTerm": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor, Operating Lease, Renewal Term", "terseLabel": "Lease renewal term (in years)" } } }, "localname": "LessorOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LessorOperatingLeaseTermOfContract": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor, Operating Lease, Term of Contract", "terseLabel": "Initial lease term (in years)" } } }, "localname": "LessorOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r25", "r74", "r136", "r158", "r191", "r192", "r193", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r319", "r320", "r321", "r343", "r367", "r368" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r19", "r74", "r158", "r343", "r369", "r386", "r404" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Equity:" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r10", "r385", "r399" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Unsecured revolving credit facility", "verboseLabel": "Borrowings outstanding" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Facility fee on revolving commitment fees (percent)" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facility borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r23", "r73" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowing supported by a written promise to pay an obligation.", "label": "Loans Payable [Member]", "terseLabel": "Term loan" } } }, "localname": "LoansPayableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LoansReceivableFairValueDisclosure": { "auth_ref": [ "r155" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of loan receivable, including, but not limited to, mortgage loans held for investment, finance receivables held for investment, policy loans on insurance contracts.", "label": "Loans Receivable, Fair Value Disclosure", "verboseLabel": "Mezzanine loan receivable" } } }, "localname": "LoansReceivableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An amount of money or property, or a portion thereof, leant to a borrower (debtor) in exchange for a promise to repay the amount borrowed plus interest at a date certain in the future.", "label": "Loans Receivable [Member]", "terseLabel": "Other", "verboseLabel": "Other loans receivable" } } }, "localname": "LoansReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetInterestandOtherIncomeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetLoansReceivableandOtherInvestmentsDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r10", "r216", "r231", "r232", "r233", "r385", "r403" ], "calculation": { "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Carrying Value" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r28" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Loans Payable, Noncurrent", "terseLabel": "Senior unsecured term loan, net" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r28", "r190" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketApproachValuationTechniqueMember": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach using price and other relevant information generated by market transaction involving identical or comparable asset, liability, or group of assets and liabilities.", "label": "Valuation, Market Approach [Member]", "terseLabel": "Valuation, market approach" } } }, "localname": "MarketApproachValuationTechniqueMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r60" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r60" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r60", "r62", "r65" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r36", "r37", "r40", "r43", "r65", "r74", "r82", "r84", "r85", "r86", "r87", "r90", "r91", "r103", "r132", "r134", "r137", "r140", "r142", "r158", "r191", "r192", "r193", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r325", "r343", "r391", "r408" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.caretrustreit.com/role/LossEarningsPerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net (loss) income", "verboseLabel": "Net (loss) income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity", "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations", "http://www.caretrustreit.com/role/LossEarningsPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/LossEarningsPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r84", "r85", "r86", "r87", "r92", "r93", "r105", "r110", "r132", "r134", "r137", "r140", "r142" ], "calculation": { "http://www.caretrustreit.com/role/LossEarningsPerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Numerator for basic earnings available to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/LossEarningsPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r94", "r99", "r100", "r101", "r102", "r105", "r110" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Numerator for basic and diluted earnings available to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/LossEarningsPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (loss):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableFairValueDisclosure": { "auth_ref": [ "r24" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of notes payable.", "label": "Notes Payable, Fair Value Disclosure", "terseLabel": "Senior unsecured notes payable" } } }, "localname": "NotesPayableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableGross": { "auth_ref": [ "r153", "r162", "r168", "r170", "r174", "r175", "r458", "r460", "r461" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of financing receivable.", "label": "Financing Receivable, before Allowance for Credit Loss", "terseLabel": "Mortgage loan receivable", "verboseLabel": "Book value" } } }, "localname": "NotesReceivableGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetLoansReceivableandOtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesReceivableNet": { "auth_ref": [ "r15", "r147", "r170" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.", "label": "Financing Receivable, after Allowance for Credit Loss", "terseLabel": "Loan receivable" } } }, "localname": "NotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetLoansReceivableandOtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfRealEstateProperties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of real estate properties owned as of the balance sheet date.", "label": "Number of Real Estate Properties", "terseLabel": "Number of facilities", "verboseLabel": "Number of properties" } } }, "localname": "NumberOfRealEstateProperties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails", "http://www.caretrustreit.com/role/OrganizationDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of states the entity operates in as of the balance sheet date.", "label": "Number of States in which Entity Operates", "terseLabel": "Number of states with properties" } } }, "localname": "NumberOfStatesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OrganizationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLeaseIncome": { "auth_ref": [ "r117", "r361", "r366" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 }, "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease, Lease Income", "terseLabel": "Rental income", "totalLabel": "Total" } } }, "localname": "OperatingLeaseLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": { "auth_ref": [ "r117", "r365" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLeaseIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease, Lease Income, Lease Payments", "terseLabel": "Contractual rent due" } } }, "localname": "OperatingLeaseLeaseIncomeLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "auth_ref": [ "r117", "r366" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of components of income from operating lease.", "label": "Operating Lease, Lease Income [Table Text Block]", "terseLabel": "Schedule of Rental Income" } } }, "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingLeasesLeaseIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease, Lease Income [Abstract]", "terseLabel": "Rental Income" } } }, "localname": "OperatingLeasesLeaseIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r4", "r322" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "Other Commitment", "terseLabel": "Funding commitment" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]", "terseLabel": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]", "terseLabel": "Other Commitments [Domain]" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherDepreciationAndAmortization": { "auth_ref": [ "r49", "r64", "r180" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.", "label": "Other Depreciation and Amortization", "terseLabel": "Catch-up depreciation" } } }, "localname": "OtherDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r57" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid on common stock" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Commissions paid on stock issuance" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r57" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Net-settle adjustment on restricted stock" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireCommercialRealEstate": { "auth_ref": [ "r54" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the acquisition of property as primarily intended to generate income for its owner.", "label": "Payments to Acquire Commercial Real Estate", "negatedTerseLabel": "Acquisitions of real estate, net of deposits applied" } } }, "localname": "PaymentsToAcquireCommercialRealEstate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireLoansReceivable": { "auth_ref": [ "r53" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the purchase of loan receivable arising from the financing of goods and services.", "label": "Payments to Acquire Loans Receivable", "negatedTerseLabel": "Investment in other loans receivable" } } }, "localname": "PaymentsToAcquireLoansReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r13", "r241" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r13", "r241" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding (shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r13", "r369" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued and outstanding as of March 31, 2022 and December 31, 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other assets, net" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromCollectionOfLoansReceivable": { "auth_ref": [ "r51" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the collection, including prepayments, of loans receivable issued for financing of goods and services.", "label": "Proceeds from Collection of Loans Receivable", "terseLabel": "Principal payments received on real estate mortgage and other loans receivable" } } }, "localname": "ProceedsFromCollectionOfLoansReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "auth_ref": [ "r56" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "label": "Proceeds from Debt, Net of Issuance Costs", "terseLabel": "Net proceeds from issuance" } } }, "localname": "ProceedsFromDebtNetOfIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r55" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Gross proceeds", "verboseLabel": "Proceeds from the issuance of common stock, net" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfUnsecuredDebt": { "auth_ref": [ "r56" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.", "label": "Proceeds from Issuance of Unsecured Debt", "verboseLabel": "Gross proceeds from issuance" } } }, "localname": "ProceedsFromIssuanceOfUnsecuredDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r56" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from Long-term Lines of Credit", "terseLabel": "Borrowings under unsecured revolving credit facility" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfRealEstateHeldforinvestment": { "auth_ref": [ "r52" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from the sale of real estate that is held for investment, that is, it is part of an investing activity during the period.", "label": "Proceeds from Sale of Real Estate Held-for-investment", "terseLabel": "Net proceeds from sales of real estate", "verboseLabel": "Proceeds from sale" } } }, "localname": "ProceedsFromSaleOfRealEstateHeldforinvestment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForLoanLeaseAndOtherLosses": { "auth_ref": [ "r63", "r149", "r393" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related loan transactions, lease transactions, credit loss from transactions other than loan and lease transactions, and other loss based on assessment of uncollectability from the counterparty to reduce the account to their net realizable value.", "label": "Provision for Loan, Lease, and Other Losses", "terseLabel": "Expected credit loss recognized" } } }, "localname": "ProvisionForLoanLeaseAndOtherLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForLoanLossesExpensed": { "auth_ref": [ "r164", "r389" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of credit loss expense (reversal of expense) for financing receivable.", "label": "Financing Receivable, Credit Loss, Expense (Reversal)", "terseLabel": "Provision for loan losses, net" } } }, "localname": "ProvisionForLoanLossesExpensed", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Real Estate [Abstract]", "terseLabel": "Real Estate [Abstract]" } } }, "localname": "RealEstateAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RealEstateDisclosureTextBlock": { "auth_ref": [ "r439", "r440", "r441", "r443", "r445" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for certain real estate investment financial statements, real estate investment trust operating support agreements, real estate owned, retail land sales, time share transactions, as well as other real estate related disclosures.", "label": "Real Estate Disclosure [Text Block]", "terseLabel": "Real Estate Investments, Net" } } }, "localname": "RealEstateDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation": { "auth_ref": [ "r406" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRealEstatePropertiesHeldforInvestmentDetails": { "order": 2.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of depreciation for real estate property held for investment purposes.", "label": "Real Estate Investment Property, Accumulated Depreciation", "negatedLabel": "Accumulated depreciation and amortization" } } }, "localname": "RealEstateInvestmentPropertyAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRealEstatePropertiesHeldforInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAtCost": { "auth_ref": [ "r407" ], "calculation": { "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRealEstatePropertiesHeldforInvestmentDetails": { "order": 1.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property, at Cost", "totalLabel": "Real estate investments" } } }, "localname": "RealEstateInvestmentPropertyAtCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRealEstatePropertiesHeldforInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyNet": { "auth_ref": [ "r407" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRealEstatePropertiesHeldforInvestmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property, Net", "terseLabel": "Real estate investments, net", "totalLabel": "Real estate investments, net" } } }, "localname": "RealEstateInvestmentPropertyNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets", "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRealEstatePropertiesHeldforInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentsJointVentures": { "auth_ref": [ "r407" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The book value of investments in real estate joint ventures including direct and indirect investments.", "label": "Real Estate Investments, Joint Ventures", "terseLabel": "Other real estate investments" } } }, "localname": "RealEstateInvestmentsJointVentures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets", "http://www.caretrustreit.com/role/OrganizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Real Estate [Line Items]", "terseLabel": "Real Estate [Line Items]" } } }, "localname": "RealEstateLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstatePropertiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Real Estate Properties [Line Items]", "terseLabel": "Real Estate Properties [Line Items]" } } }, "localname": "RealEstatePropertiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OrganizationDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetInterestandOtherIncomeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetLoansReceivableandOtherInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstateTable": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about real estate investment companies including, but not limited to, real estate investment trusts, real estate owned, retail land sales, and time share transactions.", "label": "Real Estate [Table]", "terseLabel": "Real Estate [Table]" } } }, "localname": "RealEstateTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetLeaseAmendmentsNarrativeDetails", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstateTaxExpense": { "auth_ref": [ "r309" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A tax based on the assessed value of real estate by the local government. The tax is usually based on the value of property (including the land).", "label": "Real Estate Tax Expense", "terseLabel": "Property taxes" } } }, "localname": "RealEstateTaxExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivableTypeDomain": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.", "label": "Receivable [Domain]", "terseLabel": "Receivable [Domain]" } } }, "localname": "ReceivableTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsItemsMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "RSAs" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings", "terseLabel": "Vesting of restricted common stock, net of shares withheld for employee taxes (in shares)" } } }, "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings", "terseLabel": "Vesting of restricted common stock, net of shares withheld for employee taxes" } } }, "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r42", "r74", "r128", "r129", "r133", "r138", "r139", "r143", "r144", "r146", "r158", "r191", "r192", "r193", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r343", "r395" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving credit facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]", "terseLabel": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r124", "r146" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Rental revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesTypeLeaseImpairmentLoss": { "auth_ref": [ "r164", "r359", "r360" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on net investment in sales-type lease.", "label": "Sales-type Lease, Net Investment in Lease, Credit Loss Expense (Reversal)", "terseLabel": "Adjustment for collectibility of rental income" } } }, "localname": "SalesTypeLeaseImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r312", "r313" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRecentRealEstateAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r28", "r77", "r232", "r234", "r258", "r261", "r262", "r263", "r352", "r353", "r356", "r398" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Debt Instruments" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Reconciliation of Weighted-Average Common Shares Outstanding Used in Calculation of Basic EPS to Diluted EPS" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/LossEarningsPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r285", "r298", "r305" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable": { "auth_ref": [ "r167", "r464" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about allowance for credit loss on financing receivable.", "label": "Financing Receivable, Allowance for Credit Loss [Table]", "terseLabel": "Financing Receivable, Allowance for Credit Loss [Table]" } } }, "localname": "ScheduleOfFinancingReceivableAllowanceForCreditLossesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFinancingReceivablesPastDueTable": { "auth_ref": [ "r168", "r175" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about aging analysis for financing receivable.", "label": "Financing Receivable, Past Due [Table]", "terseLabel": "Financing Receivable, Past Due [Table]" } } }, "localname": "ScheduleOfFinancingReceivablesPastDueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRealEstatePropertiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning real estate properties and units within those properties by ownership of the property.", "label": "Schedule of Real Estate Properties [Table]", "terseLabel": "Schedule of Real Estate Properties [Table]" } } }, "localname": "ScheduleOfRealEstatePropertiesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/OrganizationDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetInterestandOtherIncomeDetails", "http://www.caretrustreit.com/role/OtherRealEstateInvestmentsNetLoansReceivableandOtherInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of real estate properties and units in those properties that are included in the discussion of the nature of an entity's operations.", "label": "Schedule of Real Estate Properties [Table Text Block]", "terseLabel": "Summary of Investment in Owned Properties" } } }, "localname": "ScheduleOfRealEstatePropertiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r291", "r296", "r297" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Award and Performance Award Activity" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r286", "r301" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails", "http://www.caretrustreit.com/role/StockBasedCompensationRestrictedStockandPerformanceAwardsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r30", "r71", "r119", "r120", "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r246", "r250", "r255", "r258", "r259", "r260", "r261", "r262", "r263", "r264" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r12", "r13", "r14", "r238", "r239", "r240", "r258", "r259", "r260", "r261", "r262", "r263", "r264" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule of Stock by Class [Table Text Block]", "terseLabel": "Summary of the At-The-Market Offering Program" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r121", "r124", "r125", "r126", "r340", "r342" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedules of Concentration of Risk" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ConcentrationofRiskTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Notes payable" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtScheduleofDebtDetails", "http://www.caretrustreit.com/role/DebtSeniorUnsecuredNotesPayableNarrativeDetails", "http://www.caretrustreit.com/role/FairValueMeasurementsFaceValueCarryingAmountandFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationRestrictedStockandPerformanceAwardsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationRestrictedStockandPerformanceAwardsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationRestrictedStockandPerformanceAwardsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationRestrictedStockandPerformanceAwardsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested, ending balance (shares)", "periodStartLabel": "Unvested, beginning balance (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationRestrictedStockandPerformanceAwardsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested, ending balance (usd per share)", "periodStartLabel": "Unvested, beginning balance (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationRestrictedStockandPerformanceAwardsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Share Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationRestrictedStockandPerformanceAwardsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationRestrictedStockandPerformanceAwardsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationRestrictedStockandPerformanceAwardsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails", "http://www.caretrustreit.com/role/StockBasedCompensationRestrictedStockandPerformanceAwardsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationRestrictedStockandPerformanceAwardsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized for awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r284", "r289" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/StockBasedCompensationNarrativeDetails", "http://www.caretrustreit.com/role/StockBasedCompensationRestrictedStockandPerformanceAwardsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r31", "r38", "r39", "r40", "r79", "r80", "r81", "r83", "r89", "r91", "r118", "r161", "r257", "r264", "r302", "r303", "r304", "r310", "r311", "r323", "r345", "r346", "r347", "r348", "r349", "r350", "r420", "r421", "r422", "r466" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r79", "r80", "r81", "r118", "r380" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r13", "r14", "r257", "r264" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock, net, (in shares)", "verboseLabel": "Number of shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity", "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r13", "r14", "r257", "r264" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Share repurchase program authorization" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Remaining available authorization" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r17", "r18", "r74", "r154", "r158", "r343", "r369" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets", "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r72", "r242", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r256", "r264", "r265" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StraightLineRent": { "auth_ref": [ "r63" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLeaseIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between actual rental income due and rental income recognized on a straight-line basis.", "label": "Straight Line Rent", "negatedTerseLabel": "Straight-line rental income", "terseLabel": "Straight-line rent" } } }, "localname": "StraightLineRent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.caretrustreit.com/role/RealEstateInvestmentsNetRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityAtTheMarketOfferingDetails", "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r14", "r257", "r264" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Shares repurchased (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": { "auth_ref": [ "r104", "r107", "r108" ], "calculation": { "http://www.caretrustreit.com/role/LossEarningsPerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.", "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic", "negatedLabel": "Less: Net income allocated to participating securities" } } }, "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/LossEarningsPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredLongTermDebt": { "auth_ref": [ "r28" ], "calculation": { "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Unsecured Long-term Debt, Noncurrent", "terseLabel": "Senior unsecured notes payable, net" } } }, "localname": "UnsecuredLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]", "terseLabel": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]", "terseLabel": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/ImpairmentofRealEstateInvestmentsAssetsHeldforSaleNetandAssetSalesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/DebtUnsecuredRevolvingCreditFacilityandTermLoanNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r94", "r110" ], "calculation": { "http://www.caretrustreit.com/role/LossEarningsPerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted-average diluted common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations", "http://www.caretrustreit.com/role/LossEarningsPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator:", "verboseLabel": "Weighted-average number of common shares:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations", "http://www.caretrustreit.com/role/LossEarningsPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r92", "r110" ], "calculation": { "http://www.caretrustreit.com/role/LossEarningsPerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average basic common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.caretrustreit.com/role/CondensedConsolidatedStatementsofOperations", "http://www.caretrustreit.com/role/LossEarningsPerCommonShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 12 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "65", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2793-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "66", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2814-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL77927221-108306" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(4)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5066-111524" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5111-111524" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r155": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/subtopic&trid=2196772" }, "r156": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r157": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "321", "URI": "http://asc.fasb.org/topic&trid=75115024" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "325", "URI": "http://asc.fasb.org/topic&trid=2197064" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82921833-210448" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "79", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "80", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123398962&loc=d3e400-110220" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2599-110228" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r189": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20,22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r265": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r308": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6419918&loc=d3e35301-107843" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r322": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919101-209958" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123416613&loc=SL77930333-209968" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123420820&loc=SL77919311-209978" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(14)(d))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.11)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "360", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123605564&loc=d3e23415-158514" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "360", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123605564&loc=d3e23439-158514" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123605587&loc=d3e23528-158515" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=d3e9120-115832" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r439": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "970", "URI": "http://asc.fasb.org/topic&trid=2156125" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r440": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "972", "URI": "http://asc.fasb.org/topic&trid=2134617" }, "r441": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "974", "URI": "http://asc.fasb.org/topic&trid=2156429" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r443": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "976", "URI": "http://asc.fasb.org/topic&trid=2134846" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r445": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "978", "URI": "http://asc.fasb.org/topic&trid=2134977" }, "r446": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r447": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r448": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r449": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r450": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r451": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r452": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r453": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r454": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r455": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r456": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r457": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r458": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1404" }, "r459": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1404" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r460": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(1)" }, "r461": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(2)" }, "r462": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(3)" }, "r463": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(4)" }, "r464": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1405" }, "r465": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r78": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" } }, "version": "2.1" } ZIP 73 0001628280-22-012634-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-22-012634-xbrl.zip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�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end